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Zusammenfassung 
 
Mit der antiretroviralen Therapie (ART) konnte ein deutlicher Erfolg bei der 
Behandlung von HIV-infizierten Patienten erzielt werden. Bis jetzt ist es jedoch 
unmöglich mit antiretroviralen Medikamenten HIV-1 Patienten zu heilen. In den 
westlichen Ländern gab es in den letzten Jahren eine erneute Zunahme von HIV-1 
Diagnosen, besonders unter homosexuellen Männern. In den Entwicklungsländern 
ist es unwahrscheinlich, dass durch ART die Epidemie von HIV-1 unter Kontrolle 
gebracht werden kann. Daher ist die Erforschung eines sicheren und wirksamen HIV-
Impfstoffes von entscheidender Bedeutung um die Epidemie zu stoppen.  
Trotz grosser Bemühungen sind empirische Ansätze zur Entwicklung von HIV-1 
Impfstoffen bisher fehlgeschlagen. Zur grössten Hürde in der Impfstoffentwicklung 
gehört die enorme Variabilität der HI-Viren. Bei der HIV-1 Ansteckung werden jedoch 
nur eine oder wenige virale Varianten auf den Empfänger übertragen. Dieser 
genetische Flaschenhals könnte eine Achillesferse des HI-Virus darstellen. Beim 
Menschen wird der biologische Übertragungsmechanismus jedoch nur 
bruchstückhaft verstanden. Vertieftes Wissen über den Mechanismus des 
genetischen Flaschenhalses, sowie über die Eigenschaften der übertragenen Viren 
könnten wesentliche Schritte zu einem effektiven Impfstoff sein. Die virale Diversität 
ist einerseits ein Hindernis in der Impfstoffentwicklung, andererseits ermöglicht sie 
auch phylogentische Studien des viralen Genoms. Die phylogenetische Analyse der 
viralen Sequenzen während der primären Phase der HIV-1 Infektion ermöglicht die 
frühen Wirt-Virus Interaktionen zu studieren, welches sonst nur im Tiermodell 
möglich ist.  
 
In Kapitel 1 wird die Komplexität der übertragenen HIV-1-Populationen untersucht 
und nach Risikofaktoren geforscht, welche die Transmission von mehreren Viren 
ermöglicht. Unsere Ergebnisse legen nahe, dass die Übertragung von mehreren 
genetischen Varianten nicht ausschliesslich von den Eigenschaften der Schleimhaut 
abhängig ist, wie dies in kürzlich publizierten Studien propagiert wurde. Die 
Übertragung von Virenstämmen, die den Co-Rezeptor CXCR4 benützen, ist ein 
seltenes Ereignis. Vorsicht ist geboten bei der Vorhersage der Co-Rezeptor-Nutzung 
durch genotypische Algorithmen, denn die Konkordanz dieser bioinformatischen 
Werkzeuge ist begrenzt. 
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Im Jahr 2009 traten weltweit schätzungsweise 2,6 Millionen neue Fälle von HIV-1 
Infektion auf. Neuere Daten deuten auf eine hohe HIV-1-Übertragungsrate von 
Personen mit primärer HIV-1 Infektion. Kapitel 2 beschreibt die 
Transmissionsdynamik während der akuten Infektion über den Zeitraum der ART und 
in der chronischen Phase nach dem Absetzen der ART. Innerhalb phylogenetischer 
Cluster suchen wir mit Hilfe longitudinaler klinischer Daten nach 
Übertragungsmustern. Eine große Zahl von Neuinfektionen stammt von Patienten, 
welche die ART gestoppt hatten. Dies weist darauf hin, dass aktuelle präventive 
Bemühungen unzureichend sind. Diese Befunde sprechen für eine frühzeitige, 
kontinuierliche ART um die Ausbreitung von HIV-1, insbesondere bei Personen mit 
häufiger sexueller Aktivität, zu reduzieren. 
 
Der Erfolg der ART in einem einzelnen Patienten wird durch die Messung viraler 
RNA im Blut überwacht. Aktuelle kommerziell erhältliche „Assays“ haben eine 
Nachweisgrenze zwischen 20 und 50 viraler RNA-Kopien pro ml Blut. In 
epidemiologischen Studien bezüglich des Übertragungsrisikos unter ART ist es 
nützlich, wenn auch einzelne replizierende Viren nachgewiesen werden können. Das 
HI-Virus verändert sich in hohem Masse. Daher müssen molekulare 
Nachweisverfahren eine breite Palette von Virenstämme erkennen. Kapitel 3 dieser 
Dissertation beschreibt eine Methode um phylogenetisch diverse Viren, wie HIV-1, 
mit einer hohen Sensivität zu detektieren.  
 
Nach der primären HIV-Infektion nivelliert sich die Viruslast (VL) eines Patienten auf 
einem bestimmten Niveau ein. Dieser Wert, genannt viraler „setpoint“, kann mehr als 
1000-fach zwischen Patienten variieren und ist ein Marker für den Krankheitsverlauf. 
Der virale „setpoint“ wird durch genetische Komponenten des Wirtes und des Virus 
bestimmt. In Kapitel 4 wird mit der Anwendung von „machine learning tools“ versucht, 
eine Signatur im viralen Genom zu identifizieren, welche mit einem tiefen viralen 
„setpoint“ assoziiert ist.  
Unsere Ergebnisse legen nahe, dass Patienten mit der Präsenz von Viren, welchen 
das Aminosäure-Muster 268E/358T fehlt, eine VL von > 5000 bei Studienbeginn 
aufzeigen und mit geringer Wahrscheinlichkeit das Virus nach Absetzen der ART 
kontrollieren können. Dieses Aminosäure-Muster in HIV-1 gp120 könnte sich in vivo 
negativ auf die virale Fitness auswirken. 
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HIV-1-Infektionen werden von einer oder wenigen viralen Varianten oder 
„Quasispezies“ initiiert. Anschließend nimmt mit fortschreitender Erkrankung die 
virale Diversität mehr oder weniger linear zu. So ist die virale genetische Vielfalt 
innerhalb eines Patienten potenziell informativ für das Alter der Infektion. 
Genotypische Resistenz-Tests werden heute routinemäßig bei Patienten mit einer 
HIV-1 Infektion durchgeführt. Die dazu verwendete Methode ist eine „bulk“-
Sequenzierung der pol-Region. In Kapitel 5 analysieren wir, ob der Anteil der 
mehrdeutigen Nukleotide in den „bulk“-Sequenzen eines einzelnen Patienten 
Aufschluss über das Alter der Infektion aufgibt. Unsere Beobachtungen zeigen, dass 
der Anteil der mehrdeutigen Nukleotide mit einer Rate von 0,2% pro Jahr innerhalb 
der ersten 8 Jahre steigt. Darüber hinaus wird gezeigt, dass ein Anteil der 
mehrdeutigen Nukleotide von > 0,5% starke Beweise gegen eine frische Infektion 
liefert (Transmission < 1 Jahr vor der Probenahme). 
 
Zusammenfassend kann gesagt werden, dass phylogenetische Studien der viralen 
Sequenzen verwendet werden können, um komplexe Fragestellungen wie 
epidemiologische Studien und HIV-1 Übertragungsmechanismen zu erforschen. 
Phylogenetische Analysen können zur Identifizierung von Transmissions-Paaren 
verwendet werden und das Erkennen von Übertragungsmustern hilft dabei, 
Präventionsstrategien zu verbessern. Das genaue Verständnis der initialen Abläufe 
während einer HIV-1 Neuinfektion könnte entscheidend sein für die Entwicklung 
eines wirksamen Impfstoffes. Phylogenetische Analysen viraler Sequenzen werden 
zukünftig an Bedeutung gewinnen, da zurzeit neue Sequenzierungstechniken 
etabliert werden und die Menge an Verfügbaren Sequenzen sprunghaft Ansteigt.  
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Summary 
 
Although a marked success of antiretroviral therapy (ART) in controlling human 
immunodeficiency virus type 1 (HIV-1) infection, ART fails to cure patients from this 
virus. In addition, in developed countries there is an increase in new diagnoses of 
HIV-1, particularly in men having sex with men (MSM). In regions where HIV-1 has 
hit hardest it is unlikely to eradicate the virus by ART. Therefore, a safe and effective 
HIV-1 vaccine is crucial to halt the epidemic. Empirical approaches to the 
development of HIV-1 vaccines have so far, despite huge efforts, not been 
successful. Among the major obstacles is the enormous genetic variability. An 
Achilles heel of HIV-1 may be the genetic bottleneck during HIV-1 transmission, in 
which only one or a few viral variants, quasispecies, from a complex viral population 
in the source are transmitted to the recipient. However, knowledge about HIV-1 
transmission biology in humans is still insufficient. Understanding the mechanisms of 
the genetic bottleneck and knowledge about the characteristics of the transmitted 
viral strains may help to design an effective HIV-1 vaccine. Contrarily to the obstacle 
in vaccine design, viral diversity enables phylogenetic studies of viral sequences. The 
phylogenetic investigation of viral sequences obtained during the acute and recent 
phase of HIV-1 infection facilitate the possibility to study transmission and early 
host/virus interactions which is otherwise only possible in animal models.  
 
In chapter 1 investigation of the complexity of transmitted HIV-1 populations early 
after infection, and assessing potential factors associated with transmission of 
heterogeneous viral populations has been done. Our findings suggest that 
transmission of complex virus founder populations may not depend solely on 
mucosal factors, as suggested so far by recently published work. In addition, 
transmission of clinically relevant CXCR4-using viral strains seems to remain a rare 
event and caution is warranted predicting co-receptor usage by genotypic algorithms 
alone, because concordance of those tools is still limited. 
 
In 2009, an estimated 2.6 million new cases of HIV-1 infection occurred. Recent data 
suggests high HIV-1 transmission rates caused by individuals with primary HIV-1 
infection. Chapter 2 describes the study of transmission dynamics during the acute 
infection, during the aviremic phase over the period of ART, and during the chronic 
Summary 
7 
stage after cessation of ART. We investigated transmission patterns within 
phylogenetic clusters by using longitudinal clinical data. Large numbers of new 
infections originated from patients who stopped ART indicating that current 
preventive efforts are insufficient. These findings argue for early, continuous ART to 
reduce the spread of HIV-1, in particular in individuals with frequent sexual activity.  
 
The success of ART in an individual patient is monitored by measuring HIV RNA 
copy numbers in blood plasma. Current commercial available assays have a 
detection limit between 20 and 50 viral RNA copy numbers per ml blood. Regarding 
epidemiological studies of transmission events, also under therapy, it is of interest to 
also detect viral RNA at single copy sensitivity. In addition HIV-1 is continuously 
evolving at a high rate. Therefore molecular detection assays have to detect a wide 
range of viral strains. Chapter 3 of this dissertation describes a method to detect 
phylogenetically diverse viruses such as HIV-1 with single copy sensitivity.  
 
After primary HIV-1 infection (PHI) each individual reaches a steady state level of 
plasma viral load which is referred to as viral setpoint. These setpoints between 
individuals can vary more than 1000 fold and are surrogate markers for disease 
progression. HIV-1 RNA levels are influenced by genetic characteristics of both the 
host and the virus. In chapter 4 we aim at identifying common genetic viral signatures 
associated with virologic control by applying machine learning tools. Our results 
suggest that presence of virus lacking the amino acid pattern 268E/358T is 
associated with viral load (VL) >5000 at baseline of PHI and with low probability of 
spontaneous virologic control after cessation of ART. These residues in HIV-1 gp120 
might affect in vivo HIV-1 fitness.  
 
HIV-1 infection is initiated by one or a few closely related viruses. Subsequently, viral 
diversity increases with disease progression. Thus, the viral genetic diversity within a 
patient is potentially informative about the age of infection. Genotypic resistance tests 
are routinely done in HIV-1 infected patients by bulk sequencing of the viral pol 
region. In chapter 5, we aimed if the fraction of ambiguous nucleotides (nt) within pol 
bulk sequences obtained from an individual patient is informative about the age of 
infection. We found that the fraction of ambiguous nts increased at a rate of 0.2% per 
year within the first 8 years. Additionally, we showed that a fraction of ambiguous nts 
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of >0.5% provides strong evidence against a recent infection event <1 year prior to 
sampling.  
 
Taken together, phylogenetic studies of viral nucleotide sequences can be used to 
address complex aims such as epidemiological studies and HIV-1 transmission 
biology. Phylogenetic analysis can be used to detect transmission pairs and the 
knowledge about transmission dynamics can improve prevention strategies. Better 
understanding how HIV-1 establishes a new infection may turn out to be a 
prerequisite to design efficient HIV-1 vaccines. Additionally, in the future, the 
phylogenetic study of viral sequences will be of great importance because new 
sequencing techniques are currently developed, such as 454 sequencing, and the 
amount of available sequences will increase exponentially. 
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Introduction 
 
1. Global epidemiology 
 
At the end of 2009, it was estimated that approximately 33.3 million people worldwide 
were living with HIV-1 (146), the causative agent of the acquired immunodeficiency 
syndrome (AIDS) (11). In the same year, 2.6 million people became newly infected 
with HIV-1 and 2.0 million died of AIDS. More than two thirds of the people affected 
by HIV-1 live in Sub-Saharan Africa (22.4 million) where HIV-1 in certain areas such 
as Swaziland and in Lesotho has reached a prevalence of 25%. At the end of 2009, 
there were around 2.2 million HIV infected people living in the developed world (6.6% 
of the total). In the Western industrialized countries these numbers continue to rise 
mainly due to the life prolonging effect of ART and the new, actual rise in HIV-1 
infections among men having sex with men (MSM) (9, 32, 86).  
 
2. Epidemiology in Switzerland 
 
As in most industrialized countries, HIV-1 probably began to spread in Switzerland in 
the 1970s. Initially, the disease primarily affected MSM and intravenous drug users 
(IVDU), while infections of heterosexuals (HSX) only started increasing significantly in 
the mid-1980s, in particular also fueled by sexual spread from the IVDU population in 
to the heterosexual population (76).  
Nowadays, over 20’000 (between 19’000 and 25’000) patients are living with HIV-1 in 
Switzerland with an estimated prevalence of around 0.2% (7). In 2010, HIV-1 was 
newly diagnosed in 609 individuals. HIV-1 was predominantly acquired by MSM 
(~50%), followed by HSX (~45%), IVDU (~4%) and very rarely through mother to 
child transmission (MTCT, <1%) (8). Even though sexual HIV-1 transmission 
preferentially occurs among individuals with the same risk factors (e.g. MSM) the 
initial phase of the epidemic among heterosexuals was strongly driven by IVDU (76). 
However, new HIV-1 infections decreased among IVDU due to effective prevention 
(e.g. needle exchange programs) (98) and subsequently the spill over of IVDU to the 
HSX strongly declined (76). Thus, preventive measures undertaken for IVDU resulted 
in a strong secondary preventive effect of a reduction of transmission from IVDU to 
HSX (76). In contrast, among MSM, the numbers of positive test results almost 
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doubled between 2004 and 2008 (8). An additional layer of complexity of disease 
dynamics emerges from infections acquired abroad, either by sex tourism or 
immigration (106, 151). 
 
3. Evolution of HIV-1 
 
3.1 Origin of HIV 
 
HIV exists as two types, HIV-1 and HIV-2, which both originated in non-human 
primates in sub-Saharan Africa (figure 1). HIV-2 represents a cross-species infection 
from sooty mangabeys (55). HIV-1 strains are divided into three groups (M, major; O, 
outlier; N, non-M non-O), each of which represents an independent zoonosis, a 
transmission from simian immunodeficiency virus (SIV) in chimpanzees to humans 
(figure 1) (37, 147). Whereas two of these groups are rare, group M has spread 
throughout the world and causes more than 95% of the HIV-1 pandemic.  
Long before AIDS was described in 1981, HIV-1 must have been spreading through 
the human population. A detailed estimate of the time and place of origin of HIV-1 
and the prehistory of the AIDS pandemic is provided by comparing ancestral viral 
sequences obtained from stored biopsies and blood samples with current HIV-1 
strains (163, 165). The phylogenetic analysis of HIV-1 group M viruses gave 
estimates for the date of the common ancestor between 1902 and 1921, with 95% 
confidence intervals ranging no later than 1933 (163). The SIV strains most closely 
related to HIV-1 group M have been found in infected Chimpanzee in Cameroon 
upstream of Léopoldville, now Kinshasa, in the Democratic Republic of Congo (figure 
2) (72). Around 1900, colonialists began to penetrate this area of the remote 
rainforest and cities began to expand rapidly in west-central Africa causing strong 
migration from rural areas to these new cities. These developments were most likely 
important drivers for the subsequent spread of HIV-1 (133). 
Introduction 
11 
 
 
 
 
Figure 1: Phylogenetic tree of human and simian lentiviruses (adapted from (5)).  
HIV-1 and HIV-2 share only 50-60% sequence identity and cluster at distinct locations on the 
phylogenetic tree. Whereas HIV-2 originated from a cross-species transmission from sooty 
mangabeys in west Africa, HIV-1 is related to SIVcpz. HIV-1 is further divided into three groups, main 
(M), new (N) and outlier (O). The origin of group O might be related to a jump to Homo sapiens from 
Gorilla gorilla. HIV-1 group M can be further divided into many subtypes, which share 70-90% 
sequence identity, and seem to have arisen through founder events (5). 
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Microbiol (5), copyright (2007) 
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Figure 2: Origin of the HIV-1 pandemic (adapted from (133)).  
a) The map of west-central Africa shows the habitat of Chimpanzees carrying the SIV strains most 
closely related to the viruses of HIV-1 group M (red circle) in Cameroon, major rivers, and cities with 
explosive population growth in the twentieth century. A possible explanation how SIV jumped to 
humans would be the human migration into this tropical region along the rivers, an exposure to SIV 
infected bush meat and a subsequent transmission and spread in the dense population of the growing 
town, Léopoldville. b) Léopoldville in 1896 and c), Léopoldville around 1955 (133). 
Reprinted by permission from Macmillan Publishers Ltd: Nature (133), copyright (2008) 
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3.2 Global spread of HIV-1 
 
The expansion of HIV-1 across Africa and throughout the world has been 
accompanied by one of the most rapid evolutionary rates described for a human 
pathogen, aside from Hepatitis C virus (43). Phylogenetic analysis identified nine 
subtypes within group M, including A-D, F-H, J and K, which diverge by 20-30% in 
the envelope (env) region of the genome (figure 2). In addition, a multitude of inter 
subtype circulating recombinant forms (CRFs) and additional unique recombinant 
forms have been recognized (17). Most subtypes and CRFs are present in west-
central Africa. In contrast, in many countries, a specific viral subtype may be most 
prevalent due to founding of the local epidemic by a few individuals (figure 3) (6, 77).  
Nowadays Subtype C accounts for more than 50% of infections worldwide whereas 
subtype B accounts for just approximately 10% (figure 3) (51). The prevalence of 
non-B subtypes has been increasing in Western European countries, where the 
epidemic was initially dominated by subtype B (77). In Switzerland, the majority of 
HIV-1 infections still occur with subtype B viruses, but other clades such as A, C, 
CRF01_AE and CRF02_AG are increasingly observed, due to migration of infected 
patients or sex tourism (figure 4) (106, 151).  
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Figure 3: Geographical distribution and prevalence of HIV-1 subtypes in 2004 (adapted from 
(5)). 
The pie charts depict the proportion of each subtype or CRF in each geographical region. The size of 
the circles is proportional to the HIV-1 prevalence in the particular region (5). The countries coloured 
grey have a low level of HIV-1 or data were not available. In 2004 subtype C accounted for 50% of the 
epidemic worldwide. Subtypes A, B, D and G contributed for 12%, 10%, 3% and 6%, respectively. The 
CRF_AE and CRF02_AG each were accounted for 5% of all infections. All CRF together were 
responsible for 18% of cases.  
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Microbiol (5), copyright (2007) 
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Figure 4: Time trends in distribution of subtypes in the Swiss HIV Cohort study (adapted from 
SHCS).  
Panel A: All modes of HIV transmission (n=4767); Panel B: Heterosexual contacts only (n=2197). 
Graphs for intravenous drug users (low numbers) and homosexual men (no discernible time trend) are 
not shown (151). 
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3.3 Natural course of HIV-1 infection 
 
The natural course of the HIV-1 infection is divided into three clinical phases: the 
acute phase, the chronic phase and AIDS (figure 5) (reviewed in (79)). The acute 
phase starts with an infection and lasts 4 to 8 weeks. During this initial stage, around 
40-90% of patients show symptoms of the acute retroviral syndrome (ARS) (3). 
These large varieties of unspecific symptoms appear approximately 1-3 weeks 
following exposure to HIV-1 but can vary significantly between subjects and last from 
one to several weeks (127). During acute HIV-1 infection, there is often a marked 
decrease in CD4+ T-cell count and extensive viral replication. Subsequently, 
concurrent with the appearance of HIV-1 specific CD8+ T-cells plasma viral load falls 
abruptly (74). CD8+ T-cells may contribute to the control of HIV-1 infection through 
both innate and adaptive mechanisms (130, 162). The drop in viral load may be 
driven by other factors as well, such as loss in activated CD4+ T-cell targets or other 
immune-mediated mechanisms (61). Neutralizing antibodies develop during acute 
infection and thus may contribute to viral clearance (36, 136). Nevertheless, both 
quantity and quality of the humoral immune response improves during the course of 
infection and broader neutralization activity is predominantly found in chronic 
infection (95, 96). Taken together, the immune response is gradually building up, 
leading to a decrease of viral replication and to equilibrium between the immune 
response and viral replication after around 3 months. This viral setpoint, following 
resolution of the acute infection, is a strong predictor of long-term disease 
progression rates and characteristic for the second phase of HIV-1 infection (90). The 
viral setpoint is defined by host (~20%) and viral (~50%) characteristics (4). During 
this stage of infection the patient stays asymptomatic for a time span of around 8-10 
years in 70-80% of the cases (intermediate progressors) and for a few years or over 
12 years in rapid or late progressors, respectively (reviewed in (79)). During the 
chronic stage CD4+ lymphocytes gradually decline over time and drop below a 
threshold of approximately 200 CD4+ cells/μl. Thereby the patient enters the third 
phase of infection and becomes vulnerable to AIDS-defining illnesses such as 
opportunistic infections (caused by bacteria, mycobacteria, parasites, viruses and 
fungus) and certain tumors.  
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Figure 5: Natural course and viral diversity during HIV-1 infection 
In the acute phase, HIV replicates rapidly to maximal viremia (red) accompanied with a decline in 
blood CD4+ T cell count (blue). Later, blood CD4+ T cells rise again to a moderately subnormal level 
because evaded T cells move back from lymphoid tissue into the blood and proliferation is increased. 
In the chronic phase, viral load rises and CD4+ T cell levels decrease slowly. When CD4+ T cell levels 
drop under a certain limit (200 cells/μl blood) opportunistic infections occur, defining AIDS.  
An individual is typically infected by one or a few HIV-1 clones (depicted by the small blue circle), 
which dramatically increase in copy number but not in genetic diversity during the first 1-2 months. 
Following the acute phase genetic diversity (green) increases at a relatively linear rate with the length 
of infection until a plateau is reached in the AIDS phase. Viral diversity is also indicated as colored 
circles within the human contour and in phylogenetic trees of full length env sequences.  
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3.4 Intra-patient HIV-1 evolution 
 
An individual is typically infected by a few HIV-1 strains (described in more detail in 
section 4.2 and figure 5) (71). During disease progression, this founder population 
rapidly evolves into a mixture of different viral strains, referred to as a quasipecies. 
Viral diversity builds up mostly in a linear fashion, until a plateau is reached (75, 132). 
During AIDS, even a decrease in viral diversity has been observed (figure 5) (132).  
The extreme heterogeneity during later stages of HIV-1 infection is a result of rapid 
viral turnover, a high virus burden in an infected individual, recombination and the 
error-prone nature of the reverse transcriptase (RT) enzyme which lacks 
proofreading activity (56, 113, 114, 157). Besides stochastic forces (genetic drift) 
natural (positive) selection is the driving force of intra-host evolution. HIV 
successively fixes mutations that allow the virus to evade immune responses and to 
acquire optimale fitness in a given host. Host immune selection pressure are 
generated mainly by HIV-specific neutralizing antibodies, T-helper cells (119) and by 
cytotoxic T lymphocytes (CTLs) (14).  
Genetic viral diversity between HIV-1 infected patients varies substantially. It remains 
unclear whether HIV-1-related disease progression occurs more rapidly in patients 
harboring a viral population with low or high diversity. Various studies have described 
that patients with low viral genetic diversity have a delayed disease progression (68, 
85, 87). Others argued that higher viral diversity may induce a broader immune 
response which subsequently could control the infection (160). The loss of CD4+ T-
cells and development of AIDS would be primarily due to the increasing antigenic 
diversity that, beyond a threshold, exceeds the capacity of the immune system to 
control the virus (160). In this model, the antigenic diversity is the cause of AIDS. 
It is also a matter of debate whether the complexity of the founder population affects 
viral replication in the host and subsequently the viral setpoint (123). This steady-
state level of viral replication is generally established during the recent phase. 
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4. HIV-1 transmission 
 
4.1 Transmission mode of HIV-1 
 
Transmission of HIV-1 can occur via unprotected sexual intercourse with an infected 
partner, injection or transfusion of contaminated blood or blood products, sharing 
unsterilized injection equipment that has been previously used by someone who is 
infected and maternofetal transmission (during pregnancy, at birth, and through 
breastfeeding) (reviewed in (59)).  
 
4.2 Transmission biology of HIV-1 
 
The SIV rhesus macaque non-human primate (NHP) model of vaginal transmission 
of HIV-1 provides a window through which one can observe early infection prior to 
systemic infection (93) in a way that is not possible in HIV-1 infection. From the NHP 
model we have the following picture of the earliest stage of infection (figure 6) 
(reviewed in (46)): Virus can cross the mucosal barrier by different mechanisms 
preferentially at sites of single layered epithelium such as the endocervix and the 
transformation zone in the female genital tract. These mechanisms for HIV-1 
transmission across mucosal epithelium may include direct infection of epithelial 
cells, transcytosis through specialized microfold (M) cells, epithelial transmigration of 
infected donor cells, uptake by intraepithelial Langerhans cells and circumvention of 
the epithelial barrier through physical breaches (reviewed in (134)). Initially infected 
cells are relatively small numbers of “resting” CD4+ T-cells that lack detectable 
markers of activation. This founder population then undergoes a local expansion 
during the first week of infection to generate sufficient virus and infected cells which 
afterwards disseminate via lymphatic drainage to establish a self-propagating 
infection in the genital draining lymph nodes. Subsequently, the virus spreads 
systemically by dissemination into the bloodstream and infection of the secondary 
lymphoid organs.  
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Figure 6: Early events during vaginal HIV-1 transmission 
Virus crosses the mucosal epithelial barrier to establish a small founder population. Other transmitted 
viruses extinct because of the low target cell availability or are non-functional viruses. The small 
founder population expands locally using the influx of new target cells recruited through outside-in 
signalling. The local expansion disseminates via lymphatic drainage to genital lymph nodes where 
expansion quickly produces more virus and subsequently disseminate through the bloodstream to 
establish a self-propagating infection in secondary lymphoid organs and get systemic.  
Introduction 
21 
4.3 HIV-1 selection during transmission 
 
Despite a swarm of closely related viruses present in the donor, there is a strong 
genetic bottleneck associated with transmission so that only a limited number of 
variants are transmitted to the recipient (figure 5 & 6) (28, 118, 159, 161). Recent 
studies suggested that HIV-1 transmission results from productive infection by a 
single transmitted/founder virus in ~80% of HIV-1 infected HSX (2, 45, 71), in ~60% 
of HIV-1 infected MSM (71, 83) and in ~40% of IVDU (10). The likely transmission of 
a single viral variant in many cases provides a potential window of opportunity for 
vaccines and microbicides, which, at least in a majority of cases, would need to 
protect against a very small incoming viral dose of limited diversity.  
For this reasons it is of interest to understand factors associated with the acquisition 
of multiple viral variants versus single variants, not only because this may have 
potential implications on vaccine design but also because high diversity following 
transmission has been associated with more rapid disease progression (41, 124). 
Apart from the mode of transmission and the anatomy of encountered mucosal 
barrier, sexually transmitted infections (STI) were also found to be associated with 
increased frequency of multiple variant transmission in some studies (2, 45, 124). 
Together, the mucosal epithelial barrier may be responsible for the genetic bottleneck 
during transmission (figure 6). However, a genetic bottleneck has also been observed 
within IVDU, therefore strongly suggesting that additional selective mechanisms 
independent of the mucosal barrier most likely are relevant (10).  
It is still an unresolved question whether the bottleneck during transmission is a 
stochastic event or whether active selection of specific variants occurs during HIV-1 
transmission. Support for the later hypothesis was provided by studies showing that 
newly acquired variants of non-B subtypes have shorter and/or less glycosylated 
envelope glycoproteins than those present in the transmitting partner or among 
chronically infected patients (20, 28). Over the course of infection glycan restricted 
envelope glycoproteins develop a glycan shield due to immune pressure of 
neutralizing antibodies (156). In addition to this observation, newly acquired viruses 
are more closely related to ancestral sequences compared with the predominant 
variants circulating in a chronically infected host (52, 122). Similarly, although 
patients in a later stage of infection often harbour mixtures of viral variants that use 
chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) receptors for 
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host cell entry (figure 7), predominantly CCR5 tropic viral variants (R5) are 
transmitted (reviewed in (12)), although here studies vary significantly (1, 23, 25, 116, 
166). Together, adaptation within a host may be counterproductive for transmission 
efficiency.  
 
 
 
 
 
 
 
 
Figure 7: Model for corezeptor usage and cell tropism (adapted from (12)). 
T-tropic (X4) strains are specific for CXCR4 and M-tropic (R5) viral variants use CCR5 as corezeptor. 
Dual-tropic strains can use both corezeptors for cell entry (12).  
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5. Antiretroviral therapy (ART) 
 
5.1 HIV-1 structure 
 
HIV-1 belongs to the genus lentivirus, a member of the family of retroviridae. Its 
genome comprises two positive copies of single-stranded RNA, both of which 
contribute to replication. The viral genome is around 10 kb in length and encodes for 
15 processed proteins (figure 8 & 9). Those proteins that are derived from gag 
(group-specific antigen), pol (polymerase) and env (envelope) are structural and 
enzymatic factors that are common to all retroviruses. In addition, HIV-1 encodes two 
regulatory proteins, Tat (transcriptional transactivator) and Rev (regulator of 
expression of virion proteins) and four genes that encode accessory proteins, nef 
(negative factor), vif (virion infectivity), vpr and vpu (viral proteins R and U, 
respectively) (reviewed in (35)). 
 
The viral envelope protein  
 
Env is synthesized as a polypeptide precursor (164). During the transport through the 
Golgi apparatus env undergoes extensive glycosylation which is required for correct 
folding and conformational stability. In the trans-Golgi network the env gp160 is 
cleaved into gp120 and gp41 by the cellular protease furin (reviewed in (78)). Gp41 is 
the transmembrane unit of the viral envelope protein which is noncovalently linked to 
the surface unit gp120. During virion budding the gp120/gp41 complexes are 
incorporated into the virus envelope. Functional glycoprotein spikes on HIV-1 
particles consist of trimers of these complexes. Gp120 consists of a signal peptide 
followed by different conserved (C1/C2/C3/C4/C5) and variable regions 
(V1/V2/V3/V4/V5) (141). The conserved regions are hidden from the immune 
response by tertiary and quaternary structure of env. Gp120 is further protected by 
the “glycan shield” obstructing antibody recognition of both variable loops and 
conserved sites (156). Only antibodies that react with the intact trimer are considered 
to bear neutralizing activity (reviewed in (62)). However, both gp120 and gp41 
monomers, as also gp160 precursor proteins, are released upon disintegration of 
infected cells (161). Additionally, gp120 monomers can further dissociate from spikes 
due to the inherent instability of the trimer (164). Within gp120, the V3 loop, the 
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V1/V2 loop, and the CD4-binding site were identified as target sites for neutralizing 
antibodies (reviewed in (62)). However, V1/V2 domains protect the V3 loop on 
neighbouring gp120 subunits within the envelope trimer (120).  
The variable regions of the env are the major determinant of virus coreceptor usage 
and cell tropism (discussed further in chapter 5.2 and figure 7). V3 amino acids in X4 
strains have a significantly higher positive charge than R5 isolates (34). The 
presence of a positively charged amino acid at 11th and/or 25th positions of the V3 
loop is a predictive marker for the X4 phenotype (117).  
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Figure 8: Genetic organization of HIV-1 (adapted from www.hiv.lanl.gov).  
Open reading frames are shown as rectangles. Gag and Gag-Pol polyprotein precursors are 
processed by the viral protease into subunits: matrix (MA, p17), capsid (CA, p24), nucleopcapsid (NC) 
p1 and p6, protease (PR), reverse transcriptase (RT), which contains RNaseH and integrase (IN). Env 
(gp160) is cleaved by cellular proteases, such as furin, into gp120 and gp41 moieties. The tat and rev 
spliced exons are shown as shaded rectangles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: The structure of an HIV-1 virion (adapted from (69)). 
The structural proteins form the virion which is about 100-130 nm in diameter. Its outer layer consists 
of a lipid membrane derived from the former host cell in which trimeric gp120-gp41 complexes are 
embedded. The inner surface of the membrane is lined by the matrix which interacts with the 
cytoplasmic tail of gp41. The capsid proteins forms a conical core. The 2 HIV-1 RNA copies are 
surrounded by nucleocapsid proteins. In addition, proteins necessary for reverse transcription and 
integration of the provirus are incorporated into the virion (69).  
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Microbiol (69), copyright (2008) 
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5.2 Viral life cycle 
 
The initial step of the viral life cycle starts with the attachment of the virus to the host 
cell by binding of the viral env protein gp120 (SU protein) to the CD4 receptor 
inducing extensive conformational changes in gp120 that exposes the coreceptor 
binding site of the chemokine family. The major co-receptors required for entry of 
HIV-1 are the chemokine receptor molecules CCR5 (R5 HIV-1 isolates) and CXCR4 
(X4 HIV-1 isolates), which define the tropism of a HIV-1 strain (figure 7). Binding to 
the coreceptor results in another structural alteration of gp120 exposing the N-
terminal part of gp41 transmembrane subunit (TM protein). This part, also known as 
the fusion-peptide, mediates the fusion between the viral and host membranes.  
After fusion of the two membranes, the viral core enters the cytoplasm and 
undergoes uncoating thereby the single-stranded RNA is released and converted into 
double stranded DNA by the viral reverse transcriptase enzyme. The newly formed 
DNA copies, called proviruses, are then actively transferred to the nucleus of the host 
cell where the viral enzyme integrase (IN) inserts the proviral DNA into an active part 
of the host genome. The LTRs flanking the proviral DNA contain enhancer and 
promoter sequences, with binding sites for several transcription factors and a 
polyadenylation signal. In productively infected host cells, the proviral genome is 
transcribed into mRNA and translated into proteins. Then, viral assembly takes place 
and virus particles are released from the host. After virus budding from the surface, 
maturation of the virus particle proceeds. Gag and Gag-Pol polyproteins are 
proteolytically cleaved by the protease. Cleavage of Gag results in MA (matrix), CA 
(capsid) and NC (nucleocapsid). Cleavage of the Gag-Pol polyproteins, which are 
generated by ribosomal frameshifting during translation of unspliced RNA, results in 
the enzymatic proteins IN, RT and PR. After maturation the virus is ready for another 
round of infection (reviewed in (35, 69, 97, 107).  
 
5.3 Overview of antiretroviral drugs 
 
So far, 26 single or combination preparations from five classes of drugs are available: 
nucleoside and nucleotide analogs (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors and integrase inhibitors 
(INs) (143).  
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Nucleoside analogues target the HIV-1 enzyme reverse transcriptase and act as 
alternative substrates, thereby competing with physiological nucleotides and inducing 
the abortion of DNA synthesis, as phosphodiester bridges can no longer be built to 
stabilize the double strand. AZT and 4dT are thymidine analogs, while FTC and 3TC 
are cytidine analogs; ddI is an inosine analog, which is converted to 
dideoxyadenosine; and abacavir is a guanosine analog. There is a high degree of 
cross-resistance between nucleoside analogues (54). A classical ART regime has 
always nucleoside/nucleotide analogues as a “backbone”. Today the most important 
ones are TDF+3TC and 3TC+ABC in developed countries (reviewed in (59)). 
As with NRTIs, the target enzyme of NNRTIs is RT, however, they bind directly and 
non-competitively to the enzyme. The resulting complex blocks the catalyst activated 
binding site of RT. Not only is the risk of resistance high, it can also develop very 
rapidly. One point mutation (K103N) of the binding site is enough for resistance to the 
entire class of first generation NNRTIs. Despite the potential problems with 
resistance, they are extremely effective when combined with NRTIs (reviewed in 
(59)).  
PIs fit exactly into the active enzyme site of the HIV-1 protease thereby preventing 
proteolytic cleavage of the gag-pol polyprotein, which results in non-infectious virus 
particles. There is a considerable degree of cross-resistance between protease 
inhibitors (22). Ritonavir is a very potent inhibitor of the isoenzyme 3A4, a subunit of 
the cytochrome P450 hepatic enzyme system. Inhibition of these gastrointestinal and 
hepatic enzymes allows the most important pharmacokinetic parameters of almost all 
PIs to be significantly increased, or “boosted” (73). 
There are 2 entry inhibitors available so far. T-20 (Enfuvirtide) inhibits fusion of virus 
and cell (reviewed in (99)). Maraviroc (MVC) is a chemokine (C-C motif) receptor 5 
(CCR5) antagonist and selectively inhibits the replication of CCR-5 tropic (R5) HIV-1 
variants via an allosteric mechanism after binding to a transmembrane CCR5 
coreceptor pocket (19). CCR5 antagonists do not display activity against chemokine 
(CXC motif) receptor 4 (CXCR4)-using HIV-1 variants. As a consequence, the 
presence of detectable X4 or R5/X4 dual-tropic viruses, either as dominant strains or 
as mixtures of CCR5 and CXCR4-using strains, has been associated with treatment 
failure (30). Evaluation of HIV-1 tropism is therefore necessarily before treatment 
initiation with MVC. 
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5.4 History of ART 
 
In retrospect, the history of ART can be divided into four phases. The first phase 
started in 1987, when the NRTI AZT became available. Other nucleoside analogs 
followed a few years later. Administered as mono or dual therapy, those drugs did not 
seem to provide durable efficacy and had a modest impact on disease progression 
and mortality of HIV-1 infected patients (80). 
The first phase ended in 1996, when the drug class of PIs was introduced (48). At 
around the same time, it became apparent that a “cocktail” of several drugs 
simultaneously yielded a much better and more durable response (figure 10) (47). 
Treatment guidelines recommended ART as a combination of three drugs from two 
classes (2 NRTI and 1 PI). Subsequently, morbidity and mortality declined 
enormously among patients on combination ART (cART) (100). 
With increasing knowledge of side effects of ART many treatment recommendations 
were revised. Instead of “hit hard and early”, it changed to “hit HIV hard, but only 
when necessary” (49).  
Nowadays, the pattern of ART initiation is changing again towards earlier treatment. 
2010 recommendations of the international AIDS society - USA panel suggest ART 
for asymptomatic patients with CD4 cell count ≤500/μl, for all symptomatic patients, 
and those with specific conditions and comorbidities. ART should be considered for 
asymptomatic patients with CD4 cell count >500/ μl (140). However, the question of 
“when to start?” is still under debate and will be discussed in the next paragraph. 
 
 
Figure 10: History of ART (adapted from SHCS). 
This graph illustrates the increasing use of multiple (i.e. triple or more than 3 drugs) combinations 
therapies in the Swiss HIV Cohort study (SHCS) since 1996 (135). 
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5.5 Clinical management of acute HIV-1 infection 
 
The optimal clinical management of primary HIV-1 infection (PHI) to date is not 
known. There are several potential benefits and disadvantages of initiating ART 
during PHI (early ART).  
Early ART can have a positive effect on disease markers (40, 57, 58, 70, 101, 129), 
but whether this has long-lasting clinical significance remains unclear. Viral setpoint 
establishes within the first 6 months after infection and is prognostic of disease 
progression. Early ART reduced the viral setpoint after cessation of ART in some 
studies (39, 139). But it is not known how long the effect lasts. In the ZPHI study it 
looks like the initial benefit after approximately 1 year is lost after 2-3 years 
(unpublished data; vonWyl, Günthard).  
The acute retroviral syndrome (ARS) is characterized among others by 
mononucleosis-like symptoms, typically lasting 2 weeks but potentially continuing for 
≥ 10 weeks (127). Early ART can suppress viremia, thereby lessening direct viral 
effects.  
CD4+ T cell depletion in the gut occurs very early after infection and is a crucial event 
in the pathogenesis of HIV-1 infection (88, 148). The relationship between early ART 
and preservation of gut associated T lymphocyte depletion is under debate (50, 89, 
128, 149).  
There is an estimated more than 10-fold increased risk of transmission during the 
PHI compared to the chronic stage of HIV-1 infection (60, 154). In addition, genetic 
analyses linked between 5 and 50% of new infections to sequences obtained from 
other patients during PHI (15, 82). Therefore early ART has gained increased 
attention as a prevention method.  
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6. Factors associated with increased infectiousness and susceptibility 
 
HIV-1-associated morbidity and mortality have declined among patients with access 
to ART (29). However, this success was not matched by similar reductions in HIV-1 
transmission. Current data even suggest a recent increase in HIV-1 diagnoses in 
resource-rich settings, particularly among MSM (7, 32, 86). The reasons for this 
phenomenon may be intricate. The introduction of cART in 1996 has completely 
changed the HIV-1 epidemic (figure 10). HIV-1 infection was no longer a sentence of 
death but rather a manageable chronic disease. In response to the beneficial effects, 
sexual risk behavior and other sexually transmitted infections (STIs) increased 
among MSM (142). Due to “condom fatigue” and lack of availability of an effective 
vaccine or microbicide within a reasonable timeframe there is a need for re-
examination of the approach to control this virus.  
The infectiousness of HIV-1 in male genital fluid together with the susceptibility of the 
host, the type of sexual practice, and the viral load are most likely major determinants 
of sexual transmission. The risk of acquiring HIV-1 is directly correlated with the level 
of virus circulating in the source blood (115, 154). Highly active antiretroviral therapy 
(HAART) reduces viral replication and thus lowers the rate of HIV-1 transmission (41, 
115). The Swiss Federal Commission for HIV/AIDS suggested that seropositive 
individuals, which are on ART with undetectable viral loads for more than 6 months 
and do not have other sexually transmitted diseases, do not transmit HIV-1 (150). 
Although HAART reduces viral loads in both blood and seminal compartments, HIV-1 
RNA can still be detected in seminal fluids (136). Therefore it remains under debate if 
undetectable plasma HIV-1 RNA lowers the risk of viral transmission through seminal 
fluid not only on a population level but also at an individual level. 
Both acute and late stages of HIV-1 infection are associated with high viral loads and, 
therefore, may disproportionately contribute to the spread of the epidemic (15, 108, 
115). The importance of the acute infection period for subsequent transmission 
events is additionally related to the unawareness of the infection and potentially virus-
specific properties that confer fitness for transmission. 
Genotypic antiretroviral resistance testing has become commonplace, resulting in an 
accumulation of HIV-1 pol sequences, forthcoming for adequate phylogenetic 
reconstruction of transmission events (63). Various studies using diverse methods 
suggest that 5-50% of incident cases are acquired from newly infected individuals 
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(15, 60, 111, 154). Various definitions of acute phase, difficulties in the estimation of 
exact infection date and neglecting the transient nature of the acute stage may 
produce such varying results (16). Altogether, the success of “treatment as 
prevention” is highly dependent on the understanding of the transmission dynamics 
and necessity of identifying and characterizing of the source patient.  
STIs greatly increase the efficiency of HIV-1 transmission by increasing both the 
infectiousness of, and the susceptibility to HIV infection. STIs can be divided into four 
categories: those that produce no mucosal signs or symptoms (e.g. HIV, hepatitis B); 
those that produce mucosal inflammation (e.g. Neisseria gonorrhoeae, Chlamydia 
trachomatis); those that produce genital ulcers (e.g. herpes simplex virus (HSV) 1 
and 2); and those that cause epithelial changes (e.g. human papillomavirus). STIs 
that cause ulcers generally increase shedding of HIV in the genital tract and can also 
affect HIV levels in semen (reviewed in (33)). STIs that cause inflammation increase 
the concentration of HIV in semen (140) and cervical fluids (38). There are several 
possible mechanisms for the increased risk of acquiring HIV-1 that is seen in 
individuals with STIs. The main target cells for HIV-1 are CD4+ cells immediately 
below the epithelial layer (44) that are rendered accessible by breakdown in the 
mucosal integrity by STIs (94). Both, ulcerative and non-ulcerative diseases lead to 
cellular infiltration to the site of infection, increasing the potential target cells for HIV 
infection (24). In addition, cervical CCR5 expression is increased in woman with STIs 
(105).  
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7. Diagnosis of HIV-1 
 
Early diagnosis during the critical stages of PHI represents a tremendous opportunity 
for treatment and prevention interventions. However, acutely infected patients are 
difficult to identify. A popular strategy to study persons with PHI is to prospectively 
follow up subjects at high risk for seroconversion, such as MSM, IVDU, sex workers, 
and HIV-discordant couples. The pitfalls of this approach include (1) reduced risk of 
HIV acquisition with safe sex counselling, (2) the cost of following up HIV-negative 
persons, and (3) the difficulty in studying subjects early after transmission. Most 
persons can not be seen more than once a month. Another strategy to detect PHI-
patients is targeted screening of symptomatic PHI. Most individuals who acquire HIV-
1 develop nonspecific signs and symptoms. However, such cohorts have the 
limitation of enrolling patients with a severe ARS, which have a potential for greater 
risk of disease progression (81). Additionally, physicians may recognize an ARS 
within MSM but overlook it in HEX where HIV-1 is less common.  
Additionally, there is no absolute or widely accepted definition of acute and recent 
HIV-1 infection (16). Acquisition of HIV-1 is followed by a series of events that is 
characterised by different patterns of viral antigens and antibody responses and that 
can be used not only for diagnosis but also for staging of the infection (figure 11) 
(31). However, laboratory staging, such as the Fiebig system, is dependent on the 
sensitivity of the used assays, which has markedly improved in the last years. The 
definition is also affected by the variability of viral replication kinetics and the varying 
host immune responses among individuals. A further limitation to the Fiebig staging 
system is that the durations of each stage and diagnostic assays are based mainly 
on clade B HIV-1 infections and viral constituents, respectively (31). 
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Figure 11: Laboratory staging of early HIV-1 infection (adapted from (31)). 
This figure shows the temporal appearance of HIV-1-specific laboratory markers following HIV-1 
infection according to the classification system of Fiebig et al. (31). The eclipse phase is defined by the 
interval between transmission and first detection of viral RNA in the plasma and generally lasts about 
10 days, with a range of approximately 7 to 21 days. There are six stages defined based on laboratory 
markers: stage I (vRNA positive, p24 antigen and antibody negative), stage II (vRNA and p24 antigen 
positive, antibody negative), stage III (ELISA antibody positive, Western blot negative), stage IV 
(ELISA positive, Western blot indeterminant), stage V (ELISA and Western blot positive, p31 integrase 
antibody negative), and stage VI (ELISA, Western blot, and p31 integrase antibody positive). The 
mean durations of Fiebig stages I (7 days), II (5 days), III (3 days), IV (6 days), and V/VI (70+ days) 
are indicated.  
Reprinted by permission from (31). 
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Detection of viral RNA 
 
Viral load is defined as the level of HIV-1 RNA copies/ml of plasma. The documented 
association between the numbers of HIV-1 virions in the blood during the 
asymptomatic phase, referred to as viral setpoint, and the clinical course of infection 
has led to the use of molecular tests (figure 12) as the standard of care for treating 
patients in developed settings (91). The utility of molecular detection of HIV-1 RNA in 
body fluids and tissue has increased especially for monitoring patients on ART. 
Additionally, viral load testing has provided valuable information about the risk of 
transmission, and it can be used to diagnose HIV-1 prior to seroconversion. While 
genetic variability has a limited impact on serologic detection of HIV-1, molecular 
diagnostic assays have been more challenging (103). While primers are relatively 
forgiving in respect to target variation (21), as little as one mismatch in a fluorescent 
hydrolysis (FH-probes; TaqMan® -probes) probe’s target sequence can greatly 
perturb the results of quantitative PCR by underestimating copy numbers (26).  
Introduction 
35 
 
 
Figure 12. Schematic illustration of TaqMan® technology for viral genome quantification 
(adapted from(153)).  
The TaqMan®-probe is a dual labeled DNA sequence of a short nucleotide stretch, with a 
fluorescence reporter at the 5’ end and a quencher at the 3’ end. Due to the proximity of them, the 
fluorescence emitted by the reporter is suppressed by the quencher. A) During amplification, a 
TaqMan®-probe binding to the DNA template is digested by DNA polymerase, releasing fluorescence. 
B) Six external standards are amplified with an unknown sample in parallel. When the fluorescence 
exceeds the background signal, the cycle number of PCR is recorded and used for quantification. C) 
The more HIV-1 RNA in a sample, the earlier the fluorescence exceeds the background and the lower 
the cycle threshold (Ct) values are. The viral load of the unknown sample is indicated by the green 
cross. 
Reprinted from (153) copyright (2010) with permission from Elsevier. 
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8. ZPHI-study 
 
Figure 13: Schematic outline of the ZPHI-study 
Newly diagnosed patients who present with a documented acute or recent HIV-infection are enrolled. 
Acute is defined as: 
- an acute retroviral syndrome (ARS) (3) and negative or indeterminate Westernblot (Wb) in the 
presence of a positive p24 Ag and or detectable plasma HIV-1 RNA.  
- documented seroconversion with or without symptoms within 90 days 
A recent infection is definded as: 
- possible ARS, positive Wb and detectable HIV-RNA, and a negative HIV-gp120 avidity (13, 117), 
respectively detuned assay(63) 
- documented acute infection, however, referral to our center more than 90 days after estimated date 
of infection 
 
The Zurich primary HIV infection (ZPHI)-study enrols and longitudinally follows 
patients with documented primary HIV infection (http://clinicaltrials.gov). This is an 
open label, non-randomized, observational monocenter study at the University 
Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology, which 
started in 2002. Patients are offered early ART if treatment starts within 90 days after 
HIV-1 infection. After one year of suppressed HIV-plasma viremia (<50 copies/ml) 
patients can choose to continue early ART or switch to the observational arm (figure 
13). The primary aims of the study are to describe the epidemiology, test the effect of 
early ART, investigate early events of host-virus interactions, search for host and viral 
factors which are associated with HIV-1 transmission and influencing viral setpoint. 
The ZPHI-study includes around 55% of all primary HIV-1 infected MSM in the 
canton Zurich and is therefore representative for this transmission group.  
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9. SHCS-study 
 
The Swiss HIV Cohort study (SHCS) was already established in 1988 and some data 
going back to 1985 have been collected retrospectively. It is an ongoing multicenter, 
prospective observational study for interdisciplinary HIV research in clinical, 
translational, basic, epidemiological, and social sciences. The data collection is 
strictly anonymous and written informed consent is mandatory for inclusion and also 
for patient genetic analysis. Today the SHCS includes HIV infected individuals aged 
≥ 18 years and is estimated to cover around 51% of the cumulative number of HIV 
infections and 68% of people living with AIDS in Switzerland (www.shcs.ch). In the 
SHCS, a standardized protocol is used for data sampling. Socio-demographic and 
behavioural data are collected and various serological laboratory tests are routinely 
performed at enrolment. At each semi-annual follow-up visit laboratory, clinical data 
and ART is documented in detail. Moreover, in the SHCS plasma/serum samples 
(twice a year) and viable cells/cells pellets (once a year) are stored and available for 
research purposes (131). 
The Swiss HIV Cohort Study drug resistance database is a recent extension of the 
SHCS (149). Genotypic drug resistance testing has been performed routinely in 
Switzerland since the year 2000 and all tests are entered into a central database 
(Integrated Database Network System, IDNS (SmartGene, Zug, Switzerland)).  
According to the guidelines, drug resistance testing is recommended prior to initiation 
of ART and following a viral rebound on therapy (53). For research purposes 
genotypic drug resistance testing is also performed retrospectively with frozen 
samples. In the SHCS, one third of samples was tested at baseline, 30% have 
received resistance testing after initiation of ART and 27% of all patients ever 
enrolled in the SHCS have never been tested due to loss of follow-up or death 
(vonWyl, unpublished data). 
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10. Methods to characterize viral genomes 
 
HIV-1 exists as an evolving population in infected individuals. There are several 
techniques to characterize the variants making up a viral population each with its own 
assets and drawbacks.   
 
Heteroduplex tracking assay (HTA) 
 
The migration of a discrete double-stranded DNA molecule through a non-denaturing 
electrophoretic gel is influenced by the degree of base-pairing of the double helix. 
DNA molecules with exactly complementary single strands run more quickly than 
identically sized DNA strands with mismatched bases. Also, an insertion or deletion 
in one strand causes a perturbation in the mobility of the molecule within the gel 
matrix. A genotype can be assigned on the basis of the separation of the 
homoduplexes and heteroduplexes by electrophoresis (27). This avoids the need for 
extensive sequencing but has the pitfall that no sequences are available for further 
analysis. Therefore, this technique will not be discussed further in this thesis. 
 
Cloning and sequencing  
 
The most common practice to obtain multiple sequences is by performing RT-PCR 
on a region of the viral genome, cloning the amplified products into a vector, and 
randomly selecting a number of clones for sequencing.  
If the number of RT-PCR templates is low, it is unlikely that all sequences 
subsequently obtained by cloning will be derived from different input templates 
resulting in re-sampling of individual genomes in the population. However, a previous 
study in our laboratory revealed that there was no correlation between viral diversity 
and plasma HIV RNA (68). Thus, no evidence was found that low viral diversity was 
due to low input of HIV RNA. Because primer DNA sequences used in PCR are pre-
defined, PCR imposes a selection which may underestimate actual intra-patient 
diversity (84). Contrarily, PCR-based recombination has been observed, generating 
additional diversity (84). Nucleotide misincorporation during generation of cDNA by 
error prone reverse transcriptase results in overestimation of viral diversity. In 
addition the amplicon will contain Taq-induced nucleotide misincorporations as it is 
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molecularly cloned prior to sequencing . However, the average misincorporation rate 
is very low (0.18%) (68).  
 
Single genome sequencing (SGS) 
 
Single genome sequencing (SGS) permits individual cDNA molecules to be PCR 
amplified and sequenced in bulk. This technique eliminates re-sampling of multiple 
clones from the same initial template and in principal the effects of PCR-based 
recombination (125). However, we found that by producing full length env sequences, 
fragments are generated during RT-PCR, which are able to recombine during further 
amplification steps (unpublished data, P. Rieder). To avoid Taq polymerase errors 
and amplification from more than one template, sequences with “double peaks” in the 
chromatogram has to be excluded (71). This reduces the error rate due to PCR and 
the effects of PCR-based recombination, but elevates the effort dramatically.   
 
Ultradeep sequencing 
 
The automated Sanger method is considered as a “first generation” technology, and 
newer methods are referred to as next-generation sequencing (NGS) including 
ultradeep sequencing. Currently, 5 NGS platforms are commercially available, 
Roche/454 life science, Illumina/Solexa, Applied Biosystems/SOLiD, Life/APG and 
Helicos BioSciences. NGS platforms share a common technological feature, 
massively parallel sequencing of clonally amplified or single DNA molecules that are 
spatially separated in a flow cell. The major advance offered by NGS is the ability to 
produce an enormous volume of data cheaply.  
The 454 technology (www.454.com) is derived from the technological convergence of 
pyrosequencing and emulsion PCR (reviewed in (92)). Ultra deep sequencing is a 
new field which is largely being enabled through 454 Sequencing technology. This 
method is designed to allow mutations to be detected at extremely low levels.  
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11. Tests to evaluate HIV-1 coreceptor tropism 
 
Determination of HIV-1 coreceptor usage (figure 7) is becoming a crucial step for 
optimal therapy with drugs aimed to block the interaction of the virus with CCR5 
receptors (155). There are different methodologies to determine the ability of the 
virus to use one or both coreceptors.  
 
Phenotypic assays to predict HIV-1 coreceptor usage 
 
Original HIV-1 phenotypic classifications used the ability of the virus to cause or not 
to cause syncytia in cell cultures. MT-2 cells, are used to differentiate between 
syncytium-inducing (SI) and nonsyncytium-inducing (NSI) HIV-1 variants (65). MT-2 
cell lines express CXCR4 but not CCR5 on the cell surface and indicate the presence 
(SI) or absence (NSI) of X4 viral strains. However, this assay can not determine if 
dual tropic or R5 variants are present.  
More recent methods use HIV-1 isolates to infect reporter cell lines expressing a set 
of specific receptors. One indicator cell line frequently used is GHOST, which is 
derived from human osteosarcoma cells and carries an HIV-1 Tat-inducible GFP 
gene, CD4 receptors and either CCR5 or CXCR4 coreceptors (144).  
Both assays use HIV-1 isolates which have a few important caveats. Standard viral 
isolation procedures require coculturing of the patient’s HIV-1 infected PBMCs with 
PBMCs from HIV-seronegative donors. Extended virus culturing may lead to 
adaptation of the quasispecies to the new environment (145). Small differences in 
HIV-1 isolation protocols may alter the level of coreceptor expression on the cell 
surface (18).  
A viable alternative to the use of HIV-1 isolates involves the use of env-recombinant 
viruses and reporter cell lines expressing CD4 and coreceptors. In the commercially 
available Trofile assay (Monogram Biosciences), the entire env is amplified from 
plasma samples of HIV-infected individuals and cloned into a vector. This vector is 
contransfected into HEK293 cells with an HIV genomic vector carrying a luciferase 
reporter gene instead of env. These pseudotyped replication-defective viruses are 
used to infect U87 cells expressing CD4 and either CCR5 or CXCR4. Coreceptor 
usage is quantified by measuring luciferase activity after a single round of infection 
(158).  
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Genotypic assays to predict viral tropism 
 
The first genotypic algorithm designed to predict HIV-1 tropism took into account only 
the charge of amino acids (AA) at two key residues located within the V3 loop (AA 11 
and 25). But most current genotypic bioinformatic tools consider the entire V3 
sequence (117). Moreover, positions outside the V3 loop may influence viral tropism 
as well (104). However, most genotypic predictors have been designed based on 
HIV-1 clade B sequences (112, 138). Bioinformatic methods that use sequence 
directly the sequence are cheap and fast, because sequencing has become a routine 
task in biotechnology. 
Today, bioinformatic tools use machine-learning methods to classify the virus with 
respect to its coreceptor usage, such as support vector machines (SVM) (110, 137) 
or position-specific scoring matrices (PSSM) (66). The PSSM method assigns a 
score based on the similarity of sequence to known X4 V3 sequences at each AA 
site, effectively weighted by the site’s ability to discriminate between the two 
phenotypes. The higher the score, the more likely it is that a V3 sequence comes 
from an X4 strain. Dual-tropic viruses, thought to be evolutionary intermediates 
between R5 and X4 virus (23), are also intermediate in PSSM score (67). A support 
vector machine (SVM) is used for classification and regression analysis. A SVM 
takes a set of input data and predicts, for each given input, to which of two possible 
classes the input belongs. SVM uses a set of training examples for classification so 
that the separate categories are divided by a clear gap that is as wide as possible. 
 
12. Phylogenetic tree 
 
Evolutionary relationships among genes can be illustrated by a phylogenetic tree, 
comparable to a pedigree showing which genes are most closely related. Terminal 
nodes are the extant taxa or viral strains, whereas internal nodes are the hypothetical 
progenitors. A group of taxa that belong to the same branch have a monophyletic 
origin and is called a cluster.  
Reconstructing phylogeny results in an inferred phylogenetic tree, which may or may 
not differ from the true phylogenetic tree. There are no uniquely correct methods for 
inferring phylogenies, and many methods are used. The methods can be grouped 
first according to whether the method uses discrete character states or a distance 
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matrix of pairwise dissimilarities, and second according to whether the method 
clusters extant taxa stepwise, resulting in only one best tree, or considers all 
theoretically possible trees (exhaustive search). The majority of distance-matrix 
methods use stepwise clustering to compute the best tree, whereas most character-
state methods adopt the exhaustive-search approach. 
Maximum likelihood (ML) examines every reasonable tree topology and evaluates 
the support for each by examining every sequence position. In principle, the ML 
algorithm calculates the probability of expecting each possible nucleotide in the 
internal nodes and infers the likelihood of the tree structure from these probabilities. 
The likelihood of all reasonable tree topologies is searched in this way, and the most 
likely tree is chosen as the best tree. The ML method is complex and computationally 
demanding (126). 
Neighbor-joining (NJ) is based on the minimum-evolution criterion, i.e. the topology 
that minimizes the length of all internal branches and thus the length of the entire 
tree. However, neighbor-joining may not find the true tree topology with least total 
branch length because it is a greedy algorithm that constructs the tree in a step-wise 
fashion. Even though it is sub-optimal in this sense, it often identifies trees that are 
quite close to the optimal tree. The main virtue of neighbor-joining relative to these 
other methods is its computational efficiency (126). 
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Abstract 
 
Background. In the context of sexual transmission of human 
immunodeficiency virus type 1 (HIV-1) current findings suggest that the 
mucosal barrier is the major site of viral selection transforming the complex 
inoculum to a small, homogeneous founder virus population. We analyzed HIV-
1 transmission in relation to viral and host characteristics within the Zurich 
primary HIV-1 infection (ZPHI)–study. 
 
Methods. Clonal HIV-1 envelope sequences (on average 16 clones/patient) were 
isolated from the first available plasma samples during the early phase of 
infection from 145 patients with primary HIV-1 infection (PHI). Phylogenetic and 
tropism analyses were performed. Differences of viral diversities were 
investigated in association with several parameters potentially influencing HIV-
1 transmission, e.g., concomitant sexually transmitted infections (STI) and 
mode of transmission. 
 
Results. Median viral diversity within env C2-V3-C3 region was 0.39% (range 
0.04-3.23%). Viral diversity did not correlate with viral load, but it was slightly 
correlated with the duration of infection. Neither transmission mode, gender, 
nor STI predicted transmission of more heterogeneous founder virus 
populations that were found in 16/145 patients (11%; diversity >1%). Only two 
patients (1.4%) was assuredly infected with CXCR4-tropic HIV-1 within a R5/X4-
tropic mixed population as revealed and confirmed using several genotypic 
prediction algorithms and phenotypic assays.  
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Conclusions: Our findings suggest that transmission of multiple HIV-1 variants 
might be a complex process not dependent on mucosal factors alone. CXCR4-
tropic viruses can be sexually transmitted in rare instances, but their clinical 
relevance remains to be determined. 
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INTRODUCTION 
The extensive genetic diversity of HIV-1 is a tremendous challenge regarding the 
development of broadly effective vaccines and also for antiretroviral treatment. The 
genetic bottleneck during HIV-1 transmission may be an Achilles heel of HIV-1 [1]. 
The mucosal barrier could be a key factor in driving the genetically complex viral 
inoculum to a homogeneous founder population. The impact of the mucosal barrier 
may depend on the anatomy, physiology, concurrent sexual transmitted infections 
(STI), and sexual practice [2-4]. However, a genetic bottleneck has also been 
observed in intravenous drug users (IVDU) indicating mechanisms independent of 
the mucosa [3, 5].  
During transmission, there is also strong selection for viral variants using CCR5 as a 
co-receptor [6, 7]. In depth characterization of HIV-1 tropism in larger groups of 
patients during primary HIV-1 infection (PHI) is needed to revisit recent work 
reporting varying frequencies of CXCR4-tropic strains during PHI [8-10]. Such data is 
of particular importance, because CCR5 antagonists are approved for clinical use 
mainly in salvage treatment [11, 12].  
Here, we analyzed the complexity of virus populations within the C2-V3-C3 region of 
the HIV-1 envelope in 145 acutely and recently infected ZPHI-study patients [13-17] 
belonging to different transmission groups and infected with various viral subtypes. 
We investigated viral and host characteristics associated with elevated viral diversity 
and co-receptor tropism.  
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MATERIALS AND METHODS 
 
Patient characteristics  
Patients were enrolled in the Zurich Primary HIV-1 Infection study (ZPHI, 
http://clinicaltrials.gov, ID=NCT00537966) [13-17]. Acute/recent PHI was confirmed in 
all patients according to previously published definitions [15]. We estimated a date of 
infection for each patient by integrating all available clinical and laboratory data [15, 
18]. During the first visit, each patient was checked for symptoms and physical signs 
of concurrent STIs and serology for syphilis. When dysuria, genital ulcers, groin, 
and/or rectal pain was present, urine and/or rectal swabs were subjected to PCR 
analysis for Neisseria gonorrhoeae, Chlamydia trachomatis (when positive, specific 
PCR for lymphogranuloma venereum associated L-serovars was performed), and 
Herpes simplex. 
 
Sequencing 
RNA extraction, amplification, cloning, and sequencing of HIV-1 env C2–V3–C3 
fragments were performed according to [15] by modification of previously described 
methods [19, 20].  
 
Genotypic prediction of HIV-1 co-receptor usage 
V3-loop sequences were interpreted by three different genotypic prediction tools: 1) 
Web-PSSM (http://indra.mullins.microbiol.washington.edu/webpssm/), 2) Wetcat 
(http://genomiac2.ucsd.edu:8080/wetcat/v3.html), and 3) geno2pheno[coreceptor] [7] 
(http://coreceptor.bioinf.mpi-inf.mpg.de/index.php). We used geno2pheno[coreceptor] 
with a false-positive rate of 5.75% [21]. Wetcat analysis is based on SVM classifier. 
Chapter 1 
63 
PSSM predictions were performed by HIV-1 subtype B and C sinsi matrices for all 
non-C subtypes and clade C, respectively.  
 
Phenotyping assays 
The cell lines MT-2 (D. Richman [22]), GHOST Parental Cell Line, and GHOST Cell 
Transfectants GHOST CXCR4 and Hi-5 (VN. KewalRamani and DR. Littman [23]) 
were obtained through the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH. Syncytium-inducing (SI) phenotypes were determined 
in MT-2 cell culture assays [24]. If available, primary isolates derived from both, 
plasma and PBMCs, were tested. In addition, GHOST cell lines expressing either 
CCR5 or CXCR4 and CD4 or CD4 alone were used to determine co-receptor usage. 
Cells were infected with primary virus isolates of each patient at MOI=0.06 
(multiplicity of infection). Expression of GFP under control of the HIV-2 long terminal 
repeat promoter was detected by fluorescence microscopy [25].  
 
Phylogenetic analyses 
Sequences were edited with SeqMan-5.08 software (DNASTAR Inc., Madison, WI), 
aligned with MAFFT-6.240 [26, 27], manually corrected, and tested for 
hypermutations by Hypermut 2.0 (www.hiv.lanl.gov). Molecular evolutionary analyses 
were conducted using MEGA-4 [28]. Neighbour joining phylogenetic trees were 
constructed by MEGA-4 as well as seqboot, dnadist, and ‘neighbour and consense’ 
(PHYLIP-3.68, distributed by J. Felsenstein). The reference strain HIV-1HXB2 
(GenBank accession no. K03455) and other B and non-B strains were used as 
outgroup references and bootstrapping (1,000 or 100 replications with MEGA-4 and 
PHYLIP-3.68, respectively). Pol sequences were obtained from the Swiss HIV Cohort 
study (SHCS) drug resistance database [29]. Pairwise distances were computed by 
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using MEGA-4 [28]. Nucleotide diversities were obtained using the Tamura-Nei 
model. All reported sequences have been deposited in GenBank under accession 
numbers GU471280 to GU471390, GU471407 to GU471578 and JF958169 to 
JF960135. 
 
Statistical Analyses 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad 
Software, San Diego, CA) and STATA 11 SE (StataCorp, College Station, TX). 
Nonparametric tests were used for group comparison (Mann-Whitney test). Multiple 
linear regression was used to analyze the association of viral diversity with viral and 
host baseline characteristics. The following variables were considered in the model: 
Age, sex, transmission category, STI, antiretroviral syndrome (ARS), viral load, CD4-
cell count, viral subtype, and estimated date of infection (EDI). 
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RESULTS 
 
Patient characteristics 
We analyzed 145 patients comprising 131 males and 14 females who were enrolled 
in the ongoing ZPHI-study (table 1). The modes of transmission according to 
patients’ statements included homosexual (73%), heterosexual (22%), bisexual (2%), 
IVDU (1.4%), and others (1.4%). Concomitant STIs have been diagnosed in 20 
patients (14%). HIV-1 subtype B was most prevalent (80%) followed by CRF01_AE 
(9%), C (3%), and A (3%). The remaining 5% of patients were infected with HIV-1 
subtypes F1, G, CRF02_AG, and CFR12_BF. 
125 patients were diagnosed during documented acute HIV-1 infection. Of those, 120 
patients (96%) had an acute retroviral syndrome (ARS) [13] and 87 (70%) had a 
negative or indeterminate Western blot (WB). Recent infection was diagnosed in 20 
patients. Baseline blood samples were available within a median of 6 weeks (range 
2-18) after estimated date of infection (EDI) in acute and within 12 (range 7-24) 
weeks in recently infected patients. Fiebig staging [30] was possible for 117 patients: 
2 patients were assigned to stage II, 14 patients to stage III, 52 patients to stage IV, 
20 patients to stage V, 19 patients to stage V/VI, and 10 patients to stage VI. 
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Table 1. Baseline characteristics of 145 patients with primary HIV-1 infection  
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Phylogenetic reconstruction 
Neighbour joining phylogenetic (NJ) trees containing clonal C2-V3-C3 sequences 
from 113 (78%) patients formed individual clusters with bootstrap-values of 100%. 
Clusters with bootstrap-values <100% were found in 32 patients, most of whom 
harboured also closely related pol sequences (median genetic distance 0.0062; 
range 0–0.0124) except for 4 patients forming 2 clusters. Possible contamination was 
ruled out by analyzing an independent sample from each of these 4 patients. 
Sequences from all patients showed no clustering with reference clones used in our 
laboratory. 
 
Validity of viral diversity at baseline 
In total, 2268 clones (median 16 clones/patient; range 10-16) spanning C2-V3-C3 
region of the env gene were derived from plasma HIV-1 RNA of 145 PHI-patients 
early after transmission (median 6 weeks, range 2-24). The baseline viral diversities 
ranged from 0.04% to 3.23% (median 0.39%). To obtain representative samples of 
quasispecies, RT-PCR was performed in duplicate using HIV-1 RNA extracts from 
1ml plasma. The viral load of the plasma samples ranged from 2.4-7.6 (median 5.3) 
log10 copies/ml. Despite this broad distribution, viral loads and nucleotide diversities 
were not correlated (figure 1). The viral loads of ten patients were <5’000 copies/ml, 
however, viral diversities (median 0.44%; range 0.11-1.25%) were similar to patients 
with high viral loads (p=0.662). Thus, the sequenced clones were representative of 
the actual plasma virus populations in vivo as shown before in chronically infected 
patients [20]. Additionally, single genome amplification (SGA, median 12 
sequences/sample) was performed in a subset of 25 patients and the resulting viral 
diversities correlated well with clonal sequencing (slope=1.05, intercept=-0.28%, 
r2=0.681; data not shown). The viral diversities increased slightly with time since EDI 
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(EDI was described in previous published methods [15, 18]) (figure 2) supporting the 
reliability of the used EDI calculation. As also shown in figure 2, negative WBs have 
been detected up to 10 weeks and positive WBs between 4 and 24 weeks after EDI 
demonstrating the need to include clinical data into the diagnostic staging process. 
 
 
 
 
Figure 1. Relationship between plasma viral load and viral diversity during primary HIV-1 infection. 
Plasma viral load of the first available sample and the corresponding viral nucleotide sequence 
diversity observed in the C2-V3-C3 region of the envelope gene in 10 to 16 clones per patient is 
shown. 145 patients have been analyzed. Each dot represents one patient. The relationship between 
viral diversity and viral load is shown by linear regression (p=0.109; slope=-0.299±0.185; r2=0.018). 
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Figure 2. Relationship between viral diversity during primary HIV-1 infection and estimated duration of 
infection. For each of the 145 patients, the duration between estimated date of infection and first 
available sample and the corresponding viral diversity observed in the C2-V3-C3 region of the 
envelope gene in 10 to 16 clones is shown. The duration of infection has been estimated integrating 
all available information including patient history relating to known risk situations, occurrence of first 
symptoms, previous negative test results, avidity assays, and Western blot. The median viral 
diversities increased slightly with longer time intervals between infection and sample collection 
(slope=0.024±0.009; p=0.015; r2=0.041). Negative Western blots (WBs) were detected up to 10 weeks 
and positive WBs between 4 and 24 weeks of EDI, respectively. Neg WB, negative Western blot; indet 
WB, indeterminate Western blot; pos WB, positive Western blot; n/a, not available. 
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Viral diversity in relation to host and viral characteristics  
In our study population the median viral diversity shortly after transmission did not 
deviate between different sexual transmission categories (figure 3A). Twenty 
patients, including 1 female, 5 MSF (men having sex with females), and 14 MSM 
(men having sex with men), were diagnosed with a concomitant STI, but their median 
viral diversity did not deviate from those without concomitant STI (p=0.703, Fig. 3B). 
Next, we analysed in more detail the relation between diversity and transmission 
mode among MSM depending on the encountered mucosa. Analyzed sexual 
practises were insertive anal intercourse (iai), receptive anal intercourse (rai), and 
unsafe oral intercourse (oral). Patients practising various sexual activities or with 
unknown transmission route were excluded from this analysis. No significant 
differences between distinct transmission modes were observed (figure 3C).  
We also derived the viral subtypes from individual pol sequences to examine their 
possible effect on diversity (figure 4). Four patients have been infected with HIV-1 
subtype C. They showed a median viral diversity of 1.07% (range 0.54-1.89%) which 
significantly deviated from those observed in HIV-1 subtype B (p=0.011). In addition, 
no association between viral diversity and viral tropism was found (for tropism see 
below). Moreover, multiple linear regression testing the association of viral diversity 
with EDI, age, CD4-cell count, viral load, viral subtype, ARS, STI, and transmission 
mode showed no relationship except for EDI (slope=0.031 [95%-CI=0.001-0.061], 
p=0.046, r2=0.151). 
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Figure 3. Influence of transmission characteristics on viral diversity during primary HIV-1 infection. 
Viral diversities observed in the C2-V3-C3 region of the envelope gene in 144 primary HIV-1 infected 
patients are shown grouped according to gender and transmission category in A) (one patient infected 
by either sexual intercourse or needle sharing is not shown), according to the presence or absence of 
a concomitant sexual transmitted infection in B), and within the transmission category “men having sex 
with men (MSM) according to the sexual practice during HIV-1 acquisition in C). In the latter analysis, 
MSM patients with unknown transmission mode or practicing several sexual behaviours were 
excluded from this analysis. Bars indicate medians; MSF, men having sex with females; MSM, men 
having sex with men; w/o STI, without concomitant sexually transmitted infections; STI, with sexually 
transmitted infections; iai, insertive anal intercourse; rai, receptive anal intercourse, oral, unsafe oral 
intercourse. 
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Figure 4. Influence of HIV-1 subtypes on viral diversity during primary HIV-1 infection. Viral diversities 
observed in the C2-V3-C3 region of the envelope gene in 145 primary HIV-1 infected patients are 
shown grouped according to HIV-1 subtypes. Bars indicate medians; CRF, circulating recombinant 
form. 
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Characteristics of patients with high viral diversity 
We identified 16 subjects (11%) with a viral diversity higher than 1% despite a short 
estimated duration of infection (median 7 weeks; range 4-14). Of the 14 males 3 had 
a concomitant STI. One of the heterosexual men was infected either by sexual 
contact or by sharing needles. For detailed patient characteristics see table 2. 
Overall, no patient’s or transmission’s characteristics were overrepresented in the 
group of patients with viral diversity above 1%. These patients were infected with 
HIV-1 subtype A (1/4, 25%), B (12/116, 10%), and C (3/4; 75%).  
Phylogenetic analyses of the C2-V3-C3 region in the 16 patients with viral diversities 
>1% showed 3 different tree patterns. In four patients, a starlike diversification was 
seen whereas in 8 patients the viral clones appeared subdivided into 2 to 4 
subclusters each with diversity below 1% and average genetic distances between 
these intrapatient subgroups of 2.14% (range 1.11-4.37%). In the remaining 4 
patients a mixture of these 2 described patterns was observed including subgroups 
showing viral diversity of more than 1%.  
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Table 2. Baseline characteristics of patients with higher and lower viral 
diversity during primary HIV-1 infection  
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Viral tropism  
Using PSSM, SVMwetcat, and geno2pheno[coreceptor] to predict viral tropism in clonal 
C2-V3-C3 sequences, X4-tropic viruses or R5/X4 mixed populations were predicted 
for 10%, 19%, and 14% of the patients, respectively (table 3). In 102 patients (70%), 
all three prediction algorithms were consistent in predicting R5-tropic viral variants. 
The three bioinformatic tools yielded conflicting co-receptor usage predictions in 27% 
of the patients. In 4 patients (3%) all three tools predicted X4-tropic strains, either as 
a mixed population in three cases or as a pure X4-tropic population in one case. Full 
length env sequences obtained by SGA showed the same quasispecies composition 
and mutation patterns as clonal C2-V3-C3 sequences in these 4 patients (data not 
shown). Next, HIV-1 co-receptor usage was determined by phenotypic assays using 
175 available primary isolates (from 117 patients) derived from plasma and PBMCs 
(Table 4). In a first step, all isolates were screened by the MT-2 cell assay and if X4-
tropism was detected, this was confirmed by the GHOST cell assay allowing also 
differentiation of mixtures respectively of R5/X4 double users. Only in one of the 4 
patients with concordant genotypic X4-tropism prediction and in one patient with 
concordant CCR5-tropism prediction a mixture of R5/X4-tropic viruses was detected 
in the PBMC isolate but not in the isolate obtained from plasma.   
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Table 3. Genotypic prediction of HIV-1 tropism in patients with primary HIV-1 
infection 
 
HIV-1 subtypes
n % n %
number of patients 145 100 114 100
X4 tropism prediction by a
Geno2pheno[coreceptor] b  21 14 13 11
PSSM c             15 10 5 4
SVMwetcat              28 19 24 21
1 of 3 tools predicts X4 tropism 26 18 21 18
2 of 3 tools predict X4 tropism 13 9 6 5
3 of 3 tools predict X4 tropism 4 3 3 3
R5 tropism prediction by 3 tools 102 70 84 74
a X4 or R5/X4 mixed populations
b cutoff 5.75 (Prosperi et al.  Retrovirology 2010, 7:56) 
c using sinsi matrix
all B
 
 
 
Table 4. Phenotypic prediction of HIV-1 tropism of primary HIV-1 isolates 
obtained from plasma and PBMCs of primary HIV-1 infected patients 
 
 
phenotype
number of patients
predicted by 3 algorithms
number of patients
analysed by MT-2 assay
X4 R5 R5/X4
X4 4 4 0 3 (75%) 1 (25%) b
R5 102 83 0 82 (98.8%) 1 (1.2%) c
inconsistent 39 30 0 30 (100%) 0
a Predicted by 3 bioinformatic tools: Geno2pheno, PSSM, SVMwetcat
b Detected in PBMCs with MT-2 and GHOST cell assay
c Detected in PBMCs with MT-2 but not with GHOST cell assay 
genotype a
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DISCUSSION 
 
To investigate the complexity of transmitted HIV-1 populations, we determined viral 
diversity by HIV-1 envelope C2-V3-C3 clonal sequencing and assessed potential 
factors associated with transmission of heterogeneous viral populations in 145 
patients enrolled in a single center primary HIV-1 infection cohort (ZPHI-study). This 
analysis revealed three major findings: 1) heterogeneous virus populations (diversity 
>1%) were found in 11% of all patients. 2) neither concomitant STI, gender, nor 
differences in sexual practices could be identified as factors associated with 
transmission of heterogeneous virus populations. 3) genotypic prediction of co-
receptor tropism by three computational tools unambiguously characterized 
transmitted viruses of 73% of all patients: 70% of patients harboured R5-tropic 
viruses, and 3% (4 patients) were predicted as harbouring X4-tropic, respectively 
R5/X4-tropic viruses. However, in only one of those, CXCR4-usage could be 
confirmed phenotypically. In addition, one patient consistently predicted as 
harbouring R5-tropic viruses showed phenotypically a mixture of R5/X4-tropic 
viruses. Furthermore, results remained genotypically ambiguous in 27%.  
 
Despite various efforts [2-5, 31, 32], factors associated with increased viral 
heterogeneity which is found in approximately 10-20% of PHI-patients have not been 
fully elucidated yet. However, this is not surprising given the difficulties to identify 
large populations of well characterized patients with PHI and the multi-factorial nature 
affecting diversity upon transmission. In particular, interpretation of results may be 
complicated by differences in patient populations with regard to time of sampling after 
infection, by disparities in ethnicity and living environments such as access to health 
care, sanitation conditions, and nutritional status, by potential selection bias of 
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patients enrolled in PHI studies, by uncertainties concerning sexual practices 
adopted, by the lack of knowledge of potential host genetic factors, and finally, by 
different methodologies used to investigate early transmitted viruses.  
 
Our finding of complex HIV-1 populations in 11% of patients is in line with previous 
findings [2], although at a lower range. A likely explanation for these differences 
might be different frequencies of index patients transmitting a homogeneous virus 
population while they are in the acute phase of their HIV-1 infection. Another 
potential explanation is our rather conservative approach when compared to others 
[1] to search for complex viral populations using a cut-off of 1% diversity to 
differentiate homogeneous from heterogeneous transmitted viruses. 
 
In contrast to previous studies [3, 31-33], no elevated complexity of transmitted 
viruses was found in the 20 patients with a concomitant STI during PHI. STIs clearly 
increase the risk of HIV-1 transmission by enhancing infectiousness and 
susceptibility [34]. The lower viral diversity in our patients might be due to the time of 
the transmission of the STI. Ongoing and already established STIs prior to HIV-1 
infection may be of higher importance to render the mucosal barrier more susceptible 
for HIV-1 infection than those transmitted concurrently with HIV-1 or shortly 
thereafter. In our setting, the vast majority of patients reported first occurrence of STI 
symptoms very closely to ARS symptoms suggesting that STIs were co-transmitted 
with HIV-1. In contrast, Haaland et al. reported in their Zambian and Rwandan 
seroconverter patients that symptoms and signs of STIs were already present at the 
time of the last seronegative visit, suggesting that those STIs were present for 
comparatively longer durations, and therefore, mucosa may have been damaged 
more severely at the time of HIV-1 infection [31]. Another difference between cohorts 
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may be the proportion of female sex workers included [4]. In this group, the 
prevalence of STIs and the occurrence of mucosal microtraumata is higher than in 
males or females in general [3, 4, 35]. In our study, no female sex worker was 
participating. 
 
HIV-1 subtype C may be associated with greater propensity for transmission 
possibility than other HIV-1 group M subtypes [34]. In our study the 4 patients 
infected with HIV-1 subtype C showed a higher median viral diversity compared to 
HIV-1 subtype B infected patients (p-value = 0.011). Viral diversity of CRF01_AE and 
other circulating recombinant forms were not significantly lower compared to HIV-1 
subtype B, but none of those patients was infected with a more complex population 
(>1%). Whether higher diversity seen in our HIV-1 subtype C cases is based on HIV-
1 subtype specific viral properties or not cannot be proven at this time. Similar 
diversities found in HIV-1 subtypes B and C in other PHI cohorts question the 
biological relevance of our finding [33]. However, it has to be noted that comparisons 
between those two HIV-1 subtypes were based on different study settings in different 
countries and different centers [33]. Thus, ultimately, only studies of larger patient 
cohorts enrolled under similar conditions will yield an answer to this question.  
 
By combining three different genotypic prediction algorithms we found that 4 PHI-
patients (3%) possibly harboured CXCR4-tropic viruses during acute HIV-1 infection. 
However, in only one of those patients, X4-tropic strains could be confirmed 
phenotypically. In addition, from one patient with consistent R5-coreceptor prediction 
X4-tropic strains could be isolated within a R5/X4 mixture. Thus, in our study 
transmission of relevant replication competent X4 variants seemed to be a rare 
event. These findings are in line with Raymond et al. [8] who reported 6.4% of 
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plasma viruses as X4-tropic respectively R5/X4-tropic mixtures in acutly HIV-1 
infected patients. In contrast, a recent study using ultra-deep sequencing and 
genotypic prediction reported X4-tropic variants in approximately 50% of a small 
number of acutly HIV-1 infected patients studied [9]. Discrepant results are not 
surprising given the methodological difficulties regarding assays, prediction 
algorithms used, studied populations, and sample sizes. At present, the clinical 
relevance of transmitted X4-tropic minority variants is not known, because thresholds 
for frequencies of X4-tropic minority variants to predict maraviroc response during 
PHI are not available [36]. Furthermore, the problem with genotypic prediction is that 
it cannot predict replication competence of these minority species. On the other 
hand, phenotypic assays using primary viral isolates overcome this limitation but may 
lack sensitivity due to initial selection process during their propagation in cell cultures 
[37]. Recombinant phenotypic assays using PCR amplified HIV-1 envelope may have 
an improved sensitivity profile, but they give only information on tropism of single 
envelopes amplified and not on replication competence of these viruses. Taken 
together, despite a considerable amount of previous work [8-10, 38, 39], frequency of 
clinically relevant transmitted CXCR4-using viruses is still not known, but in our study 
transmission of such viruses seemed to occurr only rarely. 
 
In summary, our findings suggest that transmission of complex virus founder 
populations may not depend solely on mucosal factors. In addition, transmission of 
clinically relevant CXCR4-using virus strains seems to remain a rare event and 
caution is warranted predicting co-receptor usage by genotypic algorithms alone, 
because concordance of those tools is still limited. 
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Abstract 
 
Objective: To study transmission dynamics during acute infection, during the 
aviremic phase over the period of early antiretroviral therapy (ART) and during 
the phase of viral rebound after early treatment was stopped.  
 
Methods: Transmission dynamics was assessed within 111 patients, enrolled 
in the Zurich primary HIV infection study, by molecular epidemiological 
methods using pol sequences from genotypic resistance tests and clonal env 
C2–V3–C3 sequences. Coclustering of Zurich primary HIV infection sequences 
with 12 303 sequences from 8837 HIV-positive patients enrolled in the multisite 
Swiss HIV Cohort Study was identified. Furthermore, we investigated 
transmission patterns within phylogenetic clusters by using longitudinal 
clinical data and analyzed HIV transmission by stage of infection and 
attempted to localize transmission events to periods before or after early ART.  
 
Results: Six transmission clusters comprising 20 men having sex with men 
were identified. Furthermore, linkage to eight men having sex with men from 
the Swiss HIV Cohort Study could be established. Strikingly, we detected at 
least five new primary infection events originating from Zurich primary HIV 
infection patients within 16–61 weeks after stopping early ART. Viral loads of 
likely index patients varied from 314 up to 1 690 000 HIV-1 RNA copies/ml of 
plasma at the estimated time of infection.  
 
Conclusion: The large number of new infections originating from men having 
sex with men who stopped early ART indicates that current preventive efforts 
are insufficient. In contrast, these patients showed no adherence problems. 
These findings argue for early, continuous ART in sexually active HIV-1-
infected persons not only for individual patient benefits but also specifically to 
reduce the spread of HIV-1.  
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Introduction  
 
HIV-associated morbidity and mortality have declined among patients with access to 
antiretroviral therapy (ART) [1]. However, this success was not matched by similar 
reductions in HIV transmission. Current data even suggest a recent increase in HIV 
diagnoses in resource-rich settings, particularly among men having sex with men 
(MSM) [2–4]. Both acute and late stages of HIV-1 infection are associated with high 
viral loads and, therefore, may disproportionately contribute to the spread of the 
epidemic [5–7]. In-depth knowledge of the dynamics of HIV-1 transmission within 
specific transmission groups is fundamental to develop effective prevention 
strategies [8,9]. Phylogenetic analysis represents one strategy for investigating 
transmission dynamics between individuals, and occasionally also for forensic use 
[10–13]. Recent studies have used pol sequences generated for drug resistance 
genotyping [5,14–16] to reconstruct transmission histories [17].  
Here, we analyzed transmission networks within 111 well documented patients 
enrolled in the Zurich primary HIV infection (ZPHI) study [18–20] by molecular 
epidemiological data based on two HIV genes. Furthermore, we studied viral genetic 
linkage with persons enrolled in the multicenter Swiss HIV Cohort Study (SHCS), 
which includes data on approximately 50% of all HIV-infected and 75% of all treated 
individuals in the country and thus reaches an otherwise unmatched representativity 
[15,21,22]. For the linkage studies, we used pol sequences from the Swiss HIV drug 
resistance database with additional confirmation through sequencing of clonal HIV 
env C2–V3–C3 fragments. In particular, we sought to identify transmission events in 
the viremic phase during acute infection, the aviremic phase during early ART and 
during the phase of viral rebound after early treatment was stopped.  
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Methods  
 
Our analysis included clinical and genotypic data from the SHCS (for detailed 
description, see Supplemental Digital Content, http://links.lww.com/QAD/A40), a 
clinic-based study with continuous enrolment and at least semiannual visits [23,24]. 
All available HIV pol sequences (12 303) obtained from genotypic resistance tests 
were used for phylogenetic analysis to select candidates for confirmatory env 
sequencing.  
Patients enrolled in the ZPHI study (http://clinicaltrials. gov: NCT00537966) [18–
20,25] presented with documented acute or recent primary HIV-1 infection (for 
definitions and detailed patient characteristics, see Supplement, 
http://links.lww.com/QAD/A40 ). They were offered early ART and could chose after 1 
year successful treatment (viral load <50 copies/ml plasma) to stop it. Blood samples 
were collected at the time of enrolment and sequentially in at least 3-month intervals. 
The studies complied with the principles of the Declaration of Helsinki and the 
guidelines of the local ethical committee. Written informed consent was obtained 
from all participants. Patient data were anonymized for all analyses.  
For each patient, a minimal and maximal timepoint of infection was estimated 
integrating all available information, including patient history relating to known risk 
situations, occurrence of first symptoms, previous negative test results, avidity 
assays and western blot. This conjectured time after infection (mean of upper and 
lower-bound estimates) was positively correlated with env diversity (r 
2 
= 0.07, P = 
0.05). Transmission dates were also used to calculate cluster-specific infection rates 
(for detailed algorithms, see Supplement, http://links.lww. com/QAD/A40).  
RNA extraction, amplification, cloning and sequencing of HIV-1 env C2–V3–C3 
fragments was performed by modification of previously described methods [26,27] 
(for detailed description, see Supplement, http://links. lww.com/QAD/A40). 
Sequences were edited and aligned with SeqMan (DNASTAR Inc., Madison, 
Wisconsin, USA). Alignments were refined with MAFFT [28] and manually adjusted. 
Genetic distance estimates were obtained by Molecular Evolutionary Genetics 
Analysis software [29] using the Tamura–Nei model. Neighbor-joining phylogenetic 
trees were constructed using HXB2 and Non-B strains as references and 
bootstrapping (1000 replications). Maximum-likelihood trees were inferred by the 
DNA Maximum Likelihood program using randomized input order, global 
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rearrangements and multiple jumble options (PHYLIP3.6, distributed by J. 
Felsenstein). The reported env sequences were deposited in GenBank under 
accession numbers GU471280–GU471687.  
Statistical analyses were performed using Prism5 (Graph-Pad Software, San Diego, 
California, USA) and Stata10.1 (Stata Corp., College Station, Texas, USA). 
Nonparametric tests (Mann–Whitney) were used for group comparison.  
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Results  
 
We analyzed patients enrolled in the ZPHI study before December 2007. One 
hundred eleven patients were followed over 3.3 (median, range 0.5–6.7) years (for 
details see, Table S1, http://links.lww.com/QAD/A40). Ninety-three patients 
underwent early ART that was stopped in 51% of them (n = 47) after approximately 1 
year of viral suppression. Baseline blood samples were available within 5 (2–13) 
weeks after the estimated timepoint of infection in acute and within 13.5 (7–24) 
weeks in recently infected patients. To investigate transmission dynamics within the 
ZPHI study and to identify transmission networks 6500 pol sequences from 4276 well 
characterized SHCS patients were used along with those from the ZPHI patients to 
generate a neighbor-joining phylogenetic tree. Clusters, containing at least two ZPHI 
patients, with bootstrap values above 98% and genetic distances below 1.5% 
(consistent with [5,17]) were preselected. Then, in an independent analysis exploiting 
the genetic information inherent to the highly variable envelope V3 region, we 
confirmed the suggested transmission clusters by constructing maximum likelihood 
trees with clonal env sequences of the 111 ZPHI patients as well as from the SHCS 
patients clustering to ZPHI patients within the pol phylogeny.  
Six clusters containing 20 ZPHI patients (18%) and eight SHCS patients were 
identified (Fig. 1). No dual infections and no transmitted major drug resistance 
mutations [30] were observed in these populations. Transmission of minor 
populations carrying resistance mutations M184V and K103N have been observed in 
13.9% of patients in the ZPHI study [21]. The individual transmission events were 
studied among these patients within a median follow-up time of 4.0 (0.5–7.6) years 
(Fig. 2, Table S2, http:// links.lww.com/QAD/A40 ). The extent of observed 
transmissions may be underestimated, as at the time of analysis some potential 
transmitters have not yet been diagnosed. Therefore, we performed a second 
phylogenetic analysis in May 2009 including 12 300 pol sequences of the growing 
SHCS dataset from 8837 patients.  
In cluster A, ZPHI-A1 and ZPHI-A2 formed a serodiscordant couple living in 
monogamous relationship. ZPHI-A2 has been infected 304 days after ZPHI-A1 
stopped continuing early ART. Transmission occurred during the chronic phase of 
the index partner while his viral load was 33 478 copies/ml.  
In cluster B, ZPHI-B2 has been infected most likely by passive anal intercourse 
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during the chronic phase of ZPHI-B1 136 days after discontinuing early ART. The 
viral load at the estimated timepoint of infection was 930 copies/ml.  
ZPHI-C1 and ZPHI-C2 together consulted our outpatient clinic because they 
suspected HIV infection of ZPHI-C2 due to symptoms of an acute retroviral 
syndrome. Actually, ZPHI-C1 infected ZPHI-C2 146 days after stopping ART (viral 
load 2237 copies/ml) during chronic phase. Because they formed a monogamous 
relationship at that time the two additional SHCS patients within this cluster could be 
excluded as potential transmitters to patient ZPHI-C2. ZPHI-C1 was infected 
approximately 2 years earlier, possibly by SHCS-C4.  
ZPHI-D1 appeared phylogenetically linked to ZPHI-D2 (genetic distance 1.26% in 
pol, 0.92% in env). However, ZPHI-D1 was aviremic (viral load <50 copies/ml) at the 
timepoint of infection of ZPHI-D2 due to successful ART. This transmission pair, 
therefore, seems unlikely, as proven transmissions with undetectable plasma viremia 
have never been reported [31]. Moreover, in the extended second analysis, three 
other potential transmitters were found.  
In cluster E, ZPHI-E1 may have infected ZPHI-E2 8 days after having been infected. 
The viral load at this potential transmission event was 1 690 000 copies/ml. Both, E1 
or E2 may have infected ZPHI-E3 during their recent phase (mean 132 days after 
infection; max viral load 1039 copies/ml). ZPHI-E4 and ZPHI-E5 likely have been 
infected by either ZPHI-E2 or ZPHI-E3 after stopping early ART but not by ZPHI-E1 
who continued suppressive therapy (Table S2, http://links.lww.com/ QAD/A40).  
Although the complexity in cluster F with six SHCS patients and seven ZPHI patients 
prohibited analysis of the transmission dynamics, sources of new infections seem to 
be untreated chronically infected rather than acutely infected patients. Chronically 
infected patients SHCS-F8, F9 and F10 did not receive treatment during several 
years, when ZPHI-F1, ZPHI-F3, ZPHI-F6, ZPHI-F4, ZPHI-F2, ZPHI-F5 and ZPHI-F7 
were infected sequentially. All of the latter ones reached undetectable viral load 
during most of the timepoints when those new infection events happened because 
they received early ART.  
Taken together, these patients demonstrate the importance of using clinical, 
laboratory and epidemiological data to supplement phylogenetic analysis in the 
assessment of putative transmission chains [32]. Surprisingly, only in one example 
transmission may have happened during the acute phase (ZPHI-E1, ZPHI-E2) and in 
one patient within the recent phase (ZPHI-E3) of the possible source. However, in 
Chapter 2 
94 
five other patients, transmission presumably took place while the index patient was 
already in the chronic stage of infection 109– 425 days after interruption of early 
ART. Notably, under treatment, all patients showed undetectable viral load (except 
few blips) indicating that adherence to therapy was generally very good. Taking into 
account the overall time when patients were under virologically suppressive 
treatment, we estimate that 3.5 [95% confidence interval (CI) 0.9–13.5] infection 
events per person-year occurred prior to treatment initiation and 1.8 (95% CI 0.5–5.8) 
events per person-year after cessation of the initial treatment.  
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Fig. 1. Transmission clusters inferred from pol and env sequences. Maximum likelihood 
phylogenetic trees of pol sequences (left panel) and consensus sequences of clonal HIV-1 
env C2–V3–C3 sequences (right panel) isolated from ZPHI patients (green) and SHCS 
patients (blue). Broadly similar trees were inferred by neighbor-joining method. Transmission 
groups (A–F) formed six robust clusters (bootstrap support 99–100%). Reference strains of 
different HIV subtypes were included as outgroup. SHCS, Swiss HIV Cohort Study; ZPHI, 
Zurich primary HIV infection study.  
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Fig. 2. Time course analysis of transmission clusters. Time course of viral loads of HIV-
1-infected patients within clusters A to F (assumed transmission chains). In cluster A ZPHI-
A2 was infected 304 days after early ART stop of the possible transmitter ZPHI-A1. In 
clusters B and C, the infection occurred in the same way only 136 and 146 days, 
respectively, after treatment stop. In addition, ZPHI-C1, ZPHI-C2 and ZPHI-A1, ZPHI-A2 
have been confirmed as couples. In the phylogenetic cluster D, ZPHI-D1 would have infected 
ZPHI-D2 with a viral load of 50 copies/ml indicating that a third party was involved in this 
transmission chain. In the transmission chain of cluster E, ZPHI-E4 was infected 82–136 
days and ZPHI-E5 398–452 days after stop of early ART of ZPHI-E2 and ZPHI-E3. Because 
of the complexity of cluster F, index partners cannot be identified but are most probably 
chronically infected patients enrolled in the SHCS. Black arrows indicate estimated 
timepoints of infection. ART, antiretroviral therapy; SHCS, Swiss HIV Cohort Study; ZPHI, 
Zurich primary HIV infection study. 
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Discussion  
 
In this study, we took advantage of our well characterized ZPHI cohort [18–20] and 
the sequence database linked to the clinical data of the SHCS [24]. In addition to 
phylogenetic analysis of pol sequences confirmed by sequencing of clonal env 
fragments, we estimated the timepoint of infection and followed 111 patients 
longitudinally over years. Eighteen percent of the ZPHI patients formed transmission 
clusters. We further dissected eight transmission events in five phylogenetic clusters; 
only one transmission occurred during acute and another one during the recent 
phase. However, five transmissions occurred during chronic stage of the presumed 
transmitters, more than 3 months after stopping early ART. This was unexpected and 
worrisome because it shows the limitations of prevention measures in this sexually 
active MSM cohort. Infectiousness during chronic infection was quite high in this 
population also at relatively low viral load in some cases (range 314– 1 690 000 
copies/ml).  
In previous studies using phylogenetic reconstruction, patients were categorized as 
acutely or chronically infected according to their stage at diagnosis but not when 
transmission actually occurred [5,32]. This probably led to overestimation of 
transmission frequencies during acute/early infection. Phylogenetic analyses have 
limitations, as one can never rule out transmissions potentially originating from other 
index cases not known to the investigator. This effect is attenuated in our setting 
because the primary HIV infection patients enrolled represent approximately 55% of 
all newly HIV-infected MSM patients in the canton of Zurich and the likelihood that 
HIV-infected patients are enrolled in the SHCS is high [21,22]. In contrast to other 
phylogenetic studies assessing transmission dynamics [5,15,33,34], we used two 
different samples and analyzed two different genetic regions to increase genetic 
information and to exclude laboratory and database errors [13]. Moreover, plausibility 
of the transmission clusters was controlled by longitudinal viral load data.  
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Conclusion  
 
This study demonstrates that in our intensely studied sexually active MSM, collective 
preventive safer-sex counselling was insufficient as documented by the high number 
of new infections originating from patients who stopped early ART according to study 
protocol. Of note, the same individuals were very adherent to ART. Furthermore, we 
detected a remarkable proportion of new infections originating from index patients 
being already in their chronic phase, sometimes with low viral loads. These findings 
argue strongly for early, continuous ART in sexually active HIV-1-infected MSM. This 
strategy, most likely, will have a profound impact to reduce the further spread of HIV-
1.  
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Abstract 
 
Quantitative PCR (qPCR) using fluorescent hydrolysis probes (FH-probes; 
TaqMan®-probes) of variable genomes, such as HIV-1, can result in 
underestimation of viral copy numbers due to mismatches in the FH-probe’s 
target sequences. Therefore both target conservation and physical properties 
of FH-probes, such as melting temperature, baseline fluorescence and 
secondary structure, should be considered in design of FH-probes. 
Analysis of a database of 1242 near full-length HIV-1 sequences with a novel 
computational tool revealed that the probability of target and FH-probe identity 
decreases exponentially with FH-probe length. In addition, this algorithm 
allowed for identification of continuous sequence stretches of high 
conservation, from which FH-probes with global HIV-1 clade coverage could be 
chosen. To revise the prerequisites of physical FH-probe function, properties 
of 30 DNA and 21 chimeric DNA locked nucleic acid (DLNA) HIV-1 FH-probes 
were correlated with their performance in qPCR. This identified the presence of 
stable secondary structures within FH-probes and the base composition and 
thermal stability of the 5’-proximal end as novel predictors of FH-probe 
performance. 
Thus, empirically validated novel principles of FH-probe design regarding 
conservation and qPCR-performance were identified, which complement and 
extend current rules for FH-probe design. 
 
 
Abbreviations 
Ct, cycle threshold; Delta-Tm, Tm-difference of FH-probe and the primer binding the 
same strand; DLNA, chimeric DNA locked nucleid acid; FH-probe, fluorescent 
hydrolysis probe; qPCR, quantitative PCR; RT-qPCR, reverse transcriptase qPCR; 
SNR, signal to noise ratio; Tm, melting temperature 
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1. Introduction  
Monitoring qPCR by FH-probes encounters its major pitfalls in assays examining 
phylogenetically diverse viruses such as HIV-1. While primers are relatively forgiving 
in respect to target variation1, as little as one mismatch in a FH-probe’s target 
sequence can greatly perturb the results of qPCR by underestimating copy 
numbers2. This feature of FH-probes is widely exploited in genotyping of single 
nucleotide polymorphisms3,4. 
Further factors influencing the function of FH-probes are related to their physical 
properties, which are determined by primary and secondary nucleic acid structure. 
Hybridization characteristics and kinetics of the FH-probe to its target have been 
assumed to be crucial for the performance of FH-probes. Hence, to ensure optimal 
binding of FH-probe to target, a choice of binding sites devoid of secondary 
structures and with 40-60% G/C content has been proposed5-9. In addition, to ensure 
hybridisation of the FH-probe before elongation of the newly synthesized DNA 
strand, it has been postulated that the melting temperature (Tm) of FH-probes should 
be 5-10°C higher than the Tm of the primer binding to the same DNA strand as the 
FH-probe5,6. 
Performance of FH-probes in qPCR assays also depends on intensity of 
fluorescence, which is suppressed in the absence of PCR target by a quenching 
moiety commonly placed at the 3’ end of the FH-probe and elicited by nucleolytic 
detachment of the base carrying the fluorophore, usually placed at the FH-probe’s 5’ 
end. The physical proximity of fluorophore and quencher in the absence of PCR 
product has been reported to influence performance of FH-probes9. Optimal proximity 
of the two modified bases in the free FH-probe may be attained by keeping the FH-
probe length minimal10 or, if long FH-probes need to be designed, by attachment of 
the quencher to internal positions11. 
Another important rule advises to avoid guanosine at the residue carrying the 
fluorophore because it quenches fluorescence even after hydrolysis and it may be 
cleaved off with reduced efficiency9,12. 
In the present study, the phylogenetic constraints for design of FH-probes were 
addressed by analyzing the relationship of FH-probe match frequency with FH-probe 
length and single base conservation. Physical properties of FH-probes and their 
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influence on FH-probe performance were examined by testing 51 probes targeting 6 
amplica (plural of amplicon) within the HIV-1 genome.  
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2. Methods 
2.1. Conservation of FH-probes 
The conservation of the chosen amplica was calculated by taking into account all 
circulating HIV-1 groups (subtypes M, N, O, CPZ). The sequences were obtained 
from curated alignments in the Los Alamos HIV Sequence Database (download 
2007, www.hiv.lanl.gov) comprising a total of 1242 sequences including 17% 
subtype-B isolates. Due to location at the ends of the genome, the early and the nef 
amplica, respectively, were only covered by 233 (34% subtype B) and 1231 (16.5% 
subtype B) viral isolates. The levels of single base conservation were compared to a 
global consensus and calculated using Bioedit13. 
Identification of short continuous stretches of matching oligonucleotide sequences 
was carried out using the R statistical computing environment (version 2.8.1)14 and 
tools from the seqinR package available at http://pbil.univ-lyon1.fr/software/SeqinR. 
Briefly, after removal of gaps, this implementation locates all possible substrings of a 
defined length within a reference sequence and calculates the corresponding 
frequencies of perfect matches to the alignment. Each amplicon was analyzed 
separately. The source code is available upon request.  
Match frequencies (Table 1) of FH-probes were calculated based for either only B-
subtypes or all HIV-1 groups (subtypes M, N, O, CPZ). 
 
2.2. FH-probe design 
All FH-probes contained the fluorophore FAM and the quencher TAMRA. Tms of the 
DNA FH-probes were calculated with an open source program (www.biophp.org) 
using the base-stacking algorithm, which was adjusted for the presence of 3mM 
MgCl2. In all FH-probes a 5’ terminal G was avoided5,6,8. The calculated Tms were 
aimed to exceed 55°C, except for mf341, which was designed solely based on 
phylogenetic considerations. DLNA FH-probes were designed with a length of 8-14 
bases and with a content of LNA bases of 10-75%. Tm for DLNA FH-probes was 
calculated with an open source program different from that used for DNA FH-probes 
(http://lna-tm.com), considering differences in melting temperature between DNA and 
LNA bases. 
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2.3. Tm measurement 
The Tm of the FH-probes was measured by examining the denaturation kinetics of 
the FH-probe (0.1uM) and its complementary strand (1uM) in a range from 30-90°C 
in 0.5°C intervals for 10 seconds using a real-time thermocycler (IQ5, Biorad, Basel, 
Switzerland). To attain conditions close to those of qPCR, the complementary 
strands were designed with overhangs of 3 bases avoiding dangling ends and the 
experiments were performed in 1 x Hotstartaq buffer (Qiagen) lacking enzyme with 
the inclusion of 3mM MgCl2. The analysis of the melting curves was executed by 
subtracting the background fluorescence of the FH-probe without the complementary 
strand from the fluorescence signal in reactions containing the complementary target. 
The Tm was defined as the temperature at which 50% of subtracted fluorescence 
was reached. 
 
2.4. PCR and signal to noise ratios 
DNA qPCR was performed as described previously15 using HotStarTaq Master Mix 
(Qiagen), 1uM of each primer and 0.1uM FH-probe. Experiments were done in 
duplicate using the real-time thermocycler IQ5 (BioRad, Basel) and as cycling profile: 
95°C 15’, 60x (95°C 5’’, 55°C 5’’, 60°C 40’’). The following primers were used; cr1 
(TCTCTGGCTAACTAGGGAACCCACTGCTT)16 and cr2 
(TGACTAAAAGGGTCTGAGGGATCTCTAGTTACCAG)16 for the early region, ts5’gag 
(CAAGCAGCCATGCAAATGTTAAAAGA)15 and skcc 
(TACTAGTAGTTCCTGCTATGTCACTTCC)17 for the gag region, mf209 
(AAAGCGTCTAGCCATGGCGTTAGTA) and mf302 (CAAATTTCTACTAATGCTTTTATTTTTTC) 
for the pol region, mf1 (CTTAGGCATCTCCTATGGCAGGAA)18 and mf238 
(GCTATTATTGCTGCTACTACTAATGCTACTA) for the tat region, mf222 
(GGCAGGGATATTCACCATTATCGTTTCAGA) and mf83 
(GGATCTGTCTCTGTCTCTCTCTCCACC)18  for the sa7 region, and mf345 
(AATCAGGGAAGTAGCCTTGTGT) and mf346 (GAGGTGGGTTTTCCAGT) for the nef region . 
HXB2 was chosen as a standard target for all the experiments and pHXB219 was 
linearized by digestion with Xho1. Concentration of the plasmid was quantified by 
spectrophotometry. Based on the length of the linearized plasmid (13000bp), the 
molecular weight (8.5x106 g/mol) and copy number were calculated. A standard 
dilution series with 10fold dilution steps was prepared. 
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SNRs of individual FH-probes were determined by amplification of constant copy 
numbers (3x106 copies HXB2 DNA) dividing mean fluorescence of the last 5 cycles 
of the amplification when fluorescence has reached a plateau, by mean fluorescence 
of the initial 5 PCR cycles. Means of two independent experiments using duplicate 
measurements were calculated.  
 
2.5. Calculations and Statistics 
Statistical analyses were performed either using GraphPad Prism5.0 software 
(GraphPad Software, San Diego, CA) or Stata (Version 10.0; StataCorp). 
Univariable and multivariable linear regression to determine predictors for SNRs of 
FH-probes were performed using Stata. P<0.05 was considered statistically 
significant. Factors with strong colinearity (p<0.01) were not included in the 
multivariable analysis. 
The following parameters were tested in univariable analyses additionally to the ones 
shown in Table 2, but without revealing statistically significant association with SNRs: 
G/C-basepairs in 1st and 2nd position, purine in 1st and 3rd position, concentration of 
the FH-probe, Tm of the primer binding the opposite strand as the FH-probe and 
distance of FH-probe to the primer binding the same strand as the FH-probe. 
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3. Results  
3.1. Phylogenetic complexity of conserved regions of the HIV-1 genome 
Amplica in 6 regions commonly used for HIV-1 qPCR due to their conservation or 
usefulness for monitoring important splice variants were assessed in this study: An 
amplicon mapping the primary viral transcripts in the R/U5 region (early), the coding 
region for p24-gag (gag), the start of the reverse transcriptase gene (pol), the first 
coding region of the tat-gene (tat), env-gp41 flanking the major splice acceptor 7 
(sa7) and the poly-purine tract within the nef gene (nef) (Table 1, Fig. 1a). 
Phylogenetic conservation within the six chosen amplica was analyzed with 
emphasis on match frequency, defined as 100% identity of FH-probe with its target, 
by employing a novel sequence scanning program. In this algorithm, a sequence 
defined as standard is screened in a sliding window approach for match frequencies 
of all possible FH-probes by comparison to a sequence database. In the present 
study, HXB2, the commonly used first molecular isolate of HIV-119, was used as the 
reference sequence and the database was a collection of 1242 near full-length HIV-1 
genome sequences representing phylogenetically distinct viral isolates spanning the 
full scope of the HIV-1 pandemic, which was extracted from the Los Alamos HIV 
Sequence Database (hiv.lanl.gov). Figure 1b shows an analysis of 10-, 20- and 40-
base oligomers plotted against average single base conservations. Theoretically, 
match frequencies (M) are proportional to the product of single base frequencies; this 
can be approximated by 
equation 1) M = (CGM) L, 
which potentiates the geometric mean of single base conservation (CGM) with 
oligonucleotide chain length (L).  
A comparison of calculated versus observed match frequencies revealed close 
correlation (Pearson r=0.96) but significantly higher values for observed match 
frequencies (Wilcoxon signed rank test, p<0.0001). The most likely explanation for 
this discrepancy is that single base conservations were not independent from each 
other but genetically linked due to constraints of codon usage and RNA structure. 
Thus, to adjust the model for linkage, a correction factor (λ) was introduced: 
Equation 2) M = (CGM) L × λ  
Fitting the dataset to equation 2 resulted in λ=0.74 (95% confidence interval: 0.73-
0.75). The model showed significant correlation (Pearson r=0.97) between observed  
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Table 1. Properties of FH-probes 
    positionC   match (%)D   TmF 
IDA FH-probe sequenceB amplica 5’ 3’ length all nonB B SNRE m p 
mf320 AAAGCTTGCCTTGAGTGCTTCA early 530 551 22 36 29 52 4.4 64.5 67.7
mf321 TTCAAGTAGTGTGTGCCCGTCT early 548 569 22 36 29 49 3.8 64.5 68.9
mf322 TGCCCGTCTGTTGTGTGACT early 561 580 20 64 50 92 6.6 63.5 69.1
mf323 CCCGTCTGTTGTGTGACT early 563 580 18 64 50 92 5.9 57.5 64.3
mf74 AGCACTCAAGGCAAGCTTTATTGAGGC 24 early 548 522 27 87 82 97 3.9 64 72.1
ca20 TGtGtGCcCgT early 557 567 11 83 77 96 12.9 59 68 
ca21 TGtGtGccC early 557 565 9 95 92 100 9.9 57 64 
ca22 TGTGtGCCCGT early 557 567 11 83 77 96 10.5 52 56 
ca23 AGcTtGcCtTGaG early 532 544 13 96 95 97 10.7 62 67 
ca24 AGCttGCCttGaG early 532 544 13 96 95 97 27.3 62 70 
ca25 AGCtTGCCtTGAG early 532 544 13 96 95 97 8.2 53 54 
mf316 TAGAGTGCATCCAGTGCATGCA gag 1428 1449 22 0.8 0 4.8 5.8 65 68.7
mf317 ATGCAGGGCCTATTGCACCA gag 1445 1464 20 22 16 51 6.5 63 68.8
mf318 AGGCCAGATGAGAGAACCAAGG gag 1464 1485 22 24 15 65 4 69 68.9
mf319 TGCAGCTTCCTCATTGATGGT gag 1419 1399 21 43 36 78 4.8 63 66.8
Boe3 TCTATCCCATTCTGCAGCTTCCTCATT 25 gag 1431 1405 27 15 3.3 70 1.9 70.5 70.6
Boe3.2 TCTATCCCATTCTGCAGCTTCCTCATTGATGG gag 1431 1400 32 13 2.8 66 1.7 73 74.3
Boe3.3 TCCCATTCTGCAGCTTCCTCATTGATGG gag 1427 1400 28 38 32 69 2 56.3 73.5
ri17 CCAtCaAtGaGGA gag 1400 1412 13 68 64 88 5 56 59 
ri18 CTGcAgAaTgGGA gag 1415 1427 13 80 78 86 1.3 62 66 
ri19 CATgCaGgGcCT gag 1444 1455 12 59 57 70 4.2 63 72 
ri20 AGGcCcTgc gag 1455 1447 9 79 77 90 5.9 58.5 61 
ri21 TCccattc gag 1427 1420 8 87 87 89 1.2 nn 53 
mf304 ATGGCCCAAAAGTTAAACAATGGCCA pol 2599 2624 26 22 13 67 4.9 66 71 
mf305 ATTCCTGGCTTTAATTTTACTGGTACAGT pol 2596 2568 29 47 41 76 2.2 66.5 68.2
mf309 TTAAACAATGGCCATTGACAGAA pol 2611 2633 23 63 60 75 2.3 57 64.2
mf348 AAGCCAGGAATGGATGGCC pol 2586 2604 19 63 60 81 8.5 65.5 67 
ri14 ACTgTaCcAgTA pol 2568 2579 12 83 81 91 1.6 54 54 
ri15 CAGgAaTgGaTGG pol 2590 2602 13 87 86 95 9.5 59 62 
ri16 CTGtCaAtGgCCA pol 2631 2619 13 82 81 90 9.3 63.5 64 
ri23 ATGgatgg pol 2595 2602 8 97 96 98 1.5 53 54 
mf82 TCTTCGTCGCTGTCTCCGCTTCTT 17 tat 6001 5978 24 17 7.6 64 2.5 61.5 72.7
mf324 TCCCAACCCCGAGGGGA sa7 8386 8402 17 2.7 0.8 12 2.8 64.5 69.8
mf325 CCCGAAGGAATAGAAGAAGA sa7 8412 8431 20 5.4 5.9 2.9 3.9 58.5 61.2
mf326 CTCGGGGTTGGGAGGTG sa7 8398 8382 17 0.6 0 3.4 2.9 63.5 66.6
mf327 CTATTCCTTCGGGCCTGTC sa7 8424 8406 19 5.5 6 2.9 4.4 63.5 64.4
mf328 ACCCCGAGGGGACCC sa7 8391 8405 15 2.7 1.1 11 4 62 67.2
mf2tq TTCCTTCGGGCCTGTCGGGTCCC 17 sa7 8421 8399 23 18 9.2 61 6.5 74.5 77.4
mf226 AGGGGACCCGACAGGCCC 15 sa7 8397 8414 18 23 13 73 18.1 72 73.4
ri10 TGTcGgGtCcCCTC sa7 8409 8396 14 32 24 74 3.8 73 75 
ri11 CCTgTcgGGtCCC sa7 8411 8399 13 38 29 79 3.2 59 73 
ri12 CCCgACaGgCcCG sa7 8403 8415 13 36 28 77 3.9 64 77 
ri13 CGAcAgGcCCgAA sa7 8405 8417 13 31 24 69 4.3 58 76 
ri22 CGAcAggC sa7 8405 8412 8 75 73 87 1.4 53 55 
mf342 TTTTTAAAAGAAAAGGGGGGAC nef 9064 9085 22 86 88 77 1.1 66.5 62.3
mf343 AAGAAAAGGGGGGACTGGA nef 9071 9089 19 87 89 77 1.3 63 65.5
mf344 ACAGATCAAGGATATCTTGTCT nef 9133 9112 22 8 2.4 36 1.7 54 61.4
mf341 CTTTTTAAAAGAAAAGGGG nef 9063 9081 19 83 86 70 1 42 54.5
ca18 CAAGGCAGCTGTAGATCTTAGCCA nef 9039 9062 24 3.4 0.5 18 3.8 63 68.8
ca19 AGGGCTAATTCACTCCCAACGA nef 9090 9111 22 0.2 0.1 0.5 9.3 63 68.5
ca26 AGGGGgGaCtGgA nef 9077 9089 13 95 95 95 4.2 58 74 
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A ID denominates identification of FH-probes according to internal nomenclature in the 
author’s laboratory. 
B Sequence of the FH-probe (5’ to 3’): capital letters indicate DNA bases and lower case 
letters indicate LNA bases. 
C Numbering based on the HXB2 genome according to the software provided by the Los 
Alamos HIV Sequence Database (SEQUENCE LOCATOR, www.hiv.lanl.gov). 
D Conservation of all subtypes (all), nonB- (nonB) or B-subtypes (B) was calculated by 
comparison to sequences that were obtained from curated alignments in the Los Alamos HIV 
Sequence Database (download 2007, www.hiv.lanl.gov). 
E Signal to noise ratio 
F Measured (m) and predicted (p) melting temperature (Tm) (°C) 
 
 
 
and predicted match frequency and no significant difference between them (Wilcoxon 
signed rank test, p=0.32). This analysis demonstrates that the probability that an 
oligonucleotide will find its match in a viral population decreases exponentially with 
FH-probe length (Fig. 1c).  The influence of the oligonucleotide length may be 
relieved if genetic linkage results in coinheritance of clusters of bases, in which case, 
λ<1, oligonucleotide length is virtually shortened.  
In contrast to these constraints related to assay sensitivity, specificity of FH-probe 
binding (S), defined as the probability that a certain sequence would not occur in a 
random amplicon, can be approximated by 
equation 3) S = (1-(1/4)L) (A-L+1) ,  
where L is the length of the FH-probe and A the length of a random, erroneously 
amplified sequence. This equation can be justified as follows: The probability, that 
the FH-probe matches a given stretch of length L (i.e. the length of the FH-probe) is 
(1/4)L (assuming equilibrium of all 4 bases). The entire amplicon can be viewed as 
consisting of A-L+1 stretches of length L. This approximation further assumes that 
the event of matching a given stretch is independent from matching the other 
stretches. Under this assumption the probability of obtaining no match at all is (1-
(1/4)L) (A-L+1). Thus, it was estimated that the specificity of FH-probe binding exceeds 
99% with a FH-probe length of >9bases and A ranging from 40-1000 bases (Fig. 1c). 
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Figure 1. Phylogenetic complexity of conserved regions of the HIV-1 genome.(a) FH-
probes mapping to 6 regions of the HIV-1 genome were designed utilizing the HXB2 
sequence as a template. Upper panel: Small arrows mark the location of amplica in the viral 
genome. Lower panel: Conservation of the chosen amplica among all circulating HIV-1 
clades (subtypes A-O, sequences obtained from curated alignments in the Los Alamos HIV 
Sequence Database, download 2007, www.hiv.lanl.gov). The colored area shows the level of 
single base conservation as compared to a global consensus sequence, and grey bars 
signify the conservation of the actual HXB2-sequence when this deviates from consensus. 
(b) Dependence of match frequencies of oligonucleotides on base conservation and 
oligonucleotide-length (L). HIV-1 sequence alignments were scanned for the presence of all 
possible 10- (red, yellow), 20- (magenta), and 40-mers (black) in the 6 chosen amplica. 
Match frequencies (M) were plotted against average (GM, geometric mean) of single base 
conservation (C). Broken lines show prediction of M by equation 1) M = (CGM) L. Steady lines 
depict predictions by equation 2) M= (CGM) Lx λ including a correction factor (λ) to account for 
linkage. Brown lines show predictions for 10-mers, magenta lines for 20-mers and black lines 
for 40-mers. (c) Calculated match frequencies (M according to equation 2) (left y-axis; red 
circles, error bars: 95% confidence intervals, shaded area: range). Specificity (S, right y-axis) 
of FH-probe binding is modelled as a function of FH-probe length (L) and length of an 
erroneously produced amplicon (A): Equation 3) S = (1-(1/4)L) (A-L+1) (A=40 bases: blue 
crosses, A=100 bases: blue diamonds, A=1000 bases: blue asterisks)  
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3.2. Signal to noise ratios of FH-probes as indicators of DNA FH-probe 
performance 
In previous studies signal to noise ratios (SNRs) of fluorescent probes were used to 
gauge efficacy of qPCR assays20,21. To confirm this concept, SNRs of individual FH-
probes were calculated by dividing fluorescence at the end of the amplification by 
fluorescence during the initial cycles of amplification. To avoid interference of qPCR 
by possible primer dimer amplification and the resulting reduction of fluorescence in 
reactions with low copy numbers22, high amounts of template (3x106 copies HXB2 
DNA) were used. As shown in Figure 2a and Table 1, performance in a panel of 30 
DNA-based FH-probes ranged from ineffective (mf342, SNR=1.1) to excellent 
(mf226, SNR=18.7). Cycle threshold (Ct) -values and their standard deviations, 
respectively, showed significant inverse correlation with SNRs (Pearson r=-0.52; 
p=0.004 and r=-0.59; p=0.0007 respectively), confirming association of SNRs with 
sensitivity and reproducibility of qPCR. 
 
3.3. Predictors of SNRs of DNA FH-probes 
To assess the factors influencing biochemical performance of the DNA FH-probes, 
SNRs and their different potential predictors were examined in univariable and 
multivariable linear regression models (Table 2). Melting temperature (Tm) showed 
weak but significant correlation to SNRs, either when measured or predicted by 
nearest neighbour analysis (p=0.033; measured and p=0.038; predicted). High G/C 
content of the DNA FH-probe was associated (p=0.002) with high SNRs. 
Furthermore, the presence of G/C rich secondary structures within the FH-probe was, 
in contradiction to current rules, a highly significant positive predictor of SNRs 
(p<0.001). FH-probes with intramolecular stem-loop structure containing one or more 
G/C base-pairs performed better than FH-probes with no or only a weak secondary 
structure (Fig. 2b, p=0.003). A trend for association of short FH-probe length 
(p=0.102) with high SNRs was observed, while Tm-difference of FH-probe and the 
primer binding the same strand (Delta-Tm) lacked correlation (p=0.742). 
Upon encountering FH-probe bound to its template, taq polymerase can either 
remove the FH-probe by exonucleolytic cleavage or by strand displacement. We 
hypothesized that stability of the probe-template complex at its 5’ end may favour 
exonucleolytic cleavage and generation of free, unquenched fluorophore. Thus, 
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thermal stability and base composition of the 5’ ends of the FH-probes were analyzed 
in detail. 
SNRs were positively associated with the predicted Tm of the ten 5’ proximal bases 
(Pearson r=0.65, p=0.0001) (Fig. 2c). In agreement, FH-probes with a G or C at 
position 3 showed significantly elevated SNRs as compared to those with A or T 
(p=0.001, data not shown). At the second position, presence of G was favourable, 
followed by presence of A. Hence, SNRs of DNA FH-probes with a purine at position 
two were significantly higher than SNRs with a pyrimidine (Fig. 2d, p=0.01). No 
significant association of the bases at the first position with SNRs was observed. 
Multivariable analysis, including statistically significant factors (p≤0.05 in univariable 
analysis), except for those with strong colinearity (p<0.01), resulted in a model in 
which 5’-proximal Tm (p=0.006), a purine at position 2 (p=0.035) and the numbers of 
intramolecular G/C-basepairs (p=0.004), explained 67% of the variability in SNRs 
(Table 2). 
Thus, we suggest the following rules to design functional DNA FH-probes: 5’-
proximal Tm ≥ 30°C, a purine at position 2 and ≥ 2 intramolecular G/C-basepairs. 
 
Figure 2. Performance of DNA FH-probes and analysis of predictors of SNRs. (a) 
Amplification curves of DNA FH-probes in 6 amplica (n=1-7, see Table 1). Fluorescence at 
each cycle was normalized to the baseline fluorescence of the first 5 cycles. Dotted lines 
indicate baseline fluorescence. (b) Comparison of SNRs of DNA FH-probes containing <1 
(diamonds) or 0-1 G/C (triangles) base-pairs in a stem-loop. (c) Pearson correlation analysis 
of the Tm of the 5’ proximal 10 bases of the DNA FH-probes with SNRs. (d) Comparison of 
DNA FH-probes containing a purine (circles) or a pyrimidine (triangles) at the 2nd position. P-
values in (b) and (d) were calculated by Mann Whitney testing. 
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3.4. Performance of DNA FH-probes in qPCR 
Four FH-probes with SNR>2 were chosen for further analysis according to their 
phylogenetic match frequencies: mf74 within early (87% match to viral isolates from 
all clades, 97.5% clade B), mf319 in gag (42% overall, 77.5% clade B), mf348 in pol 
(63% overall, 81% clade B), and mf226 in sa7 (22.8% overall, 72.6% clade B). FH-
probes within nef and tat were not included due to low match frequencies within the 
set of utilizable FH-probes (<20%). HIV-1 DNA copies were measured by qPCR in a 
range from 3 million to 0.3 copies per PCR and the 50% endpoint of PCR-positive 
dilutions was determined as an indicator of assay-sensitivity. All qPCRs using gag, 
pol and sa7 FH-probes reached single copy sensitivity (Fig. 3b-d), while amplification 
of the early amplicon showed slightly reduced sensitivity presumably due to formation 
of primer dimers in later cycles (Fig. 3a), typically resulting in progressive diminution 
of signal amplitudes15. 
Thus, quantification of HIV-1 DNA was achieved over 6 orders of magnitude 
approaching single copy sensitivity for 3 FH-probes. Although they matched B-
subtypes with reasonable frequency, match frequencies for nonB-subtypes were 
insufficient to cover the full scope of the global pandemic. 
 
3.5. Improved short FH-probes using locked nucleic acid analogues 
To design FH-probes with higher clade coverage, shorter chimeric DNA locked 
nucleic acid (DLNA) FH-probes were used. In locked nucleic acids base pairing is 
stabilized by a 2-O,4-C-methylene bridge on the ribose moiety23. As exemplified in 
Figure 4a, a 13-mer DLNA FH-probe showed higher thermal stability when bound to 
its complementary strand than an overlapping 23mer DNA FH-probe. 
To identify candidate short FH-probes with high conservation, the sequence scanning 
algorithm was employed. An example is shown for the pol amplicon (Fig. 4b), which 
was scanned for all possible 8-, 10-, 12- and 14-mers. This procedure identified 
separate peaks of highly conserved sequence stretches from which FH-probes were 
chosen. Based on this analysis, 21 DLNA FH-probes (6 in early, 5 in gag, 4 in pol, 5 
in sa7, 1 in nef, Table 1) ranging from 8-14 bases were synthesized. 
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Figure 3. Sensitivity of qPCR using selected DNA FH-probes. DNA FH-probes with SNRs 
> 2 and the highest phylogenetic match frequencies of HIV-1 in each amplicon were used for 
amplification of HXB2 DNA in a range from 3 million to 0.3 copies per PCR. Broken vertical 
lines show the 50% endpoint of PCR-positive dilutions and thus signify sensitivity of the 
assays. qPCR for gag (b), pol (c) and sa7 (d) reached single copy sensitivity, while 
amplification of the early (a) amplicon showed reduced sensitivity presumably due to primer 
dimer formation. Experiments were performed in duplicate (3x106-3x103 copies) or 
quadruplicate reactions (<3x103 copies). Results of linear regression of log10 of DNA copy 
numbers versus Ct-values are depicted. Inserts show amplification plots of PCR-cycle (x-
axis) versus baseline subtracted fluorescence (y-axis), with dotted lines displaying the 
fluorescence threshold and grey symbols showing negative controls. 
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3.6. Predictors of SNRs of DLNA FH-probes 
SNRs of DLNA FH-probes were measured as described for DNA FH-probes. Ct-
values and their standard deviations, respectively, were inversely correlated with 
SNRs (Pearson r=-0.55; p=0.01 and Pearson r=-0.73; p=0.0003). 
SNRs of DLNAs were tested for association with Tm, FH-probe length, G or C at 
position 3 and purine at position 2. Intramolecular G/C-basepairs were not assessed 
because DLNA FH-probes generally contained no secondary structures. Similarly, 
the Tm of the ten 5’ proximal residues was not assessed as it was virtually identical 
to overall Tm. Finally, to account for the fact that not only G/C-residues promote 
strong basepairing but also LNA-residues, the presence of weakly pairing bases 
(plain A/T content, i.e. no G/C no LNA) was assessed rather than presence of 
strongly pairing bases (G/C, LNA). 
The sole statistically significant predictor identified in univariable analysis was purine 
at position 2 (p=0.009). For identification of additional potential predictors, inclusion in 
the multivariable model was extended to parameters with a univariable p-value ≤0.1. 
This resulted in a model explaining 56% of the data variability (Table 2), in which 
purine at position 2 (p=0.007) and FH-probe length (p=0.023) positively predicted 
SNRs, while plain A/T-content showed a negative association (p=0.040). 
Thus, we propose the following rules to design functional DLNA FH-probes: A purine 
at position 2, length ≥ 11 nucleotides and a plain A/T-content ≤ 35%. 
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Table 2. Predictors of SNRs of DNA and DLNA FH-probes 
    Univariate analyses   Multivariate analyses  
    Coefficient (95% CI) p  Coefficient (95% CI) p r2 
DNA Tm measured (°C)A 0.018 (0.001; 0.03) 0.038  0.005 (-0.01; 0.02) 0.356 0.68
(n=30) G/C content (%)B 0.013 (0.005; 0.02) 0.002     
 FH-probe length -0.022 (-0.05; 0.005) 0.102     
 Predicted Tm 5’ end (°C)C 0.025 (0.01; 0.04) <0.0001  0.015 (0.005; 0.03) 0.006  
 G/C-basepair in 3rd position 0.331 (0.14; 0.52) 0.001     
 Purine in 2nd position 0.27 (0.07; 0.47) 0.01  0.155 (0.01; 0.30) 0.035  
 Delta-Tm (°C)D 0.003 (-0.01; 0.02) 0.742     
  Intramolecular G/C-basepairs  0.12 (0.06; 0.17) <0.0001  0.074 (0.03; 0.12) 0.004   
DLNA Tm measured (°C)A 0.011 (-0.02; 0.05) 0.53        0.56
(n=21) Plain AT-content (%)E -0.014 (-0.03; 0.002) 0.091  -0.014 (-0.03;-0.001) 0.04  
 FH-probe length 0.068 (-0.02; 0.15) 0.107  0.077 (0.01; 0.14) 0.023  
 G/C-basepair in 3rd position 0.044 (-0.31; 0.40) 0.797      
 Purine in 2nd position 0.423 (0.12; 0.73) 0.009  0.377 (0.12; 0.64) 0.007  
  Delta-Tm (°C) D -0.009 (-0.03; 0.02) 0.453          
 
A Measured melting temperature.B Content (%) of G and C bases.C Predicted melting 
temperature of the 10 proximal bases at the 5’ end. D Difference between the Tm of the FH-
probe and the Tm of the primer binding the same strand as the FH-probe. E Content (%) of A 
and T bases, not including LNA bases 
 
 
 
 
Figure 4. Melting profiles and match frequencies of DLNA FH-probes. (a) Melting 
profiles of two FH-probes within pol. The 13-mer DLNA FH-probe ri16 is depicted in blue and 
the overlapping 23-mer DNA FH-probe mf309 in grey. Symbols connected by lines show 
relative fluorescence and plain lines show their first derivatives. (b) Matching of HXB2 
derived 8-, 10-, 12- and 14-mers to the aligned HIV-1 sequences of the Los Alamos HIV 
Sequence Database (download 2007, www.hiv.lanl.gov) starting at the indicated position 
within the pol amplicon (position 2500 to 2630, HIV-1 HXB2, GenBank accession number 
K03455). 
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3.7. Performance of DLNA FH-probes in qPCR 
Based on their SNRs and phylogenetic conservation, DLNA FH-probes representing 
gag (ri20, 79% match to viral isolates from all clades, 90% in subtype B), sa7 (ri12, 
overall 36%, subtype B 77%), nef (ca26, 95% overall and for clade B) and 2 FH-
probes for pol (ri15, 87% overall, 94% clade B and ri16, 82% overall, 90% clade B) 
were further tested for their usefulness in qPCR (Fig. 5). FH-probes for the early 
amplicon were not included in this analysis because of the slightly reduced sensitivity 
of the qPCR, as shown above for DNA FH-probes, and because the dataset for this 
amplicon compassed a smaller number of viral variants than the other amplica 
(n=233 versus n=1242) with overrepresentation of subtype B (34% versus 17%). All 
PCR assays ranged over 6 orders of magnitude and reached single copy sensitivity. 
In a previous study match frequencies of an RT-qPCR assay were boosted by adding 
two FH-probes into a single reaction18. The rationale was that fluorescence is 
expected to show up when at least one of two FH-probes A and B fits its target. This 
combined match frequency (MAvB) can be estimated as 
equation 4) MAvB = MA + MB - (MA x MB). 
This concept was employed with 2 FH-probes in pol (ri15 and ri16), which resulted in 
qPCR with single copy sensitivity (Fig. 5d). Assays performed with single FH-probes 
gave indistinguishable results (data not shown). Combinatorial analysis as described 
by equation 4, predicted that 97.8% (observed 96.7%) of viral isolates among all 
clades and 99.4% (observed 99.0%) within clade B, would match at least one of 
these two FH-probes. Thus, combination of two pol FH-probes resulted in near-
universal clade coverage. 
The nef DLNA FH-probe (ca26) showed the highest match frequency (95%) and 
good performance in DNA assays. However, when it was employed for RNA in one-
step RT-qPCR under less stringent conditions (annealing at 50°C for 30 minutes), 
false positive reactions were observed at low frequencies presumably due to the 
stretch of 6 guanosines in a row. The other 4 DLNA FH-probes in this subset 
functioned reproducibly, with great specificity and without giving rise to false positive 
results using uninfected human PBMC DNA as a template, as well as in RT-qPCR 
(unpublished results). 
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Figure 5. Sensitivity of qPCR using selected DLNA FH-probes. DLNA FH-probes with 
SNRs > 2 and the highest phylogenetic match frequencies of HIV-1 in each amplicon were 
used for amplification of HXB2 DNA in a range from 3 million to 0.3 copies per PCR. Broken 
vertical lines show 50% endpoints of PCR-positive dilutions and thus signify sensitivity of the 
assays. All qPCRs using gag (a), sa7 (b), and nef (c) DLNA FH-probes reached single copy 
sensitivity. Two pol FH-probes that had both reached single copy sensitivity in qPCR on their 
own, were combined in one qPCR (d). This assay also reached single copy sensitivity. 
Experiments were performed in duplicate (3x106-3x103 copies) or quadruplicate reactions 
(<3x103 copies). Results of linear regression of log10 of DNA copy numbers versus Ct-values 
are depicted. 
Inserts show amplification plots of PCR-cycle (x-axis) versus baseline subtracted 
fluorescence (y-axis), with dotted lines displaying the fluorescence threshold and grey 
symbols showing negative controls. 
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4. Discussion  
In the present study, both the structural as well as the phylogenetic side of FH-probe 
design for HIV-1, a paradigm for a virus with high genetic diversity, were addressed. 
In consideration of the finding that match frequencies decrease exponentially with 
sequence length, usage of short optimally conserved FH-probes was aimed for. This 
has been facilitated by a novel computational tool to systematically identify stretches 
of highly conserved regions to which FH-probes may be targeted. This and the 
availability of locked nucleic acid analogues enabled us to design short FH-probes 
matching up to 95% of a representative collection HIV-1 isolates. Similarly, by 
combining two FH-probes within the same reaction, phylogenetic coverage could 
even be increased to 97%. 
Regarding performance of FH-probes, analysis of the dataset in this study allowed to 
determine rules empirically for FH-probe design with the limitation that the collection 
of FH-probes was not strictly random and that certain rules were initially followed in 
design of FH-probes.  
In agreement with current rules6, a significant impact of stability of the probe-target 
complex both on DNA as well as on DLNA FH-probes was observed. However, more 
than the Tm, representing overall stability, the local stability near the site of 
nucleolytic cleavage of the FH-probe appeared to exert a marked influence on FH-
probe performance. Hence, the Tm of the first 10 5’-proximal bases was a significant 
positive predictor of the SNRs.  Moreover, stabilization of the probe-target duplex 
appeared to be mediated by forces beyond mere Watson Crick basepairing, as 
indicated by the observation that a purine at position 2 significantly predicted SNRs in 
the two independent datasets comprising DNA and DLNA FH-probes. This finding 
may reflect hydrophobic interaction of the FH-probe fluorophore with the extensive 
hydrophobic structure of the purine-rings. 
Paradoxically, presence of intramolecular G/C base-pairs within DNA FH-probes was 
significantly associated with high SNRs despite their potential to compete with 
hybridization to the target strands. In analogy to molecular beacon probes which rely 
on stem-loops bringing fluorophore and quencher in juxtaposition24, intramolecular 
G/C base-pairs in FH-probes may increase quenching in the absence of target. In 
agreement, significant correlation of intramolecular G/C base-pairs with baseline 
fluorescence (data not shown, Pearson r=-0.53, p=0.003) was observed. 
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Similarly to DNA FH-probes, the three identified predictors of DLNA FH-probe 
performance, purine 2, chain-length and low content of plain A/T base-pairs, all may 
influence duplex-stability. The fact that the Tm appeared not to predict FH-probe 
performance can be interpreted as a consequence of sampling, since DLNA FH-
probes were chosen to exceed, whenever possible, a predicted Tm of 55°C in order 
to have a chance to perform well. 
5. Conclusions 
In summary, the following empirically tested positive predictors of biochemical FH-
probe performance emerged from this study: 
1. A purine at position 2 (DNA and DLNA). 
2. An overall Tm ≥ 60°C and Tm of the first ten 5’ proximal bases ≥ 30°C (DNA). 
3. Presence of G/C rich (≥ 2 G/C-basepairs) secondary structures (DNA). 
4. Sequence length (≥ 11) and low contents (≤ 35%) of plain A/T bases (DLNA). 
Moreover, within the set of well performing FH-probes, application of the algorithm to 
scan sequence databases for FH-probes with optimal phylogenetic conservation, 
allowed to identify functional FH-probes in various regions of the HIV-1 genome 
approaching coverage of the global HIV-1 pandemic. It is conceivable that application 
of these phylogenetic and biochemical principles for FH-probe design may also be 
extended to other phylogenetically diverse biological systems. 
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Own contribution 
 
After primary HIV infection each individual reaches a steady state level of plasma 
viral load which is referred to as viral setpoint. These setpoints between individuals 
can vary more than 1000 fold and are predictive for disease progression to AIDS. In 
chronically infected patients, who underwent structured treatment interruptions (STI), 
low viral diversity before initiation of ART, was associated with spontaneous control 
of viremia after treatment stop. In addition, viral capacity is a driving factor in 
determining the magnitude of the viral setpoint. Taken together, viral properties 
influence disease progression and are at least in part responsible for the high 
variability in the viral setpoint.  
In the following study we took advantage of patients enrolled in the Swiss Spanish 
Intermittent Treatment Trial (SSITT). After successful ART for years, these patients 
underwent four cycles consisting of 2 weeks treatment interruption and 8 weeks 
retreatment before cessation of ART for a prolonged time period.  
Here, we aimed at identifying shared genetic signature of rebounding viruses during 
STI in patients “controlling” viremia at levels below 5000 copies/ml of viral RNA. A 
strong evidence for the genetic signature 268E/358T associated with virologic control 
has been found. Next we tried to validate this finding, amongst others, in a group of 
well characterized primary HIV infected patients enrolled in the ZPHI-study. For that, I 
provided 1610 pre-treatment clonal C2-V3-C3 sequences of 104 ZPHI patients. I 
extracted viral RNA from plasma and did subsequent PCR amplification, molecular 
cloning and bidirectional sequencing of the C2-V3-C3 region of HIV-1 env. By using 
different bioinformatic tools, I edited and aligned sequences, in addition to manually 
adjusting. To exclude laboratory contamination I constructed Neighbor-joining 
phylogenetic trees by using HXB2 and Non-B strains as references and 
boostrapping. Patient’s characteristics were consolidated from different data sources.  
The very strong positive predictive values of the signature 268E/358T associated 
with viral control in 9 SSITT patients were not confirmed in the 104 ZPHI patients 
analyzed during PHI. However, high negative predictive values were retained in this 
group. 
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Abstract 
 
HIV RNA levels are influenced by genetic characteristics of both the host and 
the virus. Here we applied machine learning techniques to determine if plasma-
derived HIV-1 amino acid sequences can be used to predict spontaneous 
virologic control. We studied the relationship between HIV-1 env genotype and 
viral load in 20 chronically infected patients undergoing treatment interruptions 
(SSITT, Swiss-Spanish Intermittent Treatment Trial) and in 104 primary HIV 
infected (PHI) patients before antiretroviral therapy (cART) and where 
applicable also after treatment stop. Extensive longitudinal sampling during 
the interruptions was performed in nine SSITT patients. Sequences obtained 
from these nine patients during the first virus rebound were used as a training 
data set and revealed a strong genetic signature (accuracy 98.6% in cross-
validation) associated with control of viremia at levels below 5000 copies/mL of 
viral RNA maintained for at least 2 months after the final cART stop. The simple 
sequence pattern at gp120 positions 268E/358T was confirmed to be predictive 
of control in the clonal sequences originating from these patients during all 
subsequent rebounds. Sequences from the remaining 11 SSITT patients with 
less frequent sampling and from the PHI patients were used for external 
validation. High sensitivities (71–100%) and negative predictive values (80–
100%) but low positive predictive values (12–40%) were achieved in the patient-
wise analysis which was based on presence of the genetic pattern in all clones. 
These results suggest that presence of virus lacking the amino acid pattern 
268E/358T is associated with VL >5000 at baseline of PHI and with low 
probability of spontaneous virologic control after treatment stop. Conversely, 
however, presence of 268E/358T does not predict control of viremia. These 
residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of 
Env function or influence susceptibility to adaptive or innate immune 
response. 
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Introduction  
 
Empirical approaches to development of HIV vaccines have so far, despite huge 
efforts, not been successful. Among the major obstacles are the enormous genetic 
variability and the high degree of glycosylation of the outer HIV envelope proteins 
enabling the virus to escape from immune recognition. Moreover, there is a narrow 
window of opportunity to clear the initial infection because latency is established 
within the first weeks, and destruction of CD4+ T cells begins early after infection 
(Johnston and Fauci, 2008). HIV induces a natural immune response involving 
neutralizing antibodies and cytotoxic T lymphocytes. However, these responses are 
typically too weak to eliminate the virus and the targeted epitope sequences are 
continuously mutated to evade the immune system. The envelope glycoproteins 
gp120 and gp41 comprise the key determinants presenting their surface to the host’s 
humoral immune system. They inevitably undergo continuous evolution driven by 
positive selection, and are therefore the most variable gene products of HIV. 
Eventually mutations arise resulting in escape from host immune recognition 
(Yamamoto and Matano, 2008). These mutations often confer considerable fitness 
cost to the virus which may subsequently be alleviated by selection of compensatory 
mutations (Goulder and Watkins, 2004).  
To explore intrapatient HIV evolution in the region of gp120 we conducted 
longitudinal clonal sequencing of the envelope C2-V3-C3 domain in HIV-1 infected 
patients with long-term suppression of plasma viremia who interrupted combination 
antiretroviral therapy (cART) within a well-controlled structured treatment interruption 
trial (Swiss Spanish Intermittent Treatment Trial). After successful cART for years, 
these patients underwent four cycles consisting of 2 weeks treatment interruption and 
8 weeks retreatment before cART was completely discontinued for a prolonged time 
period. During the strictly defined short interruptions HIV RNA usually rebounded 
within 2 weeks (Fischer et al., 2003a). Patients who maintained plasma viremia at 
levels below 5000 copies/mL of viral RNA for at least 2 months after the final 
treatment stop were classified as ‘‘controllers’’ (Fagard et al., 2003). Analysis of the 
sequences derived from plasma before the initiation of antiretroviral therapy (cART) 
revealed that lower viral diversity was associated with spontaneous control of viremia 
after treatment stop as well as with reduced in vitro replication capacity and higher 
plasma titers of neutralizing antibodies against autologous virus (Joos et al., 2005). 
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Thus, viral properties appeared to influence disease progression being at least in part 
responsible for spontaneous control of viremia after cessation of cART. We also 
performed extensive longitudinal clonal studies of plasma HIV RNA to characterize 
the rebounding virus during the short interruptions and after the prolonged treatment 
break in a subset of patients (Joos et al., 2008). Phylogenetic analysis exploiting the 
temporal relation of rebounding virus to pre-treatment sequences was in accord with 
mono-or oligoclonal reactivation of distinct virus populations from long-lived latently 
infected cells in contrast to expansion of virus populations replicating at a low level. 
Furthermore, viral diversity was restored only very slowly after the final treatment 
stop. This implies that a sustained evolutionary bottleneck was induced by 
suppressive cART. In the long term, evolution of the envelope sequences spanning 
the V3 loop and its flanking regions appeared to be driven by positive selection (Joos 
et al., 2007). Interestingly the adaptive mutations occurred almost exclusively at 
solvent exposed amino acid positions on the virion surface which confer a high 
external accessibility according to the 3D structure of the envelope gp120 (Huang et 
al., 2005) suggesting that these sites evolved in response to selection pressure 
induced by neutralizing antibodies or adaptations in the receptor interaction 
necessitated by shifting cellular tropism. However, in this analysis we detected widely 
different patterns of positively selected sites within the C2-V3-C3 region of gp120 in 
individual patients by codon-based likelihood methods (Kosakovsky Pond and Frost, 
2005).  
Here we aimed at identifying common genetic characteristics of rebounding viruses 
across 20 chronically HIV-1 infected patients having undergone multiple planned 
treatment interruptions. We employed machine learning techniques to determine if a 
shared genetic signature could be found in plasma virus rebounding during the first 
interruption after years of continuous suppressive therapy. Next, we searched for 
specific signatures associated with high or low distance from the most recent 
common ancestor (MRCA) in the phylogeny which would reflect virus populations 
replicating at different speed. In addition, we sought to determine if plasma-derived 
HIV amino acid sequences could be used to predict spontaneous control of viremia. 
We found evidence of a link between HIV Env sequence and viral load by decision 
tree learning and aimed to validate this genetic signature by analyzing amino acid 
sequences originating from different patient groups.  
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2. Materials and methods  
 
2.1. Study subjects 
 
Blood samples were obtained from chronically infected patients enrolled into the 
Swiss-Spanish Intermittent Treatment Trial (SSITT) at the University Hospital Zürich. 
Two patients were excluded because they did not complete the study. We selected 
those patients from whom a pre-treatment plasma sample was available provided 
that PCR amplification was successful. All patients had long-term combination 
antiretroviral therapy (cART) and undetectable viral loads (<50 copies/mL) for at least 
6 months before study entry and then underwent four consecutive STI cycles (2 
weeks off and 8 weeks on treatment), followed by a longer fifth treatment interruption 
of indefinite duration. Patients were classified into ‘‘controlling’’ and ‘‘noncontrolling’’ 
groups. Control of viremia was defined as spontaneous maintenance of viral RNA 
<5000 copies/mL for at least 2 months during the first 4 months after the final cART 
stop (Trkola et al., 2003). Twenty patients were eligible for the current analysis, 9 of 
them were sampled intensively during the interruptions. The salient patient 
characteristics (Joos et al., 2005, 2007; Trkola et al., 2004) and results of the clinical 
trial (Fagard et al., 2003; Fischer et al., 2003a,b, 2004a,b; Metzner et al., 2003; 
Oxenius et al., 2002a,b) have been reported previously.  
We also included 104 primary HIV infected (PHI) patients enrolled in the Zurich PHI 
Study (http://clinicaltrials.gov). All had well-documented acute or recent HIV infection 
presumably within the last 3 months based on the results of plasma HIV-1 RNA, HIV 
p24 antigen determination, Western blot, HIV-gp120 avidity assay and/or clinical 
symptoms of acute retroviral syndrome. The studied subjects include 92 men and 12 
women, the vast majority infected with HIV subtype B (77%), CRF01_AE (10%), A 
(3%), and some with C, F1, G, CFR02_AG, and CFR12_BF. Plasma samples were 
analyzed as part of an ongoing study for all subjects at the time of enrolment before 
antiretroviral therapy was started and where applicable also later on when cART was 
stopped after a median of 18 (range 7–30) months in a subset of 28 patients.  
Both studies were approved by the Ethics Committee of the University Hospital 
Zürich and written informed consent was obtained from all patients.  
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2.2. RNA extraction, RT-PCR, cloning and sequencing 
 
Extraction of viral RNA from plasma and subsequent PCR amplification, molecular 
cloning and bidirectional sequencing of the C2-V3-C3 region of HIV-1 env was 
performed as described (Joos et al., 2005). By extracting HIV RNA from a total of 1 
ml plasma our RT-PCR strategy was designed to maximize the probability that the 
sequenced clones are representative of the actual viral population present in plasma 
in vivo. The method was evaluated by testing the misincorporation rate during the RT 
step, the fidelity of the polymerase and reproducibility in analyzing identical patient 
samples (Joos et al., 2007). Representativity of the isolated viral quasispecies was 
confirmed by comparison with limiting dilution analysis. Similar quasispecies 
compositions were found in few samples tested in parallel by molecular cloning and 
by single genome analysis. This indicates that the used cloning method was not 
excessively affected by resampling bias (Joos et al., 2008). Approximately 16 
individual clones were obtained at each time point. Overall 1753 clonal sequences 
were obtained from a total of 109 longitudinal samples across 20 SSITT patients (31–
190 clones per patient) and 1610 pre-treatment clones were isolated from 104 PHI 
patients.  
 
2.3. Phylogenetic inference 
 
Sequences were edited and aligned using Lasergene software version 5.08 
(DNASTAR Inc., Madison, WI) and manually adjusted in the correct reading frame to 
the following GenBank sequences: HIV-1 subtype B isolates HXB2 (accession 
number K03455), ADA (M60472), YU2 (M93258), BAL (M68893), JRFL (U63632), 
NL4-3 (U26942), subtype A isolate U455 (M62320), subtype C isolate ETH2220 
(U46016), subtype D isolate ELI (K03454), subtype F isolate BR020 (AF005494), 
and the HIV group M envelope fragment ZR59a-2 (AF030527) isolated from a 
historical plasma sample collected in 1959 (Zhu et al., 1998). Neighbor-joining 
phylogenetic trees were inferred by MEGA version 4 (Tamura et al., 2007) using 
genetic distance estimates obtained from Tamura-Nei 6-parameter model. Bootstrap 
analysis was performed using 1000 replicates.  
Maximum likelihood phylogenetic analyses were performed by DNAML on a parallel 
computing cluster using randomized input order, global rearrangements, and multiple 
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jumble options (PHYLIP Phylogeny Inference Package version 3.6 distributed by J. 
Felsenstein, Department of Genetics, University of Washington, Seattle). The 
Slatkin–Maddison test (Slatkin and Maddison, 1989), a cladistic measure of inter-
population gene flow, was used to evaluate the degree of viral population shift 
between the different time points in the longitudinal analysis of clonal sequences 
from the 20 SSITT patients. Screening for intrapatient recombination was performed 
by GARD (Genetic Algorithm for Recombination Detection), using the single 
breakpoint detection method (Kosakovsky Pond et al., 2006). These analyses 
showed no evidence of recombination in the sequences from any individual in this 
study. No putative breakpoints could be identified, and a single phylogeny rather than 
multiple segment-specific phylogenies best described the data in all cases (AIC 
scores were not improved with multiple trees).  
 
2.4. GenBank accession numbers 
 
The reported sequences were deposited in GenBank under accession numbers 
EF424791–EF426096, DQ002058–DQ002345, AY656534–AY656549, AY656440–
AY656471, AY656249–AY6563 12, AY375663–AY375678, AY375616–AY375630, 
and AY375568– AY375583.  
 
2.5. Coreceptor usage prediction 
 
Predictions of coreceptor use were made by the WetCat algorithm (Pillai et al., 2003) 
and by use of position-specific scoring matrices trained on the syncytium-inducing 
phenotype (PSSM SI/NSI) and on the X4 or R5 coreceptor phenotype (PSSM X4/ 
R5) (Jensen et al., 2003). The former method applies a support vector machine-
based learning technique to classify the V3 loop amino acid sequences of the 
envelope glycoprotein according to sequences from viruses with known coreceptor 
phenotype. The latter derives a score by using precalculated matrices for the 35 
amino acids forming the V3 loop. Both methods yielded comparable results. CXCR4-
using virus was sporadically detected in the longitudinal sequences but in the 
combined analysis no clear switch in coreceptor usage was found.  
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2.6. Glycosylation sites 
 
Potential N-linked glycosylation sites were assessed with the N-GlycoSite tool 
provided by Los Alamos HIV Sequence database (Zhang et al., 2004).  
 
2.7. Positive selection detection 
 
Identification of positively selected amino acid positions was performed by Single 
Likelihood Ancestor Counting, Fixed Effects Likelihood, and Random Effects 
Likelihood methods using the HyPhy software package (Kosakovsky Pond and Frost, 
2005). Duplicate sequences were removed and the optimal timereversible 
substitution model was determined for each patient before the analysis.  
 
2.8. Machine learning 
 
Open source machine learning software Weka 3.5 (Waikato environment for 
knowledge analysis) was used to develop decision trees by the J48 algorithm (Frank 
et al., 2004). The minimum number of objects per leaf node was set at high values in 
all classification experiments to confine the complexity of the models and reduce 
overfitting bias (since total numbers of sequences varied the best fitting models with 
minNumObj values of 10–20 were selected). Prediction performance was evaluated 
by stratified 10-fold cross-validation method. The sensitivity (recall) is defined as 
TP/TP + FN, specificity (precision) by TP/TP + FP, where TP is the number of the 
true positives, FN the number of underpredictions and FP the number of 
overpredictions. The balanced F-score is the weighted harmonic mean of recall and 
precision given by the formula F =2 x (precision x recall)/(precision + recall). Kappa 
coefficients (observed coincidence -expected coincidence)/ ([1 - expected 
coincidence]) and the area under the ROC curve (receiver operating characteristic) 
were also used to measure the performance of the classification algorithms and are 
also reported.  
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2.9. Statistical analyses 
 
For standard statistical analyses GraphPad Prism version 5 (GraphPad Software, 
San Diego, CA) was used. Nonparametric tests with Bonferoni adjustment for 
multiple comparisons were applied for group comparisons (Mann–Whitney) and 
correlations (Spearman). Two-sided Fisher’s exact test was used to determine 
associations between categories. Positive predictive value (PPV) is defined as TP/TP 
+ FP, negative predictive value (NPV) as TN/ FN + TN (TP = true positives; FP = 
false positives; TN = true negatives; FN = false negatives).  
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3. Results  
 
To study the association between HIV-1 env genotype and viral load in chronically 
infected patients we took advantage of the Swiss-Spanish Intermittent Treatment 
Trial (SSITT) and followed 20 patients longitudinally. The first samples were obtained 
during the chronic phase of infection before any treatment was started. Subsequently 
patients received combination antiretroviral therapy for a median of 2.7 (range 1.5–
3.4) years and then underwent 4 treatment interruption cycles (2 weeks interruption 
and 8 weeks retreatment) followed by cART stop. Clonal HIV-1 env sequences 
encompassing the C2-V3-C3 region of gp120 were isolated from pre-treatment 
plasma and from the last available sample following treatment stop. Nine of the 20 
patients also had intense sampling during the interruptions. Overall, 1753 clonal 
sequences were derived from 109 samples collected over 6.5 (range 3.3–8.6) years 
(Joos et al., 2007, 2008). A Neighbor-joining phylogenetic tree including all 
sequences failed to show any evidence of cross contamination between study 
subjects or contamination with laboratory strains (Fig. 1). Phylogenetic trees were 
also constructed with the sequences of each patient alone by using much more 
computer intensive maximum likelihood method. This allowed us to infer the 
individual most recent common ancestral sequences (MRCA) and to explore the 
structure of the phylogenetic trees in regard to sampling time.  
The relationship between sampling time and viral population diversity was 
determined in the nine patients analyzed before treatment as well as during the four 
structured treatment interruptions and sequentially thereafter (Fig. 2). Relatively 
homogenous virus populations emerged during the short 2-week interruptions (time 
0–0.8 years) but at different time points often phylogenetically distinct virus 
populations appeared. After treatment cessation, diversity increased gradually with a 
substantial delay. On average the level of pre-treatment diversity was not achieved 
until 2.5 years after beginning of the study, when appreciable divergence from the 
virus populations observed before treatment was also apparent (Fig. 3). Evolution of 
the genetic distances to the MRCA in the nine frequently sampled patients is shown 
in Fig. 4. While the average branch lengths to the MRCA remained relatively stable 
over the observed time period, transient drops were observed during STI in all 
individuals. In comparison with the genetic distance to the MRCA at pre-treatment, 
marked reductions by>1% occurred in 7/9 patients (range 1.1–2.7%) suggesting 
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rebound of archived viral variants which were already present generations before the 
initiation of cART or even at the time of infection. Increasing branch lengths to the 
MRCA indicating ongoing evolution were observed in the majority of patients after the 
final treatment stop.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Phylogenetic tree. Inferred neighbor-joining phylogenetic tree of clonal HIV-1 env C2-V3-C3 sequences 
derived from 20 patients. Elongated triangles represent the compressed subtrees containing 31–190 clones 
isolated from plasma of each patient before antiretroviral therapy and after treatment interruptions. The length of 
the triangle corresponds to the respective intrapatient diversity, thickness is proportional to the number of taxa. 
The bar denotes 2% nucleotide divergence and diversity (determined using the MEGA software), bootstrap values 
corresponding to 1000 replications are indicated below the branches. 
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Fig. 2. Diversity. Longitudinal changes in viral diversity of clonal C2-V3-C3 sequences from nine 
patients before treatment and following structured treatment interruptions starting at time 0. The dark 
line indicates the median time course, patients have the same colour coding in this figure and Fig. 3 
and Fig. 4. Distances were estimated by Tamura-Nei 6-parameter model. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of the article.) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Divergence. Longitudinal changes of average genetic distances (net divergence) from pre-
treatment C2-V3-C3 sequences in nine patients following structured treatment interruptions starting at 
time 0. The dark line indicates the median time course, patients have the same colour coding in this 
figure and Fig. 2 and Fig. 4. Distances were estimated by Tamura-Nei model. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of the article.)  
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Fig. 4. Distance from MRCA. Longitudinal changes in average branch lengths to the most recent 
common ancestor (MRCA) of clonal C2-V3-C3 sequences from nine patients before treatment and 
following structured treatment interruptions starting at time 0. The dark line indicates the median time 
course, patients have the same colour coding in this figure and Fig. 2 and Fig. 3. Distances were 
estimated by Tamura-Nei model. (For interpretation of the references to colour in this figure legend, 
the reader is referred to the web version of the article.) 
 
 
 
Table 1. Env C2-V3-C3 sequence classification based on control of viremia following treatment stop 
(cross-validation statistics).  
 
Class variable control of viremia 
Sequences first rebound 1st-5th 
rebound 
all sequences
Total number of instances 140 614 1753 
Correctly classified 
instances 
138 (98.6 %) 607 (98.9 %) 1743 (99.4 %) 
Kappa coefficient  0.971 0.977 0.989 
Sensitivity  1.000 0.993 0.996 
Specificity  0.975 0.983 0.991 
F- score  0.987 0.988 0.994 
ROC Area  0.997 0.988 0.997 
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3.1. Genetic characteristics of rebounding virus 
 
The distinct phylogenies and low diversities observed in plasma virus rebounding 
during the first treatment interruption after years of continuous suppressive therapy 
suggested potential reservoirs as the source of viral rebound. We posited that such 
virus might share some compartment-specific genetic signatures and features that 
could be obscured by interpatient sequence differences as has been shown for CSF 
virus and virus in genital secretions (Pillai et al., 2005, 2006). To explore this further, 
we employed machine learning techniques to search for a specific signature 
associated with first rebound among the clonal sequences originating from the nine 
patients with frequent longitudinal sampling.  
Initially we compared the C2-V3-C3 sequences (126 amino acids) obtained during 
the first treatment interruption with those collected at pre-treatment, at later structured 
interruptions and during the last prolonged treatment interruption. In addition we also 
compared the first rebound sequences with those from all 20 patients at all time 
points. Testing showed no evidence of a genetic signature shared by the amino acid 
sequences derived from the first virus rebounds in plasma. Sensitivities of the 
predictions ranged from 0.357 to 0.736 and specificities from 0.71 to 0.893 resulting 
in balanced F-scores of 0.51–0.747. Kappa coefficients (chance-corrected 
proportional agreement) ranged from 0.488 to 0.641. Next, we applied decision tree 
learning to classify the sequences collected during the first STI on the basis of their 
distance to the MRCA. However, no clear genetic signature associated with high or 
low branch length to the MRCA could be detected.  
Strong evidence for a genetic signature was found when the sequences derived from 
rebounding virus in the nine patients with frequent sampling were classified by 
control of viremia (defined by maintenance of viral loads <5000 RNA copies/mL for at 
least 2 months) after treatment stop (kappa coefficients >0.95, Table 1). Somewhat 
different classification models were inferred by using the sequences isolated during 
the first rebound alone (Fig. 5A) and those from the first to fifth rebounds (Fig. 5B) as 
training data sets. Interestingly, the common feature consisting of just glutamic acid 
at amino acid position 268 in combination with threonine at position 358 (268E/358T) 
was present in 647 out of 715 sequences obtained during all time points from 
controlling patients as opposed to only 63 of 687 sequences in non-controllers (Table 
2, Fisher’s exact p < 0.0001, kappa coefficient of agreement 0.813). The accuracy of 
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this association was consequently even slightly improved when the entire 
classification model (as illustrated in Fig. 5B) was linked to control of viremia in these 
patients (kappa 0.886; 670/715 sequences versus 35/687 sequences). A more 
complex, but also highly accurate decision tree was achieved when all envelope 
sequences from all individuals were tested. The signatures associated with control or 
no control of viremia primarily comprised the surface exposed amino acid residues at 
positions 268, 358, 269, 352 and 278 where significant positive selection has partially 
been detected before (relative surface accessibility 48.0 ± 18.8%, data shown 
elsewhere; Joos et al., 2007). Of note, this genetic signature found in patients 
spontaneously controlling plasma viremia was already present in the pre-treatment 
sequences and thus was not attributable to treatment interruptions.  
 
3.2. Association of genetic signature with control of viremia 
 
The depicted exploratory analysis of sequences isolated from the nine frequently 
sampled SSITT patients revealed that presence of the simple pattern 268E/358T in 
HIV envelope protein gp120 could be strongly associated with virologic control. Next 
we tried to validate this finding rigorously in different populations. For this purpose we 
evaluated clonal sequences from the remaining 11 SSITT patients with less frequent 
sampling and from a group of well-characterized primary HIV infected patients. These 
analyses were done by categorizing individual patients upon presence of 268E/358T 
in all clones isolated before treatment was started. We chose this restrictive condition 
under the assumption that a minority of fitter viruses might eventually overgrow the 
‘‘beneficial’’ variants which presumably have reduced replication capacity.  
While the predictive performance of the genetic pattern was naturally in the clonal 
analyses of the training data sets (Table 3,A– C), a different picture was found in the 
patient-wise analyses (Table 3, D–G). The very strong positive predictive values of 
the signature 268E/358T associated with viral control in the 9 frequently sampled 
SSITT patients were not confirmed in the 11 SSITT patients with less frequent 
sampling (Table 3, D). However, high negative predictive values were retained in this 
group as well as in the combined analysis of all chronically infected patients of the 
SSITT study (Table 3, E). Basically the same result, very high sensitivity and 
negative predictive value, was achieved by analyzing the sequences isolated from 
the first plasma samples of 104 primary HIV infected patients before treatment (Table 
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3, F). Participating in an ongoing study, most of the PHI patients currently remain 
under combined antiretroviral therapy. In 28 of them treatment was meanwhile 
stopped and viremia was contained at levels below 5000 copies/mL in some patients. 
Acceptable sensitivity and negative predictive value but low positive predictive value 
was also obtained in this group (Table 3, G). Interestingly, raising the cut-off for 
virologic failure from 5000 to 10,000 RNA copies/mL did practically not influence the 
result of the analysis. Five thousand was chosen here in order to be consistent with 
the definitions of the SSITT study.  
The signature 268E/358T is present in 50% of the Env sequences which are 
collected in the Los Alamos National Laboratory HIV Sequence Database and 
represent the full spectrum of worldwide HIV-1 and SIVcpz sequences (year 2007 
web alignment, 1766 sequences, 
(http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html). A fraction of 73% 
was found among the currently available sequences of subtype B viruses, in 
particular 71% and 79% of those with predicted CCR5 and CXCR4 coreceptor 
usage, respectively.  
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Table 2. Env C2-V3-C3 sequence classification according to control of viremia following treatment stop. 
Validation of patterns inferred from the training data sets (rebounding virus) in longitudinal samples collected from 
nine patients before treatment (pre), during 5 structured interruptions (STI), and 1-2 years as well as ≥2.5 years 
following treatment stop. Numbers indicate frequencies of matching clonal sequences. 
Patient Control of viremia Time 268E & 358T 
Signature associated 
with control 
   present absent present absent 
106 yes pre 32 0 32 0 
  STI 78 1 79 0 
  1-2y 48 0 48 0 
  ≥2.5y 31 0 31 0 
107 yes pre 6 10 14 2 
  STI 31 1 32 0 
  1-2y 12 4 13 3 
  ≥2.5y 11 21 11 21 
118 yes pre 16 0 16 0 
  STI 80 0 80 0 
  1-2y 41 7 41 7 
  ≥2.5y 31 1 31 1 
123 yes pre 12 4 10 6 
  STI 63 0 63 0 
  1-2y 46 2 46 2 
  ≥2.5y 24 8 29 3 
124 yes pre 16 0 16 0 
  STI 30 0 30 0 
  1-2y 32 0 32 0 
  ≥2.5y 7 9 16 0 
109 no pre 10 22 10 22 
  STI 1 94 1 94 
  1-2y 21 2 21 2 
  ≥2.5y 0 16 0 16 
113 no pre 0 16 0 16 
  STI 0 63 1 62 
  1-2y 3 45 0 48 
  ≥2.5y 11 21 0 32 
120 no pre 0 16 0 16 
  STI 0 94 0 94 
  1-2y 0 47 0 47 
  ≥2.5y 0 32 0 32 
128 no pre 3 13 0 16 
  STI 7 71 2 76 
  1-2y 2 45 0 47 
  ≥2.5y 5 27 0 32 
Total with control of viremia: 647 68 670 45 
Total without control of viremia: 63 624 35 652 
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Fig. 5.Decision tree learning. Genetic characteristics of rebounding virus in nine patients with frequent 
longitudinal sampling. Signature associated with control of viremia after treatment stop (yes or no) in 
C2-V3-C3 sequences from first rebound (A, n = 140) and those from first to fifth rebound (B, n = 614). 
J48 decision tree learning algorithm and stratified 10-fold cross-validation by Weka. Residues are 
numbered according to HXB2 gp160 positions. Minus sign (−) denotes an amino acid deletion in the 
sequence. Numbers in parentheses indicate the total number of instances classified by the node and, 
if a second value is present, how many instances are incorrectly classified. Controlling patients are 
preferentially characterized by glutamic acid (E) at position 268 in combination with threonine (T) at 
358. 
 
Table 3: Association of genetic signature with control of viremia 
pt (n) CTR (n) a clones (n) type of 
analysis b
sensitivity specificity PPV c NPV c
A SSITT first 
rebound
9 5 140 cl 0.987 0.937 0.95 0.983
B SSITT all 
rebounds
9 5 614 cl 0.993 0.976 0.972 0.994
C SSITT all 
timepoints
9 5 1402 cl 0.905 0.908 0.911 0.902
D SSITT 
external 
validation
11 2 176 pt 1 0.444 0.286 1
E SSITT all 
patients
20 7 352 pt 0.714 0.615 0.5 0.8
F PHI 
baseline
104 8 1610 pt 1 0.375 0.118 1
G PHI plateau 28 8 429 pt 0.75 0.55 0.4 0.846
  Data set
 
a) control of viremia <5000 copies/mL for at least 2 months after cART stop, resp. viral load <5000 (set 
F)  
b) analysis based on individual clones (cl) or patients (pt) 
c) PPV = positive predictive value, NPV = negative predictive value. 
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4. Discussion  
 
It is well accepted that the replicative capacity of HIV in vivo is influenced by both 
genetic characteristics of the host and those of the virus. Interactions between virus 
and the host’s immune system are complex and better understanding of the 
underlying mechanisms is important for planning optimized treatment strategies and 
for vaccine development. In a comprehensive longitudinal study we examined the 
virus characteristics of HIV envelope in a well-defined group of chronically HIV 
infected patients undergoing structured treatment interruptions. Patients were 
enrolled in the Swiss HIV-cohort study for years and were studied prior to cART, 
during continuous cART and subsequently during a structured treatment interruption 
trial (Swiss Spanish Intermittent Therapy Trial) (Fagard et al., 2003; Fischer et al., 
2003a, 2004a; Joos et al., 2005, 2007; Oxenius et al., 2002a,b; Trkola et al., 2003). 
Here, we specifically attempted to find a common pattern in the phylogeny of the 
rebounding virus, to relate HIV-1 env genotype with HIV RNA levels and to test 
whether spontaneous virologic control after cessation of cART can be predicted from 
plasma-derived amino acid sequences.  
Remarkable features could be deduced from the phylogenetic analyses (Joos et al., 
2008). During the short treatment interruptions distinct mono-or oligoclonal virus 
rebounded but no significant evolution with regard to the MRCA was detected 
between the investigated time points. This indicates random reactivation of archived 
virus populations from latently infected cells without any significant residual 
replication in patients receiving potent cART. Unexpectedly, after the final treatment 
stop it took 1–2 years until the virus diversity reached the extent from before 
treatment. This long lasting effect shows that treatment introduced a strong 
bottleneck in viral evolution. Total divergence rate from the first to the last time 
points, averaged over the drug free periods only, was about 1% per year which is in 
agreement with previous reports (Shankarappa et al., 1999).  
By applying machine learning techniques we further explored whether specific 
sequence patterns of HIV-1 env are associated with spontaneous virologic control. A 
decision tree inducer revealed in the sequences derived from the first virus rebound 
in plasma a strong genetic signature associated with maintenance of viremia at low 
levels after treatment stop. The signature was very simple and comprised two 
externally accessible amino acid sites located in the N-terminal and C-terminal 
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flanking regions adjacent to the V3 loop (Fig. 6). The pattern at gp120 positions 
268E/358T was also found in the clonal sequences isolated during all subsequent 
rebounds. However, since all sequences originated from the same patients, this 
could also be due to overfitting. Indeed, attempts to verify the predictive capacity of 
the genetic pattern by external validation in a different group of SSITT patients and in 
primary HIV infected patients failed because specificity was lost. However, high 
sensitivity and negative predictive value were retained even in the large group of 104 
PHI patients. This implies that presence of virus lacking the amino acid pattern 
268E/358T was clearly associated with high viral loads at baseline and after 
treatment interruptions in both primary and chronically HIV infected patients. 
Conversely, however, presence of 268E/358T was not able to predict spontaneous 
control of viremia after treatment stop. It is conceivable that mutations at these two 
positions in HIV envelope gp120 affect in vivo fitness of the virus either at the level of 
Env function or by influencing susceptibility to adaptive or innate immune control.  
A potential limitation of this study is that only a fragment of gp120 and not full length 
env sequences were analyzed. It is not clear whether the two identified positions 
alone contribute to differential replication capacity since the occurrence of 
compensatory mutations due to changes elsewhere in the envelope cannot be 
excluded. Additionally, the influence of host genetic polymorphisms and HLA types 
on the virologic outcomes could also not be assessed. Overall, the relatively small 
number of patients in this study may limit the power of our analysis and prohibit 
generalization.  
The key finding of our analyses was that patients harbouring virus variants differing 
from gp120 268E/358T may have a lower probability of spontaneous virologic control 
after treatment stop. Intrinsic viral characteristics were, at least in part, responsible 
for reduced in vivo replication capacity. Whether incorporation of baseline genotypic 
analysis of HIV envelope will help in allocating different treatment options in the 
future, e.g. in patients who are not willing to continue lifelong therapy needs to be 
assessed in further trials.  
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Own contribution 
 
An individual is typically infected by a few HIV-1 clones which dramatically increase 
in copy numbers but not in genetic diversity during the first month of infection. 
Following this acute infection period genetic diversity increase at a relatively linear 
rate with the length of infection. Thus, the diversity of the HIV-1 population within an 
infected patient may potentially classify an infection status into recent or chronic. This 
classification may be useful, for example, in epidemiological studies to evaluate the 
incidence of HIV-1. Here we evaluated the usefulness of ambiguous nucleotide calls 
from routinely generated HIV pol sequences as a potential measure of viral diversity. 
For this we investigated three different patient groups: patients with unknown date of 
infection (time of infection was calculated using a statistical backcalculation model, 
patients with known seroconversion and the ZPHI patients. 
The study with the most stringent known date of infection was the the ZPHI data set. 
For each patient, a minimal and maximal timepoint of infection was estimated 
integrating all available information, including patient history relating to known risk 
situations, occurrence of first symptoms, previous negative test results, avidity 
assays and western blot. 
Moreover, to evaluate the ZPHI set, the diversity of clonal env sequences of 130 
patients with 10- 16 clones per sample have been used. I extracted viral RNA from 
plasma and did PCR amplification, molecular cloning and bidirectional sequencing of 
the C2-V3-C3 region of HIV-1 env. By using different bioinformatic tools, I edited and 
aligned sequences, in addition to manually adjusting. To exclude laboratory 
contamination I constructed Neighbor-joining phylogenetic trees by using HXB2 and 
Non-B strains as references and bootstrapping. The C2-V3-C3 derived clonal 
diversity was used to validate diversity as defined by ambiguous nucleotide calls from 
overall numbers of patients. Furthermore, it also allowed to test whether diversity 
measured on one gene (HIV pol) also correlated with the one of another gene (HIV 
env). 
We observed a significant correlation between the fraction of ambiguous nucleotides 
in the pol gene and the diversity of clonal env sequences, which confirms that the 
fraction of ambiguous nucleotides is a good marker for viral diversity. In addition, the 
fraction of ambiguous nucleotides in the ZPHI data set is consistent with that found in 
the other data sets.  
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Abstract 
 
BACKGROUND: The time passed since the infection of a human 
immunodeficiency virus (HIV)-infected individual (the age of infection) is an 
important but often only poorly known quantity. We assessed whether the 
fraction of ambiguous nucleotides obtained from bulk sequencing as done for 
genotypic resistance testing can serve as a proxy of this parameter. 
 
METHODS: We correlated the age of infection and the fraction of ambiguous 
nucleotides in partial pol sequences of HIV-1 sampled before initiation of 
antiretroviral therapy (ART). Three groups of Swiss HIV Cohort Study 
participants were analyzed, for whom the age of infection was estimated on the 
basis of Bayesian back calculation (n = 3,307), seroconversion (n = 366), or 
diagnoses of primary HIV infection (n = 130). In addition, we studied 124 
patients for whom longitudinal genotypic resistance testing was performed 
while they were still ART-naïve. 
 
RESULTS: We found that the fraction of ambiguous nucleotides increased with 
the age of infection with a rate of .2% per year within the first 8 years but 
thereafter with a decreasing rate. We show that this pattern is consistent with 
population-genetic models for realistic parameters. Finally, we show that, in 
this highly representative population, a fraction of ambiguous nucleotides of 
>.5% provides strong evidence against a recent infection event <1 year prior to 
sampling (negative predictive value, 98.7%). 
 
CONCLUSIONS: These findings show that the fraction of ambiguous 
nucleotides is a useful marker for the age of infection. 
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Introduction 
 
Human immunodeficiency virus type 1 (HIV-1) infections are initiated in most cases 
by a single virus [1], leading initially to a monomorphic viral population. 
Subsequently, viral diversity builds up gradually during HIV infection, first in a linear 
fashion but then at decreasing rates until a plateau is reached [2, 3]. In late-stage 
HIV infection, even decreases in viral diversity have been observed [3]. Thus, the 
diversity of the HIV population within an individual patient is potentially informative 
about the age of the infection, which is an important parameter because it allows an 
assessment of how far and how fast the infection has progressed. Seroconversion 
data are often lacking, and acute retroviral syndrome may have not occurred or may 
not have been recognized as such [4]. Thus, a method to estimate the infection 
duration based on viral sequences would be attractive, given the abundance of HIV 
sequence data from genotypic drug resistance tests.  
Genotypic resistance tests use nucleotide sequences to infer to what degree different 
drugs may inhibit a given viral population of an HIV-infected individual. For economic 
reasons, these sequences are obtained by bulk sequencing; that is, the sequencing 
procedure is applied to a diverse sample of the HIV population. If the frequency of 
the most frequent nucleotide at a given position exceeds a threshold (typically around 
80%), bulk sequencing returns the predominant nucleotide at this position. However, 
if this is not the case, then so-called ambiguous nucleotide calls are reported, 
implying that the patient harbors viral strains with different nucleotides at this locus. 
Thus, the fraction of ambiguous nucleotides is a measure of the degree of 
polymorphism of the HIV population within a patient, which in turn should scale with 
the age of infection. Here, we assess to what degree the proportion of ambiguous 
nucleotides correlates with the time elapsed between HIV infection and sampling for 
genotyping. To this end, we relate the fraction of ambiguous nucleotides to the age of 
infection derived with methods of different accuracy from 4 data sets. 
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Materials and Methods 
 
We used previously analyzed nucleotide sequences from patients included in the 
Swiss HIV Cohort Study (SHCS) drug resistance database (see Kouyos et al [5] and 
GenBank accession numbers therein for a random sample of sequences). The SHCS 
is a nationwide, prospective, clinic-based cohort study with continuous enrollment 
and semiannual study visits [6, 7]. The SHCS has been approved by the ethical 
committees of all participating institutions, and written informed consent has been 
obtained from the participants. The SHCS drug resistance database contains the 
results of 13,201 genotypic resistance tests from 9,231 patients performed by the 4 
laboratories engaged in HIV resistance testing in Switzerland, stored in a central 
database developed and hosted by SmartGene (Zug, Switzerland; Integrated 
Database Network System, version 3.5.0) [8]. Resistance data stem from routine 
clinical testing (60% of tests) and from tests performed retrospectively from frozen 
repository plasma samples (40% of tests). Retrospective sequencing was performed 
systematically by analyzing the earliest plasma sample available for each patient. All 
laboratories perform population-based sequencing of the full protease gene and at 
minimum codons 28–225 of the reverse transcriptase gene by means of commercial 
assays (Viroseq version 1, PE Biosystems; Virsoseq version 2, Abbott AG; 
vircoTYPE HIV-1 assay, Virco Lab) and in-house methods [9].  
Subtype B dominates the Swiss HIV-1 epidemic [10, 11], and we therefore focused 
on this subtype (n = 9,157 sequences). Because antiretroviral therapy strongly 
distorts viral diversity [12], we included only sequences from patients who were 
therapy-naïve at the time of sampling and for whom an independent estimate of 
infection time was available (3,307 sequences, each from a different patient). The 
year of infection was estimated as described elsewhere [13] as the median of patient-
specific infection time estimates based on a Bayesian back calculation model 
incorporating the dates of the first positive or last negative HIV test results and CD4 
counts as predictor variables. Note that this infection time estimate is independent of 
the viral sequence. We refer to this data set as the full data set. Furthermore, we 
considered 3 additional sets of patients, for whom times or time differences are 
known with better accuracy: (1) In the set of seroconverters (366 patients), patients 
were recruited to the cohort within 1 year after infection, based on documented 
negative and positive HIV test results no longer than 180 d apart [11]; (2) The 
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longitudinal set contains 124 patients for whom sequences are available at 2 time 
points (at least 6 months apart). Although for this data set the time of infection is not 
more precise than for the large data set, the age difference of the 2 samples is 
known exactly; and (3) The Zurich Primary HIV Infection Study (ZPHI; 
ClinicalTrials.gov identifier, NCT00537966) set contains 130 patients with sequences 
obtained during acute infection (median time from infection, 41 d; interquartile range 
[IQR], 28–56 d) [14].  
The relationship between the proportion of ambiguous positions (the dependent 
variable) and the time since infection was investigated using linear regression 
analysis. Because model residuals were not normally distributed, we performed a 
bootstrap analysis with 1,000 replicates to obtain 95% confidence intervals (CIs). We 
verified results by repeating all analyses on logit-transformed fractions by use of a 
generalized linear model for proportions. Both crude and adjusted analyses, using 
the patient's mode of HIV acquisition, ethnicity, sex, and age, were performed. In 
addition, a variable coding for the sequence-generating laboratory was included to 
account for assay- or laboratory-specific effects. All P values were 2-sided, and the 
level of statistical significance was set at .05.  
We sought to identify a cutoff in the proportion of ambiguous sites to classify a 
patient's infection status into recent (infected for ≤1 year) or chronic (infected for >1 
year). The classification performance of 2 categorizations of the proportion of 
ambiguous sites was evaluated with receiver operating characteristic (ROC) 
analyses. The first analysis included ambiguous sites as a categorical variable with 5 
groups based on quintiles, whereas for the second analysis only 2 categories were 
included based on an a priori defined cutoff of ≤.5% or >.5% ambiguous positions.  
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Results 
 
In this study, we included HIV subtype B sequences of 3,307 patients. As shown in 
Table 1, the majority of individuals in our sample were male (n = 2,593; 78.4%) and 
of white ethnicity (n = 2,933; 88.7%). Of these 3,307 patients, 1,482 (45%) had 
acquired HIV through homosexual contacts, 862 (26.1%) through intravenous drug 
use, and 857 (25.9%) through heterosexual intercourse. The median year of infection 
was 1995 with an IQR of 1991–2000, and the median duration from infection to 
sampling for genotypic sequencing was 4.7 years (IQR, 3.3–6.9 years). 
We found that for HIV-1 sequences sampled before initiation of antiretroviral therapy, 
the fraction of ambiguous nucleotides increases significantly with the age of infection. 
This relationship is shown in Figure 1A for the full data set (3,307 patients) for whom 
the age of infection has been estimated with the back calculation algorithm (see 
Materials and Methods and Taffe and May [13]). Figure 1A shows that the fraction of 
ambiguous sites grows linearly with time in the first few years of infection and then 
flattens off. This effect can be described by including time since infection as a linear 
and a quadratic term in an adjusted regression model with the fraction of ambiguous 
nucleotides as outcome: if all patients are taken into account, both the positive linear 
and the negative quadratic components significantly improve the quality of the fit 
(model with linear term, r2 = .14; model with additional quadratic term, r2 = .17) 
(Figure 1B; Table 1). Because the initial increase in the proportion of ambiguous 
positions is almost linear during the first phase of infection, we further restricted our 
analyses to patients with an HIV sequence obtained in this phase of linear increase, 
that is, within the first 8 years of infection (n = 2,729). These adjusted analyses 
revealed a yearly increase in the proportion of ambiguous sites of ∼.2 percentage 
points per year (Table 1), which was comparable with results from unadjusted 
regression analyses with yearly increases of .25% (95% CI, .23%–.28%) for the full 
sample and .19% (95% CI, .18%–.21%) for the sample restricted to patients with an 
infection duration of ≤8 years. Interestingly, Table 1 indicates that the mode of HIV 
acquisition significantly affects the level of diversity. In particular, intravenous drug 
users exhibit a larger fraction of ambiguous nucleotides than do both heterosexuals 
and men who have sex with men, which may suggest broader transmission 
bottlenecks for blood-transmitted than for sexually transmitted HIV. 
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Table 1 
 N (%) All patients N (%) Patients infected <8 years 
N 3307 (100)  2729 (100)  
     
Time since infection (per year)  0.195 [0.170 to 0.221]  0.158 [0.141 to 0.175] 
Time since infection (quadratic term)  -0.007 [-0.008 to -0.005]  NA 
     
Female sex 714 (21.6) 0.034 [-0.053 to 0.121] 542 (19.9) 0.054 [-0.047 to 0.159] 
     
Age by quartile;  [min;max]     
[25 ; 30] 949 (28.7) Referent 862 (31.6) Referent 
[33 ; 35] 789 (23.9) 0.146 [0.060 to 0.233] 605 (22.2) 0.140 [0.047 to 0.233] 
[38 ; 41] 781 (23.6) 0.232 [0.144 to 0.319] 613 (22.5) 0.247 [0.145 to 0.338] 
[45 ; 54] 788 (23.8) 0.237 [0.146 to 0.328] 649 (23.8) 0.252 [0.153 to 0.348] 
     
Ethnicity     
White 2933 (88.7) Referent 2455 (90.0) Referent 
Black 63 (1.9) 0.169 [-0.060 to 0.399] 58 (2.1) 0.080 [-0.122 to 0.290] 
Hispano-American 97 (2.9) 0.325 [0.141 to 0.509] 89 (3.3) 0.343 [0.140 to 0.546] 
Asian 57 (1.7) 0.090 [-0.147 to 0.328] 55 (2.0) 0.095 [-0.109 to 0.290] 
Unknown ethnicity 157 (4.7) -0.039 [-0.200 to 0.122] 72 (2.6) 0.001 [-0.186 to 0.211] 
     
Mode of HIV acquisition     
Heterosexual risks 857 (25.9) Referent 722 (26.5) Referent 
Intravenous drug use 862 (26.1) 0.233 [0.142 to 0.323] 595 (21.8) 0.247 [0.140 to 0.357] 
Homosexual risks 1482 (44.8) -0.066 [-0.154 to 0.021] 1326 (48.6) -0.063 [-0.154 to 0.031] 
Unknown risk 106 (3.2) 0.121 [-0.062 to 0.305] 86 (3.2) 0.186 [-0.006 to 0.416] 
     
Laboratory     
Laboratory A 213 (6.4) Referent 178 (6.5) Referent 
Laboratory B 1450 (43.8) 0.407 [0.274 to 0.540] 1176 (43.1) 0.357 [0.246 to 0.456] 
Laboratory C 319 (9.6) 0.404 [0.247 to 0.562] 264 (9.7) 0.312 [0.180 to 0.430] 
Laboratory D 1325 (40.1) 0.787 [0.653 to 0.921] 1111 (40.7) 0.705 [0.594 to 0.803] 
     
Calendar year of sequencing  
(median [interquartile range]) 
2007  
[2006-2008] 0.119 [0.101 to 0.137] 
2007  
[2006-2008] 0.111 [0.093 to 0.127] 
     
Log10 HIV RNA copies/mL at time of GRT     
 (by 33 percentiles) [min, max]     
[3.3 ; 4.0] 1013 (30.6) Referent 829 (30.4) Referent 
[4.5 ; 4.8] 1013 (30.6) 0.097 [0.017 to 0.176] 859 (31.5) 0.043 [-0.050 to 0.128] 
[5.2 ; 5.7] 1011 (30.6) 0.136 [0.056 to 0.217] 853 (31.3) 0.063 [-0.020 to 0.151] 
HIV RNA missing 270 (8.2) -0.106 [-0.235 to 0.023] 188 (6.9) -0.130 [-0.273 to 0.026] 
     
Constant term  -1.046 [-1.231 to -0.860]  -0.885 [-1.042 to -0.732] 
     
1 unit = 1%     
 
Table 1: Summary of the adjusted least squares regression for the full data set. The 95% confidence 
intervals were estimated with bootstrapping over 1000 replicates. Note that for the quadratic model 
(first column) both the linear and the quadratic term significantly improve the fit, but not when only the 
first 8 years of infection were considered Point estimates printed in bold-face were statistically 
significant by Wald test. 
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Figure 1.  
Relationship between the year of infection and the fraction of ambiguous nucleotides (f). A, Mean of f 
as a function of the age of infection, where data points have been binned according to the age of 
infection in years (n = 3,307 patients). The shaded area corresponds to the 95% confidence interval 
of the means of f. These confidence intervals have been determined by bootstrap (with 1,000 
samples). The red point corresponds to the mean of f for the Zurich Primary HIV Infection Study data 
set (n = 130), for which all sequences stem from the first few months after the infection. The 
associated red line gives the 95% confidence interval of this mean. B, Quadratic and linear fit of the 
full data set. Note that the linear fit is restricted to ages of infection of ≤8 years. C, Linear fit of the 
different data sets. Only sequences obtained within the first 8 years after infection were considered. D, 
Distribution of the age of infection (in years) for different fractions of ambiguous nucleotides. The left 
plot depicts the density plot of the age of infection for the 5 quintiles of f. The right plot depicts, for 
each of the 5 quintiles of f, the 25%–75% percentiles (green lines) and 5%–95% percentiles (black 
lines) of the year of infection. 
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To further assess the validity of the relationship between ambiguity and age of 
infection, we examined the smaller seroconverter set, which consists of 366 
individuals who were recruited to the cohort in the early phase of their infection and 
for whom therefore the time point of infection was known within a given time interval 
of 6 months, and the longitudinal set, which contains 124 patients with sequence 
samples obtained from 2 time-points at least 6 months apart from each other. In the 
latter data set, inclusion was restricted to those patients for whom both samples were 
obtained within the first 8 years of infection. For these patients, we correlated the 
length of the time interval between the 2 measurements with the increase of the 
fraction of ambiguous nucleotides. Figure 1C shows that both additional data sets 
yield an estimate for the increase of ambiguous nucleotides over the first 8 years 
after infection that is similar to the estimate yielded by the original data set. Finally, 
we used the ZPHI data set, which contains the most stringent infection time estimate, 
to test the diversity around the time point of infection. Figure 1A shows that the 
fraction of ambiguous nucleotides in the ZPHI set is consistent with that found in the 
other 3 data sets. Moreover, for the ZPHI set, we observed a highly significant 
correlation (Spearman ρ = 36; P < .001) between the fraction of ambiguous 
nucleotides in the pol gene and the diversity of clonal env sequences [14], which 
confirms that the fraction of ambiguous nucleotides is a good marker for viral 
diversity.  
In order to explore whether the observed correlation between infection time and the 
fraction of ambiguous sites could be exploited for age classification of individual HIV 
sequences, we subdivided our data set into quintiles of the fraction of ambiguous 
nucleotides f and inferred the distribution of the time of infection for each of these 
quintiles. Figure 1D shows that the fraction of ambiguous nucleotides provides useful 
information mainly on the lower bound of the age of infection: whereas sequences 
with f < .68% (ie, the first two quintiles) (Table 2) may stem from the early phase of 
an infection, this is unlikely for sequences with a larger fraction of ambiguous 
nucleotides. However, it is important to note that although it is unlikely that the HIV 
sequence from a recent HIV infection has a large fraction of ambiguous nucleotides, 
this may occur if the HIV population is founded by >1 virus, in which case diversity is 
large from the beginning on. This effect can be clearly seen in the ZPHI data set: a 
substantial minority of 24 (18%) of 130 patients exhibit a fraction of ambiguous 
nucleotides >.68%, even though all patients’ samples have been sequenced in the 
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first months of their infection. This can be explained by results of Keele et al [1], who 
found that 23% of HIV infections are founded by >1 virus and hence should exhibit a 
large diversity even during primary infection. 
 
 
 
 
Figure 2.  
Temporal increase of the fraction of ambiguous nucleotides in the Wright-Fisher model (WFM) for a 
population size of 500 and a mutation rate of 3 × 10−5 mutations per generation (solid green line) and 
at 4-fold degenerate third-codon positions in the full data set (dashed black line). The curve for the 
WFM has been obtained by averaging over 104 runs of the model. N and m denote the effective 
population size and the mutation rate, respectively. The WFM describes discrete and nonoverlapping 
generations in a population with fixed size N. Every generation, each of the N genomes undergoes 
mutation with probability m. Then the N genomes for the next generation are determined from the 
gene pool by drawing every offspring genome with uniform probability from the N parental genomes. 
Note that the WFM assumes selective neutrality.  
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Table 2 
Strata 
number 
Stratification 
cut-off 
N per 
strata 
N (%) of 
patients 
infected < 1 
year 
Comparison of 
strata 1 Sensitivity 2 Specificity 3 
Correctly 
classified 
 Pre-defined       
1 <0.5% 1117 184 (16.5%) 1 vs. 2 86.8% 69.9% 70.9% 
2 >0.5% 2190 28 (1.3%)     
        
 By quintiles       
1 0% to 0.15% 679 146 (21.5%) 1 vs. 2, 3, 4, 5 68.8% 82.8% 81.9% 
2 0.16% to 0.67% 649 44 (6.8%) 1, 2 vs. 3, 4, 5 89.6% 63.2% 64.9% 
3 0.68% to 1.35% 691 14 (2.0%) 1, 2, 3 vs. 4, 5 96.2% 41.4% 44.9% 
4 1.36% to 2.07% 633 7 (1.1%) 1, 2, 3, 4 vs. 5 99.5% 21.1% 26.2% 
5 2.08% to 6.65% 655 1 (0.2%)     
        
1 Indicates how strata are collapsed for comparison, e.g. strata 1 vs. all remaining strata  
2 Sensitivity: Proportion of patients infected <1 year whose HIV sequence had <0.5% ambiguous positions 
3 Specificity: Proportion of patients infected >1 year whose HIV sequence had >0.5% ambiguous positions 
 
 
Table 2: Summary of the two cut-off methods discussed in text: i) a priori defined threshold of 0.5% 
and ii) cutoffs based on quintiles.  
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We explicitly evaluated 2 different stratifications for cutoffs to predict whether a 
patient was infected for <1 year at the time of sampling for the genotypic test. As 
shown in Table 2, the selection of a cutoff of ≥.5% ambiguous positions predicted 
recent infections quite well in our full data set of 3,307 patients. Of 212 patients with 
a recent infection at the time of genotypic testing, 184 had ≤.5% ambiguous positions 
in their HIV sequence (sensitivity, 86.8%), but the specificity, which is the proportion 
of chronically infected patients with >.5% ambiguous positions, was only 70% (ROC 
area under curve, 78.3%). Therefore, this cutoff of ≤.5% may not be very useful to 
identify recently infected patients, but it can very accurately discriminate against 
patients with a chronic infection: only 28 (1.3%) of 2,190 patients with >.5% 
ambiguous positions had an infection duration of ≤1 year at the time of genotyping. 
Thus, if the observed fraction of ambiguous positions is >.5%, then there is a 
probability of 98.7% (95% CI 98.2%–99.1%) that the genotypic test was performed 
>1 year after infection (negative predictive value). Stratification by quintile did not 
improve the classification performance but essentially confirmed the above finding: 
when quintiles 1 and 2 are collapsed into a single category and compared with the 
remaining strata (ie, sequences with <.68% vs those with ≥.68% ambiguous 
positions), sensitivity increased to 89.6% but specificity decreased to 63.2%. When 
testing the .5% cutoff in the sample of observed seroconverters (n = 366), the 
performance was very similar to that in the full sample. Sensitivity and specificity 
were 84.3% and 59.8%, respectively (data not shown). Overall, 79.8% of patients 
were correctly classified, and the area under the ROC curve was 72.0%.  
The observed increase in ambiguous positions over the time of infection likely 
reflects the diversification of the HIV population after the genetic bottleneck at the 
infection event. In the simplest scenario, this diversification is controlled only by 
mutation and genetic drift (ie, random extinction of viral strains). We modeled this 
scenario by simulating the Wright-Fisher model (WFM) [15], starting from an initially 
uniform population (ie, with no initial diversity). As the WFM assumes neutrality, we 
focused on ambiguous nucleotides at 4-fold degenerate third-codon positions for 
which the assumption of neutrality is best justified. We found that the WFM can 
reproduce the temporal increase of the fraction of ambiguous sites for parameters 
that have been shown to reproduce neutral evolution in HIV (see Kouyos et al [16] 
and references therein) (Figure 2). This finding implies that, at least for 4-fold 
degenerate third-codon positions, the increasing diversity of the HIV population can 
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be understood as the combined effect of mutation and genetic drift acting on a virus 
population, which is homogenous at the time point of infection. 
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Discussion 
 
The most relevant clinical result of this study is that a large fraction of ambiguous 
nucleotides provides evidence against a recent infection event. In particular, we 
found that a threshold of .5% ambiguous nucleotides yields a negative predictive 
value of 98.7%. It is important to note that, by definition, the negative predictive value 
depends on the overall composition of the considered population at time of diagnosis. 
A strength of the sample studied here, however, is the high representativeness of the 
SHCS for the epidemic in Switzerland [6–8]. Thus, the composition of our sample is 
likely to be very similar to that of the population of HIV-1-infected individuals at the 
time of HIV infection diagnosis, and therefore the negative predictive value inferred 
here closely describes the situation in clinical practice. Finally, we find that although 
the frequency of ambiguous nucleotide calls differs significantly between laboratories 
(Table 1), the negative predictive value varies only marginally when calculated for 
samples from each laboratory separately (range, 98.5%–99.5%; χ2 test, P = .668).  
In order to test the robustness of our findings, we additionally assessed the impact of 
HLA types, transmitted resistance, and subtype. HLA types may affect viral diversity, 
for instance, by stabilizing selection (and possibly by maintaining detrimental viral 
mutations, as may be the case for type HLA-B*57) or, in the opposite, by leading to 
increased viral replication and diversity by triggering only suboptimal cytotoxic T 
lymphocytes responses, for instance, in the presence of homozygous HLA alleles. 
Using available HLA data from 352 individuals, we considered the homozygosity of 
HLA-B (n = 32) and the following HLA-B haplotypes: HLA-B*57 (n = 23), HLA-B*27 
(n = 25), HLA-B*5801 (n = 7), and HLA-B*35 (n = 80). Upon inclusion of these 
variables in the adjusted regression model (restricted to a time of ≤8 years), neither 
of these HLA-B alleles reached statistical significance. There was a nonsignificant 
trend for higher viral diversity among carriers of homozygous HLA-B alleles of .243 
(95% CI -.054 to .551). Concerning HIV subtype, it should be noted that the present 
analysis focused on subtype B, because most patients in the SHCS have been 
infected with that subtype. We found, however, very similar results for other subtypes 
(Table 3), indicating that our methodology extends beyond subtype B. However, it is 
also clear from the limited data available for non-B subtypes that additional tests are 
required for these subtypes. Finally, transmitted resistance mutations (present in 
10% of the included patients) did not seem to have an impact when included in an 
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adjusted model analogous to that in Table 1 (with time restricted to ≤8 years), since 
the parameters were not statistically significant (data not shown). In summary, these 
3 tests suggest that our findings are robust against HLA type, subtype, and 
transmitted resistance.  
A potential limitation of our analysis is the accuracy of infection date estimates. We 
have confirmed the correlation between the age of an infection and the fraction of 
ambiguous base calls in several data sets with different estimation methods for 
infection duration. Moreover, we performed a sensitivity analysis to assess the impact 
of the uncertainty of infection date estimates from the back calculation model (data 
not shown). This was done by repeating the adjusted and unadjusted regression 
analyses on a random time point between the upper and the lower bound of the 
posterior infection date distribution [13]. Time trends were somewhat attenuated due 
to the introduction of additional variation with an increase of.13% per year (95% CI, 
.11%–.14%) for the unadjusted analysis and an increase of .11% per year (95% CI, 
.12%–.13%) for the adjusted analysis, but these point estimates still reached 
statistical significance.  
We would like to emphasize that this study represents a proof of principle and that 
the details of the method should ideally be replicated and calibrated for each 
sequencing laboratory or method (especially in the light of our finding of significant 
differences between laboratories) (Table 1). Moreover, it is important to note that 
10%–20% of recently infected patients do have a high viral diversity because they 
are infected with several strains. Therefore, the fraction of ambiguous nucleotides 
should be only one of several measurements used to decide whether a patient is 
recently infected.  
Detection of ambiguous nucleotides is a byproduct of bulk sequencing. Here, we 
have shown that this byproduct carries important information on the age of the 
infection at sampling time. In particular, a large frequency of ambiguous nucleotides 
argues against a recent infection event. The qualitative pattern of an initially linearly 
increasing amount of diversity and subsequent saturation is consistent with the 
diversification pattern observed for the env gene [3]. Overall, our study highlights the 
usefulness of diversity measures as markers for infection age. This usefulness might 
further increase with the advent of array-based pyrosequencing, which allows the 
diversity of the HIV population to be analyzed in much more detail. 
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Despite an enormous body of knowledge accumulated in the last 30 years, a number 
of key questions regarding HIV-1 transmission, pathogenesis, and therapy remain 
unresolved. The primary HIV-1 infection (PHI) has attracted tremendous attention 
because of the importance of this stage of infection to all of these aspects of HIV-1. 
In addition it has been recognized that longitudinal studies of PHI patients may be 
key to better understanding of HIV-1 infection. Therefore, the Zurich Primary HIV-1 
infection (ZPHI) – study is the basic for the present dissertation to address key 
questions of the early viral / host interaction. In addition to the PHI- patients the 
sources of the infection are of interest to understand transmission biology and viral 
and host contribution to the pathogenesis. Therefore, in this dissertation the 
identification of transmission pairs was one of the key aspects. We were able to link 
patients phylogenetically into transmission clusters and identified transmission events 
by using longitudinal clinical data. In contrast to the previous published literature we 
did a deep analysis of these transmission events with a surprising finding. A large 
number of new infections originated from patients in the chronic stage after stopping 
early ART. These findings argue for early, continuous ART not only for individual 
patient benefits but also for “treatment as prevention”.  
These transmission clusters are the basic for further aims addressing mechanism 
and properties of viruses that are transmitted. In this project full length env clones 
from plasma HIV-RNA of transmitter-recipient pairs will be characterized. In detail, we 
will employ machine learning tools to look for evidence of a genetic signature by 
newly transmitted viruses. Then we will compare those specific codons with viral 
strains from transmitters and chronically infected patients and analyze if differences 
effectively exist between transmitted and non-transmitted viruses.  
 
The second aim of the present dissertation is to define viral determinants explaining 
variations in viral setpoints reached in PHI patients after cessation of early ART. We 
studied viral diversity at the time of PHI by clonal sequencing of the HIV-1 envelope 
C2-V3-C3 region. We analyzed if differences in the mucosa are associated with 
differences in the complexity of the founder population. Specifically, we investigated if 
concomitant STI attenuated the genetic bottleneck and if single layered mucosal 
epithelium is more susceptible than multiple layered mucosas. In contrast to previous 
studies we did not found any differences in the complexity of the founder populations 
Synthesis 
174 
between differences in the nature of the mucosal frontline. This indicates that other 
mechanisms than the mucosal barrier is involved in the genetic bottleneck. 
Moreover, we wanted to test the hypothesis that higher viral diversity is associated 
with higher viral setpoints. However, because of the conclusions in project one that 
treatment is a prevention option and the improvements in medical treatment and drug 
tolerance, now, most patients stay on therapy. Therefore, too few viral setpoints 
reached after cessation of early ART could be analyzed for a significant conclusion 
about viral diversity during PHI as a surrogate marker for disease progression.  
 
In the fourth chapter, we described a method for the optimal FH-probe design for 
qPCR in phylogenetic diverse organisms, such as HIV-1. All circulating and newly 
emerging variants of HIV-1 must be detected. In addition, FH-probes are very 
sensitive to mismatches which could lead to an underestimation of RNA copy 
numbers. We developed an algorithm to scan sequence databases for FH-probes in 
various genomic regions of HIV-1 approaching coverage of the global HIV-1 
pandemic. Highly sensitive and accurate measurement of RNA transcripts is for 
example important for therapy monitoring and to evaluate the risk of HIV-1 
transmission under ART as studied in chapter two. 
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Abbreviations 
 
AIDS acquired immunodeficiency syndrome 
ARS acute retroviral syndrom 
ART antiretroviral therapy 
CA  capsid protein 
cART combination antiretroviral therapy 
CCR5 chemokine receptor 5 
CRF circulating recombinant form 
CTL cytotoxict lymphocytes 
CXCR4 CXC chemokine receptor 4 
DNA deoxyribonucleic acid 
ELISA enzyme-linked immunosorbent assay  
env envelope 
FH-probes fluorescent hydrolysis probes 
gag group-specific antigen 
HAART highly active antiretroviral therapy 
HIV-1 human immunodeficiency virus type I 
HSX heterosexual 
IN integrase 
IVDU intravenous drug users 
MA matrix protein 
MSF men having sex with female 
MSM men having sex with men 
MTCT mother to child transmission 
NC nucleocapsid protein 
nef negative factor 
NHP non-human primate 
NNRTI non-nucleoside reverse transcriptase inhibitors 
NRTI nucleoside reverse transcriptase inhibitors 
PHI primary HIV-1 infection 
PI protease inhibitor 
pol polymerase 
PR protease 
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R5 CCR5 tropic viral strain 
Rev regulator of expression of virion proteins 
RNA ribonucleic acid 
RT reverse transcriptase 
SHCS Swiss HIV Cohort Study 
SIV simian immunodeficiency virus 
STI sexually transmitted disease 
SU surface unit 
Tat transcriptional transactivator 
TM transmembrane subunit 
vif virion infectivity 
vpr viral protein R 
vpu viral protein U 
X4 CXCR4 tropic viral strain 
ZPHI Zurich Primary HIV-1 Infection 
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